



Pharmacist-led management of chronic pain in primary care: results from a randomised controlled exploratory trial

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-002361
Article Type:	Research
Date Submitted by the Author:	16-Nov-2012
Complete List of Authors:	Bruhn, Hanne; University of Aberdeen, Health Services Research Unit Bond, Christine; University of Aberdeen, Elliott, Alison; University of Aberdeen, General Practice and Primary Care Hannaford, Phil; University of Aberdeen Lee, Amanda; University of Aberdeen, Division of Applied Health Sciences McNamee, Paul; University of Aberdeen Smith, Blair; University of Dundee, Watson, Margaret; University of Aberdeen, General Practice and Primary Care Blyth, Annie; University of East Anglia, Norwich Medical School Wright, David; University of East Anglia, Infection Holland, Richard; University of East Anglia,
Primary Subject Heading:	General practice / Family practice
Secondary Subject Heading:	General practice / Family practice, Health services research
Keywords:	PAIN MANAGEMENT, PRIMARY CARE, Clinical trials < THERAPEUTICS

SCHOLARONE™
Manuscripts

only

Title page

Pharmacist-led management of chronic pain in primary care: results from a randomised controlled exploratory trial

Hanne Bruhn, Christine M Bond, Alison M Elliott, Philip C Hannaford, Amanda J Lee, Paul McNamee, Blair H Smith, Margaret C Watson, Annie Blyth, Richard Holland, David Wright

Centre for Healthcare Randomised Trials, Health Services Research Unit, University of Aberdeen, 3rd floor Health Sciences Building, Foresterhill, Aberdeen, AB25 2ZD, UK Hanne Bruhn, Trial Manager

Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Polwarth West Block, Foresterhill, Aberdeen, AB25 2ZD, UK, Christine M Bond, Professor of Primary Care: Pharmacy

Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Polwarth West Block, Foresterhill, Aberdeen, AB25 2ZD, UK, Alison M Elliott, Senior Research Fellow

Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Polwarth West Block, Foresterhill, Aberdeen, AB25 2ZD, UK, Philip C Hannaford, NHS Grampian Chair of Primary Care

Population Health, 1st floor, Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, UK, Amanda J Lee, Professor of Medical Statistics

Health Economics Research Unit, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, UK, Paul McNamee, Reader

Mackenzie Building, Kirsty Semple Way, Ninewells Hospital and Medical School, Dundee, DD2 4RB, UK, Blair H Smith, Professor of Population Science

Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Polwarth West Block, Foresterhill, Aberdeen, AB25 2ZD, UK, Margaret C Watson, Senior Research Fellow

Norwich Medical School, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK, Annie Blyth, Research Associate

Norwich Medical School, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK, Richard Holland, Professor of Public Health Medicine

School of Pharmacy, University of East Anglia, Norwich Research Park, NR4 7TJ, UK, David Wright, Chair in Pharmacy Practice

1
2 Correspondence to: Professor CM Bond c.m.bond@abdn.ac.uk, Centre of Academic Primary
3 Care, Division of Applied Health Sciences, University of Aberdeen, Polwarth West Block,
4 Foresterhill, Aberdeen, AB25 2ZD, UK
5

6
7 The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all
8 authors, [a worldwide licence](#) to the Publishers and its licensees in perpetuity, in all forms, formats and
9 media (whether known now or created in the future), to i) publish, reproduce, distribute, display and
10 store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints,
11 include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii)
12 create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the
13 Contribution, v) the inclusion of electronic links from the Contribution to third party material where-
14 ever it may be located; and, vi) licence any third party to do any or all of the above.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives

To compare the effectiveness of pharmacist medication-review, with or without prescribing, with standard care, for patients with chronic pain.

Design

An exploratory randomised controlled trial.

Setting

Six general practices with prescribing pharmacists in Grampian (3) and East Anglia (3).

Participants

Patients on repeat prescribed pain medication (4815) were screened by GPs, and mailed invitations (1397). 196 were randomised and 180 (92%) completed. Exclusion criteria included: severe mental illness, terminally ill, cancer related pain, history of addiction

Randomisation and intervention

Patients were randomised using a remote telephone service to: (i) pharmacist medication-review with face-to-face pharmacist prescribing; or (ii) pharmacist medication-review with feedback to GP and no planned patient contact; or (iii) treatment as usual (TAU). Blinding was not possible.

Outcome measures

Primary outcomes were the Chronic Pain Grade (CPG) and the SF-12v2, together with Hospital Anxiety and Depression Scale (HADS). Outcomes were collected at 0, 3, and 6 months. Ethical approval was obtained.

Results

In the prescribing arm (n=70) two patients were excluded/nine withdrew. In the review arm (n=63) one was excluded/three withdrew. In the TAU arm (n=63) four withdrew. Compared with baseline, patients had an improved CPG in the prescribing arm, 47.7% (21/44; p=0.003), and in the review arm, 38.6% (17/44; p=0.001), but not the TAU group, 31.3% (15/48; ns). The SF-12 PCS showed no effect in the prescribing or review arms but improvement in TAU

(p=0.02). The SF-12 MCS showed no effect for the prescribing or review arms and deterioration in the TAU arm (p=0.002). HADS scores improved within the prescribing arm for Depression (p=0.022) and Anxiety (p=0.007), between groups (p=0.022 and p=0.045 respectively)

Conclusion

This is the first RCT of pharmacist-prescribing in the UK, and suggests a benefit for patients with chronic pain. A larger trial is required.

Trial registration: www.isrctn.org/ISRCTN06131530. Medical Research Council funding.

Focus:

- Chronic pain, (lasting >3 months) affects up to half the adult population, most of whom are primarily managed in primary care but prescribing is often sub-optimal.
- Pharmacists now have prescribing rights but no published research has compared the effectiveness of their prescribing with that of GPs.
- The hypothesis was that pharmacist advice (with or without pharmacist prescribing) would lead to better outcomes than usual care

Key messages:

- The findings suggest improved pain related outcomes for patients receiving pain related care from a pharmacist prescriber
- A larger trial is called for.

Strengths and Limitations

- This the first randomised controlled trial of pharmacist prescribing in the UK looking at patient reported clinical outcomes
- The study was designed as an exploratory trial so no power calculation was done

Introduction

Chronic pain (pain lasting more than three months) affects up to half the adult United Kingdom (UK) population, and is considered severely limiting in about 15% of cases (1). Recovery is uncommon with nearly 80% of those identified with chronic pain at baseline still reporting chronic pain four years later (2). It adversely affects many aspects of a person's physical and psychological health, and social and economic well being (3-6).

In the UK, most patients with chronic pain present, and are managed, in primary care (7). Although non-pharmacological treatments are available, these are accessed by few patients, with mixed success (e.g. (8-10)). Analgesics prescribed in primary care remain the mainstay of treatment (4), representing substantial workload and cost. Sub-optimal prescribing may lead to poor pain control and other adverse patient outcomes. One study found that the most common medications involved in adverse drug reaction-related emergency admissions involved non-steroidal anti-inflammatory drugs (NSAIDs) (11). Improved prescribing could result in better outcomes and remove the need for more costly, scarce, alternatives.

Pharmacists working in UK general practices are well-placed to improve pain pharmacotherapy because of their expertise in therapeutics, understanding of the poly-pharmacy regimens (12) frequently used in chronic pain management, and established relationships with other primary care colleagues. In the UK National Health Service (NHS), recent regulatory changes now allow accredited pharmacists (as well as some other health care professionals such as nurses) to prescribe prescription-only medicines (POMs) (13).

However, despite the increasing number of non-medical prescribers, including pharmacists, there has been no rigorous comparisons of the outcomes of non-medical versus GP prescribing. This information is needed to assess the clinical effectiveness of different care models.

This paper reports findings from an exploratory randomised controlled trial (RCT) comparing pharmacist medication review, with or without pharmacist prescribing, with standard care for patients with chronic pain. Development of the trial was informed by earlier feasibility work (14,15).

The hypothesis was that, in patients with chronic pain, pharmacist advice (with or without pharmacist prescribing) would lead to better patient functioning and/or better pain control at

1
2 six months than treatment as usual (TAU). The hypothesis was developed prior to data
3 collection.
4
5
6
7

8 **Methods**

9 *Regulatory Issues*

10
11 Ethical approval was granted by the National Research Ethics Service Committee – North of
12 Scotland (reference number 09/S0801/107). NHS Research and Development approval was
13 granted by NHS Grampian and East Norfolk & Waveney Research Governance Committees.
14
15 Patients gave informed consent before taking part.
16
17
18
19

20 *Design*

21
22 An open, exploratory RCT in which patients were randomised to one of three study arms.
23
24 Participants were not blind to allocated treatment arm due to the nature of the intervention.
25
26

27 *Recruitment of practices and independent prescribing pharmacists*

28
29 Practices in Grampian, Scotland (n=18) and East Anglia, England (n=4) known to have an
30 attached Royal Pharmaceutical Society of Great Britain registered independent pharmacist
31 prescriber, were eligible to take part. From those indicating a willingness to participate,
32 convenience sampling was used to identify six general practices: three in Grampian and three
33 in East Anglia.
34
35
36
37

38 *Patient inclusion and exclusion criteria*

39
40 Patients registered with the recruited practices were eligible for inclusion if they were over 18
41 years of age, living in their own home, and receiving regular prescribed medication for pain.
42
43 Patients were identified by a computerised search {5 McDermott, M. E. 2006} of the drug
44 records of all individuals registered with the practice, to identify those who had received either
45 two or more acute prescriptions, and/or one repeat prescription within the last 120 days, for
46 an analgesic (British National Formulary (BNF section 4.7) and/or non-steroidal anti-
47 inflammatory medication (NSAID) (BNF section 10.1.1). Medications which can be used for
48 analgesia but whose primary indication is not chronic pain (e.g. triptans, anti-epileptics or anti-
49 depressants) were excluded as these drugs identify few additional eligible patients (16). In
50 accordance with trial criteria, GPs excluded and recorded reasons for patients who had: a
51
52
53
54
55
56
57
58
59
60

1 concomitant severe mental health problem or terminal illness; had suffered recent
2 bereavement; had a known alcohol or drug addiction; suffered pain caused by cancer or other
3 malignancy; were unable to give informed consent; other (unspecified) reasons.
4
5
6

7 *Patient recruitment*

8 Eligible patients were sent an invitation pack (letter, information sheet, consent form) by
9 practice staff between March and June 2010. Consent forms were returned directly to the
10 researchers, who sent out a baseline questionnaire. Patients returning completed
11 questionnaires were randomised by the researcher using a telephone randomisation service
12 with a random number allocation which ensured allocation concealment. The allocation
13 sequence was 1:1:1.
14
15
16
17
18
19
20

21 *Intervention*

22 All participating pharmacists took part in a two-day course updating them about pain
23 management. As part of the training, participants defined and agreed the treatment algorithm
24 they would all use.
25
26
27
28

29 'Prescribing' arm: Pharmacists invited patients to a face-to-face consultation. Prior to the
30 consultation, pharmacists completed a paper-based medication review of each patient's
31 medical record and patients were asked to complete a pain diary to inform the consultation. A
32 pharmaceutical care plan was agreed between the pharmacist and the patient. The plan
33 assessed and documented relevant past medical history and current conditions; known
34 allergies and adverse drug reactions; relevant laboratory results; pain-related medications
35 prescribed in the previous 10 years; current pain related prescription medications; current
36 symptoms; lifestyle issues, including units of alcohol consumed per week; recommendations
37 for changes to medication (if any); whether non-pharmaceutical treatments had been
38 considered; and, any other relevant issues. At the end of the consultation any required
39 prescriptions for medicines were issued by the pharmacist. Due to Controlled Drug (CD)
40 regulations in place at the time, prescribing for CDs was done using a supplementary
41 prescribing Clinical Management Plan (17), rather than independent prescribing. Patients were
42 followed up either by phone or face-to-face, at each pharmacist's discretion.
43
44
45
46
47
48
49
50
51
52
53

54 'Review arm': The pharmacists conducted a paper-based medication review focussed on pain-
55 related prescription medications, before creating a pharmaceutical care plan which detailed
56
57
58
59
60

1
2 any recommendations for medication changes. The plan was passed to the patient's GP for
3 implementation. The GPs were asked subsequently about actions taken as a result of the
4 recommendations.
5
6

7
8 Treatment as usual (TAU): Patients received standard general practice care.
9

10 *Outcome measures*

11
12 There were two primary outcome measures: the Chronic Pain Grade (CPG) and the Medical
13 Outcomes Study 12-item short form version 2 (SF-12v2). Use of both a pain specific and generic
14 outcome measure was based on Initiative on Methods, Measurement, and Pain Assessment in
15 Clinical Trials (IMMPACT) recommendations (18) and an earlier (18,19) feasibility study (15).
16
17

18
19 The CPG (20) is a seven item scale which assesses pain severity on two dimensions: disability
20 and intensity. The scale classifies pain according to level of intensity and disability (I (low
21 disability-low intensity) to IV (high disability-severely limiting)).
22
23

24
25 The SF-12v2 is a generic health and functioning scale (21), previously used in population-based
26 studies of pain (22,23). A Physical (PCS) and Mental Component Score (MCS) was calculated,
27 ranging from 0 to 100; a higher score indicates better functioning.
28
29

30
31 A secondary outcome measure was the Hospital Anxiety and Depression Scale (HADS) (24), a
32 14-item screening instrument which identifies the possible and probable caseness of anxiety (7
33 items (HADS-A)) and depression (7 items (HADS-D)); each item scored from 0 (not present) to 3
34 (highly present). Standard thresholds and previously used labels (25) were applied (no
35 depression/anxiety (0-7), mild (8-10), moderate (11-15) or severe (>15)).
36
37

38 *Data collection*

39 *Participant questionnaires*

40
41 Questionnaires were posted to participants at baseline (pre-randomisation), and 3 and 6
42 months post-randomisation (follow-up was conducted between July 2010 and January 2011).
43
44 Up to two reminders were sent. Questionnaire content included the outcome measures
45 described above together with items on: demographic status (baseline only); screening items
46 to confirm eligibility (baseline only); duration of pain condition (baseline only); location of pain;
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 Morisky Medication Adherence Scale 4 (MMAS-4) (26); participant satisfaction (11 statements
3 derived from the feasibility study for the prescribing arm (3 months only) and additional
4 comments by participants. The MMAS-4 provides a score of self-reported adherence to
5 medication regimen. Scores range from 0 (low adherence) to 4 (high adherence).
6
7

8 9 10 *Follow-up interviews with staff*

11 Post-intervention, all pharmacists and all GPs in participating practices were invited to take part
12 in semi-structured interviews, carried out face-to-face when possible, otherwise by telephone.
13 Interviews were taped, transcribed verbatim and content analysis was carried out.
14
15

16 17 18 *Sample size*

19 As this was an exploratory trial to estimate the effect size for a larger trial, no formal sample
20 size calculation was possible (27). We aimed to recruit 30 participants per practice (excluding
21 those recruited for training purposes) i.e. 180 in total. This was deemed sufficient to give
22 reliable effect size estimates for the primary outcome measures of chronic pain grade or health
23 status.
24
25
26
27

28 29 30 *Data management and analysis*

31 Data were entered into identical SPSS databases at each site and accuracy checks carried out
32 on 10% before databases were merged. Descriptive statistics included means and standard
33 deviations (SD) for normally distributed continuous data, medians (interquartile range (IQR))
34 for skewed continuous data and percentages (n) for categorical data. Analysis was conducted
35 on an intention-to-treat basis for participants with complete data on relevant measures using
36 SPSS version 18.
37
38
39
40
41

42
43 Exploratory analyses for parametric data included the paired t-test for within-arm comparisons
44 and one-way ANOVA for between arm comparisons. For non-parametric data it included the
45 Wilcoxon Signed Rank test for within-arm comparisons and the Kruskal Wallis test for between
46 arm comparisons. Categorical data was analysed using the marginal homogeneity test for
47 within-arm comparisons and the Chi-squared test for between arm comparisons; analyses
48 reported here are based on 6 month follow-up data (other than for participant experiences).
49
50
51
52
53
54

55 **Results**

56 57 *Response rates and demography*

58
59
60

1 Six of the seven practices approached participated. GPs excluded 12% (392/3281) of patients,
2 mostly those with dementia. There was no statistically significant difference between
3 participants and non-participants in terms of age, gender, and index of multiple deprivation.
4
5 Figure 1 shows the flow of participants through the study. Overall, the consent rate was 25%
6
7 (356/1397) and the recruitment rate was 14% (196/1397).
8
9

10
11 [INSERT FIGURE 1 HERE]
12

13
14 Eighty six percent of participants (251/289) returned baseline questionnaires, of whom 232
15 were randomised (36 participants were randomised to one of the two intervention arms for
16 training purposes and were not included in any further analysis and 19 were not included as
17 recruitment target had been met). The overall follow-up rate at 3 months was 86%
18 (161/187) and at 6 months 84% (152/180).
19
20

21
22 As shown in Table 1, groups were similar at baseline for demographic and socioeconomic
23 variables and pain data. Most participants were married, Caucasian and female, older (mean
24 (SD) age 65 (12.6) years), had an annual income of <£25,000 and had suffered from pain for at
25 least five years. Most (57%;103/181) reported being fully adherent to their medication
26 regimen (MMAS-4, median 4.0 (IQR 3.0- 4.0)) (15 missing MMAS scores).
27
28
29
30
31

32
33 [INSERT TABLE 1 HERE]
34
35

36 In the prescribing arm, 78% (53/68) attended an initial prescribing consultation, 31 had at least
37 one planned follow-up (generally conducted by phone) and 130 recommendations were made
38 for 92% (49/53) of participants seen. Examples are shown in Box 1. The median time taken for
39 the note-based record review was 35 minutes (IQR 20.0, 45.0), the consultation was 30 minutes
40 (IQR 20.0, 40.0), careplan preparation 10 minutes (IQR 10.0, 20.0) and median duration of
41 follow-ups was 10 minutes (IQR 5.0- 15.0).
42
43
44
45
46

47 [INSERT BOX 1 HERE]
48
49

50 In the review arm 97% (60/62) of participants' records were reviewed (note there was one post
51 randomisation exclusion) for whom 197 recommendations were made. Where GP feedback
52 was provided (n=48), they generally agreed with pharmacists' recommendations, which were
53 fully implemented for 20 participants (two by the pharmacist following request by GP), partially
54 for 19 participants and not at all for nine participants. The median time taken for the note-
55
56
57
58
59
60

1 based record review was 30 minutes (IQR24.3, 45.0), and careplan preparation was 10
2 minutes (IQR 5.0, 20.0).
3
4
5
6
7

8 *Clinical outcome measures*

9
10 Table 2 shows the mean (SD) or median (IQR) of the CPG for each arm at baseline and 6 month
11 follow-up. Table 3 shows the SF-12 scores and Table 4 shows the HADS-A and HADS-D results.
12

13
14 [INSERT TABLE 2,3,4, HERE]
15

16
17 In the prescribing arm, there was a statistically significant within arm improvement for the CPG
18 intensity ($p=0.002$) and disability ($p=0.003$) subscales, and between arms on the intensity sub-
19 scale ($p=0.02$), but not the disability subscale ($p=0.55$) (Table 2). There was a significant within-
20 arm improvement in overall CPG grade in the prescribing ($p=0.003$) and review arm ($p=0.001$),
21 but not in the TAU arm. The SF-12 Physical Component Score showed a statistically significant
22 within arm improvement in the TAU arm ($p=0.02$, Table 3), but not between trial arms. The SF-
23 12 Mental Component Score showed a statistically significant deterioration in the TAU arm
24 ($p=0.002$, Table 3), as did the HADS-D ($p=0.03$, Table 4). Analysis was also carried out on the
25 non-categorised HADS scores which showed a statistically significant improvement within the
26 prescribing arm for Depression ($p=0.022$) and Anxiety ($p=0.007$). These were both significant
27 between groups ($p=0.022$ and $p=0.045$ respectively) (Table 5).
28
29
30
31
32
33
34
35
36

37 *Acceptability of the pharmacist prescribing intervention*

38 All six pharmacists and 56% of the GPs (23/41) were interviewed. All pharmacists and most GPs
39 were positive about the intervention, although some GPs suggested that the pharmacists'
40 recommendations had been minor and questioned the cost-effectiveness of the service.
41 Patient participants were generally positive about the pharmacist prescribing service although
42 some concerns were identified, as illustrated by the quotes shown in Box 2.
43
44
45
46
47

48 [INSERT BOX 2 HERE]
49

50 **Discussion**

51 *Principal findings*

52
53 This exploratory RCT of pharmacist-led management of patients with chronic pain suggests that
54 pharmacist prescribing (and possibly pharmacist review alone) may be effective in improving
55
56
57
58
59
60

1 pain-related outcomes and be acceptable to both patients and professionals. There was an
2 indication of a positive effect on emotional health, but no measurable effect on general
3 health.
4
5
6

7 *Strengths and weaknesses*

8 This was the first RCT to assess clinical and humanistic outcomes after pharmacist prescribing
9 for any clinical condition compared to usual GP care, and the first RCT to specifically assess
10 pharmacist-led management of chronic pain, compared with usual GP care. It was based on
11 extensive development and feasibility work (14,15) in line with MRC framework for
12 development and evaluation of complex interventions (28). A range of validated outcome
13 measures was included, as well as a parallel qualitative process evaluation which demonstrated
14 satisfaction and acceptability. The inclusion of six practices and their associated pharmacists
15 from both Scotland and England increased the generalisability of the findings. Pharmacists
16 agreed and used a common treatment algorithm which should have increased standardisation
17 of treatment.
18
19
20
21
22
23
24
25
26

27 There were, however limitations. Although high follow-up response rates were achieved at
28 both three (86%) and six months (85%) only 25% of eligible patients entered the trial. This low
29 initial consent rate is in line with other studies (29,30), but may cause unknown biases
30 including problems of generalisability. Rewording of participant recruitment documentation
31 could address some of the concerns identified by participant feedback e.g. having too many
32 people involved in one's care. More participants withdrew in the prescribing arm compared
33 with the other two arms, which might be attributed to the need for an additional practice visit.
34 The study was an exploratory trial so no formal power calculation was undertaken because of
35 no prior knowledge of effect size. Due to the nature of the intervention, no participants were
36 blind to their group allocation, and so some outcomes, especially the qualitative components,
37 may have been affected by social desirability bias.
38
39
40
41
42
43
44
45
46
47

48 Our main outcome measures were self-reported, but this is the norm in pain studies as pain is a
49 subjective experience (18). Furthermore we do not know how important the observed
50 differences were to participants. Following precedents set in previous research (25), and
51 because there is no consensus on an alternative measure (31) we used the HADS as a tool to
52 classify people by severity of depression and anxiety. However it is strictly a screening tool, and
53
54
55
56
57
58
59
60

1 the four levels of severity have not been formally validated. We therefore also compared
2 outcomes using it as a continuous scale.
3
4

5 *Relationship with other studies*

6 This study is important because no other RCT has evaluated pharmacist prescribing and few
7 studies, and importantly no RCTs, have evaluated pharmacist interventions for pain. In
8 pharmacist prescribing most research has focussed on reported experiences of professionals
9 and patients, and not used validated outcome measures. Yet pharmacist prescribing is now
10 widely practised. For pain, there have been a few small studies. Briggs et al (2008) (32)
11 conducted a small before-and-after evaluation (involving 65 patients) of a nurse and
12 pharmacist-led chronic pain clinic in primary care. Pain intensity Visual Analogue Scale scores
13 reduced significantly over six months. Another evaluation of 26 patients using a medication
14 review service provided jointly by a physiotherapist and pharmacist, reported improvement in
15 pain control for 88% of patients (33).
16
17

18 The CPG was found to show a graded effect across the three arms, showing discrimination with
19 both direction and strength of improvement, suggesting maximum benefit for those in the
20 pharmacist prescribing arm. However, the reduction in overall score appears to be mediated by
21 a change in the intensity of pain subscale rather than in pain-related disability. In contrast, the
22 SF-12, a measure of general health and functionality showed no significant difference between
23 intervention arms, reflecting either no effect or or lack of power to detect an effect.
24
25

26 Whilst most participants in this study were already within the normal range on the HADS scale,
27 and therefore had minimal chance of improvement, there were nonetheless suggestions of
28 better outcomes in participants in the prescribing arm. Including a range of instruments is
29 in line with IMMPACT recommendations (34), which state that focus should be on the whole
30 person, not just about pain. However, this needs to be balanced with minimising participant
31 burden.
32
33

34 *Explanations, implications, and future research*

35 The number of pharmacists' recommendations per participant was higher in the review arm
36 than in the prescribing arm. This might seem contradictory to the possible greater benefit
37 found in the prescribing arm. However, in the prescribing arm pharmacists met the participant
38 and may have more readily identified and dismissed suggestions previously tried. The
39
40
41
42
43
44
45
46
47
48

1
2 interview feedback highlighted that some recommendations for change, whilst sensible, had
3 been tried already. This might also be the reason why there were only 60% of pharmacist
4 recommendations with which the GP fully agreed. Self-reported adherence to medication at
5 baseline was good. Despite this, the pharmacists still improved pain outcomes in the
6 prescribing arm. This could have been due to changes in medications and/or participant
7 education about optimal timing for administration of analgesic medicines. Further research is
8 needed to confirm the beneficial effect of pharmacist prescribing and its sustainability.
9
10
11
12
13

14 **Conclusion**

15
16 Our results suggest that pharmacist prescribing (and possibly pharmacist review alone) for
17 patients with chronic pain is feasible, acceptable and leads to improvements in pain and other
18 measures. A larger fully-powered trial is now needed to confirm these findings.
19
20
21
22

23 **Data sharing statement**

24
25 Consent was not obtained from participants for data sharing; the presented data are
26 anonymised and there is no risk of individual identification. Requests for data should be made to
27 the contact author who will provide this in a format in which risk of patient identification will be
28 minimal.
29
30
31

32 **Conflict of interest statement**

33
34 All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf
35 (available on request from the corresponding author) and declare: no support from any organisation for
36 the submitted work; no financial relationships with any organisations that might have an interest in the
37 submitted work in the previous 3 years; no other relationships or activities that could appear to have
38 influenced the submitted work.
39
40
41
42

43 **Authors' contributions**

44
45 HB and CB drafted the manuscript.

46
47 All authors:

- 48
49
50 1) made substantial contributions to conception and design, or acquisition of data, or analysis and
51 interpretation of data;
52
53 2) were involved in drafting the manuscript or revising it critically for important intellectual content; and
54
55 3) have given final approval of the version to be published.
56
57
58
59
60

Acknowledgements

We thank the participating patients, practices and pharmacists. We would also like to thank Kirsten Harrild (Medical Statistics, UOA) for statistical support. Rick Adams (School of Pharmacy, UEA) helped design and deliver the pharmacist training and Lesley Thomson (NHS Grampian) helped design the pharmacist data collection forms. The patient postal questionnaire was based on work by Nicola Cooper and the Norfolk Arthritis Register (NOAR) research team. The Pharmacy-Led Management of Chronic Pain Study Team acknowledges the financial support of NHS Research Scotland (NRS), through Scottish Primary Care Research Network Northeast. The work was conducted as part of the Aberdeen Pain Research Collaboration. The project was funded by the Medical Research Council. They had no further involvement in any aspect of study conduct; all researchers were independent of the funding body.

All authors had access to all of the study data and can take responsibility for the integrity of the data and the accuracy of the data analysis.

References

- (1) Elliott AM, Smith BH, Penny KI, Smith WC, Chambers WA. The epidemiology of chronic pain in the community. *Lancet* 1999;354:1248-1252.
- (2) Elliott AM, Smith BH, Hannaford P, Smith WC, Chambers WA. The course of chronic pain in the community: results of a 4-year follow-up study. *Pain* 2002;99:299-307.
- (3) Becker N, Bondegaard Thomsen A, Olsen AK, Sjøgren P, Bech P, Eriksen J. Pain epidemiology and health related quality of life in chronic non-malignant pain center patients referred to a Danish multidisciplinary. *Pain* 1997;73:393-400.
- (4) Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. *Eur J Pain* 2006;10:287-333.
- (5) Gureje O, Von Korff M, Simon GE, Gater R. Persistent pain and well-being: a World Health Organization Study in Primary Care. *JAMA* 1998;280:147-151.
- (6) Magni G, Marchetti M, Moreschi C, Merskey H, Luchini SR. Chronic musculoskeletal pain and depressive symptoms in the National Health and Nutrition Examination. I. Epidemiologic follow-up study. *Pain* 1993;53:163-168.
- (7) Sullivan MD, Turner JA, Romano J. Chronic pain in primary care: identification and management of psychological factors. *J Fam Pract* 1991;32:193-199.
- (8) Green S, Buchbinder R, Hetrick SE. Physiotherapy interventions for shoulder pain. *Cochrane Database of Syst Rev* 2010(9):Art. No.: CD004258. DOI: 10.1002/14651858.CD004258.

1
2 (9) Eccleston C, Williams, A. C. D. C., Morley S. Psychological therapies for the management of
3 chronic pain (excluding headache)
4 in adults. Cochrane Database Syst Rev 2009 Apr 15;(2):CD007407. DOI:
5 10.1002/14651858.CD007407.pub2.
6

7
8 (10) Haetzman M, Elliott AM, Smith BH, Hannaford P, Chambers WA. Chronic pain and the use
9 of conventional and alternative therapy. Family Practice 2003;20(2):147-154.
10

11 (11) Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug
12 reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ
13 2004;329:15.
14

15
16 (12) Krska J, Cromarty JA, Arris F, Jamieson D, Hansford D, Duffus PR, et al. Pharmacist-led
17 medication review in patients over 65: a randomized, controlled trial in primary care. Age and
18 Ageing 2001;30:205-211.
19

20
21 (13) Department of Health. Improving patients' access to medicines: A guide to implementing
22 nurse and pharmacist independent prescribing within the NHS England. Department of Health
23 2006.
24

25
26 (14) McDermott ME, Smith BH, Elliott AM, Bond CM, Hannaford P, Chambers WA. The use of
27 medication for chronic pain in primary care, and the potential for intervention by practice-
28 based pharmacist. Family Practice 2006;23:46-52.
29

30
31 (15) Bruhn H, Bond CM, Elliott AM, Hannaford PC, Lee AJ, McNamee P, et al. Developing an RCT
32 of general practice-based, pharmacist-led, management of chronic pain: the PIPPC study. IJPP
33 2010;18(Supplement 2).
34

35
36 (16) Smith BH, Read JRM, Chambers WAC, Watt B, Grimshaw JM. Researching chronic pain:
37 identification of a community based sample. The Pain Clinic 1996;9:73-76.
38

39
40 (17) Department of Health. Supplementary prescribing by nurses and pharmacists within the
41 NHS in England: A guide for implementation. Department of Health 2003.
42

43
44 (18) Turk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB, et al. Core outcome
45 domains for chronic pain clinical trials: IMMPACT recommendations. Pain 2003 12;106(3):337-
46 345.
47

48
49 (19) The Community Pharmacy Medicines Management Project Evaluation Team. The
50 MEDMAN study: a randomized controlled trial of community pharmacy-led medicines
51 management for patients with coronary heart disease. Family Practice 2007;24:189-200.
52

53
54 (20) Von Korff M, Ormel J, Keefe FJ, Dworkin SF. Grading the severity of chronic pain. Pain
55 1992;50:133-149.
56


57
58 (21) Ware JE, Kosinski M, Turner-Bowker DM, Sundaram M, Gandek B, Maruish ME. User's
59 Manual for the SF-12v2 Health Survey. Second edition ed.: QualityMetric, Incorporated, 2009;
60 2009.

- 1
2 (22) Nicholl BI, Macfarlane GJ, Davies KA, Morriss R, Dickens C, McBeth J. Premorbid
3 psychosocial factors are associated with poor health-related quality of life in subjects with new
4 onset of chronic widespread pain - results from the EPIFUND study. *Pain* 2009;141:119-126.
5
6 (23) Carmona L, Ballina J, Gabriel R, Laffon A. The burden of musculoskeletal diseases in the
7 general population of Spain: results from a national survey. *Ann Rheum Dis* 2001;60:1040-1045.
8
9 (24) Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand*
10 1983 Jun;67(6):361-370.
11
12 (25) Snaith RP, Zigmond AS. HADS: Hospital Anxiety and Depression Scale. Windsor: NFER
13 Nelson; 1994.
14
15 (26) Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported
16 measure of medication adherence. *Med Care* 1986 Jan;24(1):67-74.
17
18 (27) Lancaster GA, Dood S, Williamson PR. Design and analysis of pilot studies:
19 recommendations for good practice. *J Eval Clin Pract* 2004;10(2):307-312.
20
21 (28) Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and
22 evaluating complex interventions: the new Medical Research Council guidance. *BMJ*
23 2008;337:a1655.
24
25 (29) Community Pharmacy Medicines Management Project Evaluation Team. The MEDMAN
26 study: a randomized controlled trial of community pharmacy-led medicines management for
27 patients with coronary heart disease. *Family Practice* 2007;24:189-200.
28
29 (30) Treweek S, Mitchell E, Pitkethly M, Cook J, Kjeldstrøm M, Johansen M, et al. Strategies to
30 improve recruitment to randomised controlled trials. *Cochrane Database Syst Rev*
31 2010;(4):MR000013 2011.
32
33 (31) Cameron IM, Cardy A, Crawford JR, du Toit Schalk W, Hay S, Lawton K, et al. Measuring
34 depression severity in general practice: discriminatory performance of the PHQ-9, HADS-D, and
35 BDI-II. *Br J Gen Pract* 2011;61:e419-e426(8).
36
37 (32) Briggs M, Closs SJ, Marczewski K, Barratt J. A feasibility study of a combined
38 nurse/pharmacist-led chronic pain clinic in primary care. *Qual Prim Care* 2008;16:91-94.
39
40 (33) Anonymous. Pharmacist and physiotherapist-led community outreach pain programme
41 improve quality of life. *The Pharmaceutical Journal* 2005;275:14.
42
43 (34) Turk DC, Dworkin RH, Revicki D, Harding G, Burke LB, Cella D, et al. Identifying important
44 outcome domains for chronic pain clinical trials: An IMMPACT survey of people with pain.
45 2008;137:276-285.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Figure 1: CONSORT Flow Diagram



1
2 *In Grampian, on the basis of response rates in the earlier feasibility study (241 screened patients
3 resulted in 22 recruited) only a random sample of eligible participants were screened (15). In East Anglia
4 all eligible patients were screened.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1: Baseline demographic, socio-economic and pain data of patients by study arm, prescribing, review and treatment as usual (TAU)

	Prescribing*	Review*	TAU*
	(n = 68)	(n = 62)	(n = 63)
Age: mean (SD)	66.1 (12.1)	65.7 (14.2)	64.9 (11.6)
Missing	1	1	0
Gender (% female)	54.4 (37)	74.2 (46)	58.7 (37)
<i>Marital status</i>			
Married	43	30	41
Single	6	6	3
Divorced/widow	10	21	13
Other	6	4	6
Missing	3	1	0
<i>Highest educational level achieved</i>			
No qualifications	30	27	21
O grade or equivalent	12	6	14
Higher/A-level/NVQ3/SVQ3	6	8	7
Tertiary education/NVQ4/NVQ5	18	17	14
Other	2	1	4
Missing	0	3	3
<i>Employment status</i>			
Employed	16	14	9
Unemployed	3	5	1
Retired	38	35	34
Long term sick/disabled	7	5	9
Other	3	2	7
Missing	1	1	3
<i>Household annual income before tax</i>			
Less than £9,999	13	15	10
£10,000 - £14,999	14	18	22
£15,000 - £24,999	14	12	12
£25,000 – or more	22	11	8
Missing	5	6	11
<i>Ethnic group</i>			
Caucasian	67	62	61
Other	1		
Missing	0	0	2
<i>Pain duration</i>			
< 1 year	3	2	4
1 – 3 years	12	12	7
3 – 5 years	10	13	9
5 – 10 years	17	13	15
> 10 years	26	22	28
<i>Pain localisation (% , n)</i>			
Back	27.9 (19)	32.3 (20)	20.6 (13)
Neck, shoulders	7.4 (5)	9.7 (6)	9.5 (6)
Limbs or hips	42.6 (29)	30.6 (19)	50.8 (32)
Other	8.8 (6)	4.8 (3)	7.9 (5)
Missing	9	14	7

*Denominator based on numbers allocated to the specific arms, minus any exclusions due to protocol violations.

Table 2: Mean (standard deviation, SD) CPG intensity, median (interquartile range, IQR) CPG disability, and count CPG grade at baseline, 6 months follow-up and difference between the two assessment points for each arm, prescribing, review and treatment as usual (TAU). P-values for within and between arm differences are also reported.

	Prescribing		Review		TAU		P (between groups)
	n*	Mean (SD)	n*	Mean (SD)	n*	Mean (SD)	
Baseline CPG intensity	47	66.1 (16.0)	45	68.4 (17.6)	54	65.4 (18.0)	0.02
6 month follow-up CPG intensity		58.1 (19.5)		67.4 (21.7)		65.6 (19.6)	
Difference CPG intensity		-8.0 (16.3)		-1.0 (16.0)		0.2 (14.9)	
P (within groups)		0.002		0.67		0.93	
		Median [IQR]		Median [IQR]		Median [IQR]	
Baseline CPG disability	48	60.0 [30.0; 75.8]	46	66.7 [45.0; 80.0]	53	56.7 [36.7; 80.0]	0.55
6 Month follow-up CPG disability		40.0 [20.0; 60.0]		53.3 [29.2; 73.3]		50.0 [25.0; 80.0]	
Difference CPG disability		-8.3 [-23.3; 0.0]		-3.3 [-16.7; 10.0]		-3.3 [-21.7; 5.0]	
P (within groups)		0.003		0.15		0.05	
Baseline CPG grade	44	Count (%)	44	Count (%)	48	Count (%)	0.16
I		5 (11.4)		3 (6.8)		5 (10.4)	
II		16 (36.4)		9 (20.5)		13 (27.1)	
III		7 (15.9)		10 (22.7)		13 (27.1)	
VI		16 (36.4)		22 (50.0)		17 (35.4)	
6 month follow-up CPG grade							
I		13 (29.5)		8 (18.2)		6 (12.5)	
II		13 (29.5)		15 (34.1)		17 (35.4)	
III		8 (18.2)		8 (18.2)		11 (22.9)	
IV		10 (22.7)		13 (29.5)		14 (29.2)	
Difference CPG grade							
≤-1		21 (47.7)		17 (38.6)		15 (31.2)	
0		17 (38.6)		25 (56.8)		25 (52.1)	
≥1		6 (13.6)		2 (4.5)		8 (2.1)	
P (within groups)		0.003		0.001		0.17	

*Number of participants in each group who completed the appropriate part of the CPG at both baseline and follow-up.

Table 3: Mean (standard deviation, SD) SF12 Physical Component Score (PCS) and median (interquartile range, IQR) Mental Component Score (MCS) at baseline and 6 month follow-up and difference between the two assessment points for each arm, prescribing, review and treatment as usual (TAU). Within and between arm p-values are also reported.

	Prescribing		Review		TAU		P (between groups)
	n*	Mean (SD)	n*	Mean (SD)	n*	Mean (SD)	
Baseline SF12 PCS	41	33.5 (10.8)	43	32.59(11.38)	45	29.60 (9.71)	0.75
6 month follow-up SF12 PCS		35.3 (10.8)		34.62 (11.26)		32.59 (9.14)	
Difference SF12 PCS		1.8 (7.5)		2.02 (7.56)		2.99 (8.11)	
P (within groups)		0.12		0.09		0.02	
		Median [IQR]		Median (IQR)	45	Median (IQR)	
Baseline SF12 MCS	42	52.4 [42.0; 58.8]	43	47.9 [38.5; 59.9]		51.5 [41.3; 60.7]	0.04
6 month follow-up SF12 MCS		49.6 [42.8; 58.1]		47.9 [38.9; 56.2]		44.7 [37.6; 55.8]	
Difference SF12 MCS		-0.4 [-3.7; 6.0]		-1.2 [-6.6; 4.2]		-3.0 [-10.0; 1.3]	
P (within groups)		0.64		0.37		0.002	

* Number of participants in each group who completed the appropriate part of the SF-12 at both baseline and follow-up.

Table 4: The HADS-Depression (HADS-D) and HADS-Anxiety (HADS-A) count of patients according to severity (normal, mild, moderate or severe) and the difference in severity category between the two assessment points for each arm, prescribing, review and treatment as usual (TAU). Within and between arm p-values are also reported.*

	n	Prescribing	n	Review	n	TAU	P (between groups)
Baseline HADS-D	44	Count (%)	45	Count (%)	53	Count (%)	
Normal		32 (72.7)		31 (68.9)		38 (71.7)	
Mild		8 (18.2)		11 (24.4)		7 (13.2)	
Moderate		3 (6.8)		3 (6.7)		8 (15.1)	
Severe		1 (2.3)		0		0	
6 month follow-up HADS-D							
Normal		32 (72.7)		32 (71.1)		32 (60.4)	
Mild		7 (15.9)		6 (13.3)		10 (18.9)	
Moderate		5 (11.4)		6 (13.3)		8 (15.1)	
Severe		0		1 (2.2)		3 (5.7)	
Difference HADS-D							
≤-1		5 (11.4)		4 (8.9)		2 (3.8)	
0		34 (77.3)		37 (82.0)		40 (75.5)	
≥1		5 (11.4)		4 (8.9)		11 (20.8)	Not valid**
P (within groups)		1.0		0.71		0.03	
Baseline HADS-A	44	Count (%)	43	Count (%)	48	Count (%)	
Normal		25 (56.8)		30 (69.8)		29 (60.4)	
Mild		8 (18.2)		7 (16.3)		9 (18.8)	
Moderate		8 (18.2)		5 (11.6)		8 (16.7)	
Severe		3 (6.8)		1 (2.3)		2 (4.2)	
6 month follow-up HADS-A							
Normal		27 (61.4)		29 (67.4)		32 (66.7)	
Mild		7 (15.9)		6 (14.0)		5 (10.4)	
Moderate		8 (18.2)		6 (14.0)		10 (20.8)	
Severe		2 (4.5)		2 (4.7)		1 (2.1)	
Difference HADS-A							
≤-1		6 (13.6)		3 (7.0)		10 (20.8)	
0		35 (79.5)		33 (76.7)		29 (60.4)	
≥1		3 (6.8)		7 (16.3)		9 (18.8)	0.14
P (within groups)		0.25		0.21		0.55	

* Number of participants in each group who completed the appropriate part of the HADS at both baseline and follow-up.

**Between arms p-value not valid due to low numbers in multiple cells, even after collapsing to three categories.

Table 5: Median HADS-Depression (HADS-D) and HADS-Anxiety (HADS-A) scores (interquartile range, IQR) at baseline and 6 month follow-up and difference between the two assessment point for each arm, prescribing, review and treatment as usual (TAU). Within and between arm p-values are also reported.

	Prescribing		Review		TAU		P (between groups)
	n	Median [IQR]	n	Median [IQR]	n	Median [IQR]	
Baseline HADS-D	42	5.0 [3.0; 8.0]	44	4.5 [2.3; 8.0]	51	5.0 [3.0; 8.0]	0.02
6 month follow-up HADS-D		4.0 [2.0; 8.0]		5.0 [2.0; 8.8]		5.0 [2.0; 10.0]	
Difference HADS-D		-1.0 [-2.0; 0.0]		0.0 [-1.0; 1.8]		0.0 [-1.0; 2.0]	
P (within groups)		0.02		0.33		0.22	
Baseline HADS-A	44	7.0 [3.3; 10.8]	43	5.0 [3.0; 10.0]	48	6.0 [4.0; 10.0]	0.05
6 month follow-up HADS-A		5.0 [2.3; 9.8]		6.0 [3.0; 9.0]		7.0 [4.0; 10.0]	
Difference HADS-A		-1.0 [-2.0; 0.0]		0.0 [-2.0; 2.0]		0.5 [-3.0; 2.0]	
P (within groups)		0.01		0.45		0.81	

* Number of participants in each group who completed the appropriate part of the HADS at both baseline and follow-up.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Box 1 Examples of pharmacist interventions in the prescribing arm

Changes to pain management: 'use paracetamol regularly', 'take tramadol if needed' 'add piroxicam gel PRN', 'given web links to self help groups'

Compliance aid: 'gave written times that this drug could be taken'

Addressing side effects/safety: 'take paracetamol after initial NSAID', 'take senna', 'ordered blood monitoring', 'stop use of two NSAIDS'

General health: 'discussed weight loss', 'invited to practice nurse for BP', 'glucose, lipids and lifestyle update',

Cost minimisation: 'change aspirin EC to plain',

1
2 BOX 2 Examples of quotes from Pharmacists (n=6), GPs (n=23) and patient participants (n=40)
3 on the prescribing intervention
4

5 **Pharmacists (from interviews):**

6
7 **Satisfying** (n=6): 'contact with patients', 'being able to help patients', 'being able to make a
8 difference to long-standing pain'...'even in small ways'
9

10
11 **Interesting** (n=6): 'learning about pain'
12

13 **Challenging** (n=6): 'complex, chronically ill patients'
14

15 **GPs (from interviews):**

16
17 **Support for the service** (n=17): 'it's been a very positive thing'
18

19
20 **Agreement with pharmacists' recommendations** (n=23): 'oh very reasonable suggestions',
21 'tinkering round the edges', 'had been tried already'.
22

23 **Trust in the practice pharmacist** (n=23): 'I respect his professional judgement'
24

25 **Cost effectiveness** (n=6): 'if there's limited resources do we want to spend the money on a
26 pharmacist'.
27

28
29 **Patients (from 3 month questionnaire):**

30
31 **Closed questions:**

32 Proportion agreeing that:

33 The pharmacist was interested in them (89%; 39/44)

34 They were totally satisfied (85%; 39/46)

35 They were told about their treatment (82%; 38/46)

36 Their consultation was thorough (79%; 34/44)

37 They would have liked more time (9%; 4/44)

38 They would have preferred to see their GP (9%; 4/44)

39 Too many people were now involved in their treatment (11%; 5/44).
40
41

42
43 **Open text questions:**

44
45
46 Positive (n=39): 'She was professional, relaxed, pleasant and interested. Excellent!'
47

48 Negative (n=1): 'A waste of time, altered my tablets which made my pain worse'.
49
50
51
52
53
54
55
56
57
58
59
60



CONSORT 2010 checklist of information to include when reporting a randomised trial*

Section/Topic	Item No	Checklist item	Reported on page No
Title and abstract			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	3-4
Introduction			
Background and objectives	2a	Scientific background and explanation of rationale	5
	2b	Specific objectives or hypotheses	5-6
Methods			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	6
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	N/A
Participants	4a	Eligibility criteria for participants	6
	4b	Settings and locations where the data were collected	6
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	7-8
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	8
	6b	Any changes to trial outcomes after the trial commenced, with reasons	N/A
Sample size	7a	How sample size was determined	9
	7b	When applicable, explanation of any interim analyses and stopping guidelines	N/A
Randomisation:			
Sequence generation	8a	Method used to generate the random allocation sequence	7
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	N/A
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	7
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	7
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those	N/A

1			
2		assessing outcomes) and how	
3			
4		11b If relevant, description of the similarity of interventions	N/A
5	Statistical methods	12a Statistical methods used to compare groups for primary and secondary outcomes	9
6		12b Methods for additional analyses, such as subgroup analyses and adjusted analyses	N/A
7			
8	Results		
9	Participant flow (a	13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and	10, figure
10	diagram is strongly	were analysed for the primary outcome	1(p.18)
11	recommended)	13b For each group, losses and exclusions after randomisation, together with reasons	10, figure
12			1(p.18)
13			
14	Recruitment	14a Dates defining the periods of recruitment and follow-up	7-8
15		14b Why the trial ended or was stopped	N/A
16	Baseline data	15 A table showing baseline demographic and clinical characteristics for each group	10, Table 1
17			(p20)
18			
19	Numbers analysed	16 For each group, number of participants (denominator) included in each analysis and whether the analysis was	See Tables
20		by original assigned groups	2,3,4,5 and
21			page 9 (ITT)
22			
23	Outcomes and	17a For each primary and secondary outcome, results for each group, and the estimated effect size and its	See pages
24	estimation	precision (such as 95% confidence interval)	10/11, and
25			Tables
26			2,3,4,5.
27			P values
28			reported
29			
30		17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended	N/A
31	Ancillary analyses	18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing	N/A
32		pre-specified from exploratory	
33			
34	Harms	19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	N/A
35	Discussion		
36	Limitations	20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	12
37	Generalisability	21 Generalisability (external validity, applicability) of the trial findings	12-13
38			
39	Interpretation	22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	13
40	Other information		
41	Registration	23 Registration number and name of trial registry	4
42			

1			
2			
3	Protocol	24	Where the full trial protocol can be accessed, if available
4	Funding	25	Sources of funding and other support (such as supply of drugs), role of funders
5			
6			
7			
8			
9			
10			
11			
12			
13			
14			
15			
16			
17			
18			
19			
20			
21			
22			
23			
24			
25			
26			
27			
28			
29			
30			
31			
32			
33			
34			
35			
36			
37			
38			
39			
40			
41			
42			
43			
44			
45			
46			
47			
48			
49			

*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.

For peer review only



Pharmacist-led management of chronic pain in primary care: results from a randomised controlled exploratory trial

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-002361.R1
Article Type:	Research
Date Submitted by the Author:	25-Jan-2013
Complete List of Authors:	Bruhn, Hanne; University of Aberdeen, Health Services Research Unit Bond, Christine; University of Aberdeen, Elliott, Alison; University of Aberdeen, General Practice and Primary Care Hannaford, Phil; University of Aberdeen Lee, Amanda; University of Aberdeen, Division of Applied Health Sciences McNamee, Paul; University of Aberdeen Smith, Blair; University of Dundee, Watson, Margaret; University of Aberdeen, General Practice and Primary Care Blyth, Annie; University of East Anglia, Norwich Medical School Wright, David; University of East Anglia, Infection Holland, Richard; University of East Anglia,
Primary Subject Heading:	General practice / Family practice
Secondary Subject Heading:	General practice / Family practice, Health services research
Keywords:	PAIN MANAGEMENT, PRIMARY CARE, Clinical trials < THERAPEUTICS

SCHOLARONE™
Manuscripts

only

Title page

Pharmacist-led management of chronic pain in primary care: results from a randomised controlled exploratory trial

Hanne Bruhn, Christine M Bond, Alison M Elliott, Philip C Hannaford, Amanda J Lee, Paul McNamee, Blair H Smith, Margaret C Watson, Annie Blyth, Richard Holland, David Wright

Centre for Healthcare Randomised Trials, Health Services Research Unit, University of Aberdeen, 3rd floor Health Sciences Building, Foresterhill, Aberdeen, AB25 2ZD, UK Hanne Bruhn, Trial Manager

Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Polwarth West Block, Foresterhill, Aberdeen, AB25 2ZD, UK, Christine M Bond, Professor of Primary Care: Pharmacy

Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Polwarth West Block, Foresterhill, Aberdeen, AB25 2ZD, UK, Alison M Elliott, Senior Research Fellow

Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Polwarth West Block, Foresterhill, Aberdeen, AB25 2ZD, UK, Philip C Hannaford, NHS Grampian Chair of Primary Care

Medical Statistics Team, Division of Applied Health Sciences, Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, UK, Amanda J Lee, Professor of Medical Statistics

Health Economics Research Unit, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, UK, Paul McNamee, Reader

Mackenzie Building, Kirsty Semple Way, Ninewells Hospital and Medical School, Dundee, DD2 4RB, UK, Blair H Smith, Professor of Population Science

Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Polwarth West Block, Foresterhill, Aberdeen, AB25 2ZD, UK, Margaret C Watson, Senior Research Fellow

Norwich Medical School, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK, Annie Blyth, Research Associate

Norwich Medical School, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK, Richard Holland, Professor of Public Health Medicine

School of Pharmacy, University of East Anglia, Norwich Research Park, NR4 7TJ, UK, David Wright, Chair in Pharmacy Practice

1
2 Correspondence to: Professor CM Bond c.m.bond@abdn.ac.uk, Centre of Academic Primary
3 Care, Division of Applied Health Sciences, University of Aberdeen, Polwarth West Block,
4 Foresterhill, Aberdeen, AB25 2ZD, UK
5

6
7 The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all
8 authors, [a worldwide licence](#) to the Publishers and its licensees in perpetuity, in all forms, formats and
9 media (whether known now or created in the future), to i) publish, reproduce, distribute, display and
10 store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints,
11 include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii)
12 create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the
13 Contribution, v) the inclusion of electronic links from the Contribution to third party material where-
14 ever it may be located; and, vi) licence any third party to do any or all of the above.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives

To compare the effectiveness of pharmacist medication-review, with or without pharmacist prescribing, with standard care, for patients with chronic pain.

Design

An exploratory randomised controlled trial.

Setting

Six general practices with prescribing pharmacists in Grampian (3) and East Anglia (3).

Participants

Patients on repeat prescribed pain medication (4815) were screened by GPs, and mailed invitations (1397). 196 were randomised and 180 (92%) completed. Exclusion criteria included: severe mental illness, terminally ill, cancer related pain, history of addiction

Randomisation and intervention

Patients were randomised using a remote telephone service to: (i) pharmacist medication-review with face-to-face pharmacist prescribing; or (ii) pharmacist medication-review with feedback to GP and no planned patient contact; or (iii) treatment as usual (TAU). Blinding was not possible.

Outcome measures

Primary outcomes were the Chronic Pain Grade (CPG) and the SF-12v2, together with Hospital Anxiety and Depression Scale (HADS). Outcomes were collected at 0, 3, and 6 months. Ethical approval was obtained.

Results

In the prescribing arm (n=70) two patients were excluded/nine withdrew. In the review arm (n=63) one was excluded/three withdrew. In the TAU arm (n=63) four withdrew. Compared with baseline, patients had an improved CPG in the prescribing arm, 47.7% (21/44; p=0.003), and in the review arm, 38.6% (17/44; p=0.001), but not the TAU group, 31.3% (15/48; ns). The SF-12 PCS showed no effect in the prescribing or review arms but improvement in TAU

1
2 (p=0.02). The SF-12 MCS showed no effect for the prescribing or review arms and deterioration
3 in the TAU arm (p=0.002). HADS scores improved within the prescribing arm for Depression
4 (p=0.022) and Anxiety (p=0.007), between groups (p=0.022 and p=0.045 respectively)
5
6
7

8 Conclusion

9
10 This is the first RCT of pharmacist-prescribing in the UK, and suggests there may be a benefit
11 for patients with chronic pain. A larger trial is required.
12

13
14 Trial registration: www.isrctn.org/ISRCTN06131530. Medical Research Council funding.
15
16
17

18 *Focus:*

- 19 • Chronic pain, (lasting >3 months) affects up to half the adult population, most
20 of whom are primarily managed in primary care but prescribing is often sub-
21 optimal.
22
- 23 • Pharmacists now have prescribing rights but no published research has
24 compared the effectiveness of their prescribing with that of GPs.
25
- 26 • The ~~theory~~ hypothesis was that pharmacist advice (with or without pharmacist
27 prescribing) would lead to better outcomes than usual care
28

29 *Key messages:*

- 30 • The findings suggest [there may be](#) improved pain related outcomes for patients
31 receiving pain related care from a pharmacist prescriber
32
- 33 • A larger trial is called for.
34

35 *Strengths and Limitations*

- 36 • This the first randomised controlled trial of pharmacist prescribing in the UK
37 looking at patient reported clinical outcomes
38
- 39 • The study was designed as an exploratory trial so no power calculation was
40 done
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Chronic pain (pain lasting more than three months) affects up to half the adult United Kingdom (UK) population, and is considered severely limiting in about 15% of cases (1). Recovery is uncommon with nearly 80% of those identified with chronic pain at baseline still reporting chronic pain four years later (2). It adversely affects many aspects of a person's physical and psychological health, and social and economic well being (3-6).

In the UK, most patients with chronic pain present, and are managed, in primary care (7). Although non-pharmacological treatments are available, these are accessed by few patients, with mixed success (e.g. (8-10)). Analgesics prescribed in primary care remain the mainstay of treatment (4), representing substantial workload and cost. Sub-optimal prescribing may lead to poor pain control and other adverse patient outcomes. One study found that the most common medications involved in adverse drug reaction-related emergency admissions involved non-steroidal anti-inflammatory drugs (NSAIDs) (11) which are commonly used to manage pain. Improved prescribing could result in better outcomes and remove the need for more costly, scarce, alternatives.

Pharmacists working in UK general practices are well-placed to improve pain pharmacotherapy because of their expertise in therapeutics, understanding of the poly-pharmacy regimens (12) frequently used in chronic pain management, and established relationships with other primary care colleagues. In the UK National Health Service (NHS), recent regulatory changes now allow accredited pharmacists (as well as some other health care professionals such as nurses) to prescribe prescription-only medicines (POMs) (13). Pharmacists can either be qualified as supplementary prescribers, in which case they operate within an agreed clinical management plan (CMP) in partnership with the doctor and patient, or as an independent prescriber, in which case they can either prescribe completely independently or within a CMP.

However, despite the increasing number of non-medical prescribers, including pharmacists, there has been no rigorous comparisons of the outcomes of non-medical versus GP prescribing. This information is needed to assess the clinical effectiveness of different care models.

This paper reports findings from an exploratory randomised controlled trial (RCT) comparing pharmacist medication review, with or without pharmacist prescribing, with standard care for

1 patients with chronic pain. Development of the trial was informed by earlier feasibility work
2
3 (14,15).
4

5
6 The *a priori* theory was that, in patients with chronic pain, pharmacist advice (with or without
7
8 pharmacist prescribing) would lead to better patient functioning and/or better pain control at
9
10 six months than treatment as usual (TAU).
11

12 **Methods**

13 *Regulatory Issues*

14
15 Ethical approval was granted by the National Research Ethics Service Committee – North of
16
17 Scotland (reference number 09/S0801/107). NHS Research and Development approval was
18
19 granted by NHS Grampian and East Norfolk & Waveney Research Governance Committees.
20
21 Patients gave informed consent before taking part.
22
23

24 *Design*

25
26 An open, exploratory RCT in which patients were randomised to one of three study arms.
27
28 Participants were not blind to allocated treatment arm due to the nature of the intervention.
29
30

31 *Recruitment of practices and independent prescribing pharmacists*

32
33 Practices in the Grampian Health Board area, Scotland (n=18) and East Anglia region of England
34
35 (n=4) known to have an attached Royal Pharmaceutical Society of Great Britain registered
36
37 independent pharmacist prescriber, were eligible to take part. From those indicating a
38
39 willingness to participate, convenience sampling was used to identify six general practices:
40
41 three in Grampian and three in East Anglia.
42

43 *Patient inclusion and exclusion criteria*

44
45 Patients registered with the recruited practices were eligible for inclusion if they were over 18
46
47 years of age, living in their own home, and receiving regular prescribed medication for pain.
48
49 Patients were identified by a computerised search (14) of the drug records of all individuals
50
51 registered with the practice, to identify those who had received either two or more acute
52
53 prescriptions, and/or one repeat prescription within the last 120 days, for an analgesic (British
54
55 National Formulary (BNF section 4.7) and/or non-steroidal anti-inflammatory medication
56
57 (NSAID) (BNF section 10.1.1). Medications which can be used for analgesia but whose primary
58
59 indication is not chronic pain (e.g. triptans, anti-epileptics or anti-depressants) were excluded
60

1 as these drugs identify few additional eligible patients (16). In accordance with trial criteria,
2 GPs excluded and recorded reasons for patients who had: a concomitant severe mental health
3 problem or terminal illness; had suffered recent bereavement; had a known alcohol or drug
4 addiction; suffered pain caused by cancer or other malignancy; were unable to give informed
5 consent; other (unspecified) reasons.
6
7
8
9

10 *Patient recruitment*

11 Eligible patients were sent an invitation pack (letter, information sheet, consent form) by
12 practice staff between March and June 2010. Consent forms were returned directly to the
13 researchers, who sent out a baseline questionnaire. Patients returning completed
14 questionnaires were randomised by the researcher using a telephone randomisation service
15 with a random number allocation which ensured allocation concealment. The allocation
16 sequence was 1:1:1.
17
18
19
20
21
22
23

24 *Intervention*

25 All participating pharmacists took part in a two-day course updating them about pain
26 management. As part of the training, participants defined and agreed the treatment algorithm
27 they would all use.
28
29
30
31

32 'Prescribing' arm: Pharmacists invited patients to a face-to-face consultation. Prior to the
33 consultation, pharmacists completed a paper-based medication review of each patient's
34 medical record and patients were asked to complete a pain diary to inform the consultation. A
35 pharmaceutical care plan was agreed between the pharmacist and the patient. The plan
36 assessed and documented relevant past medical history and current conditions; known
37 allergies and adverse drug reactions; relevant laboratory results; pain-related medications
38 prescribed in the previous 10 years; current pain related prescription medications; current
39 symptoms; lifestyle issues, including units of alcohol consumed per week; recommendations
40 for changes to medication (if any); whether non-pharmaceutical treatments had been
41 considered; and, any other relevant issues. Copies of the pain diary and pharmaceutical care
42 plan are available from the authors on request. At the end of the consultation any required
43 prescriptions for medicines were issued by the pharmacist. Due to Controlled Drug (CD)
44 regulations in place at the time, prescribing for CDs was done using a supplementary
45 prescribing Clinical Management Plan (17), rather than independent prescribing. Patients were
46 followed up either by phone or face-to-face, at each pharmacist's discretion.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 'Review arm': The pharmacists conducted a paper-based medication review focussed on pain-
3 related prescription medications, before creating a pharmaceutical care plan which detailed
4 any recommendations for medication changes. The plan was passed to the patient's GP for
5 implementation. The GPs were asked subsequently about actions taken as a result of the
6 recommendations.
7
8
9

10
11 Treatment as usual (TAU): Patients received standard general practice care.
12
13

14 *Outcome measures*

15
16 There were two primary outcome measures: the Chronic Pain Grade (CPG) and the Medical
17 Outcomes Study 12-item short form version 2 (SF-12v2). Use of both a pain specific and generic
18 outcome measure was based on Initiative on Methods, Measurement, and Pain Assessment in
19 Clinical Trials (IMMPACT) recommendations (18) and an earlier feasibility study (15).
20
21
22
23

24
25 The CPG (19) is a seven item scale which assesses pain severity on two dimensions: disability
26 and intensity. The scale classifies pain according to level of intensity and disability (I (low
27 disability-low intensity) to IV (high disability-severely limiting)).
28
29
30

31
32 The SF-12v2 is a generic health and functioning scale (20), previously used in population-based
33 studies of pain (21, 22). A Physical (PCS) and Mental Component Score (MCS) was calculated,
34 ranging from 0 to 100; a higher score indicates better functioning.
35
36
37
38

39
40 A secondary outcome measure was the Hospital Anxiety and Depression Scale (HADS) (23), a
41 14-item screening instrument which identifies the possible and probable caseness of anxiety (7
42 items (HADS-A)) and depression (7 items (HADS-D)); each item scored from 0 (not present) to 3
43 (highly present). Standard thresholds and previously used labels (24) were applied (no
44 depression/anxiety (0-7), mild (8-10), moderate (11-15) or severe (>15)).
45
46
47
48

49 *Data collection*

50 *Participant questionnaires*

51
52 Questionnaires were posted to participants at baseline (pre-randomisation), and 3 and 6
53 months post-randomisation (follow-up was conducted between July 2010 and January 2011).
54
55

56
57 Up to two reminders were sent. Questionnaire content included the outcome measures
58
59
60

1 described above together with items on: demographic status (baseline only); screening items
2 to confirm eligibility (baseline only); duration of pain condition (baseline only); location of pain;
3 Morisky Medication Adherence Scale 4 (MMAS-4) (25); participant satisfaction (11 statements
4 derived from the feasibility study for the prescribing arm (3 months only) and additional
5 comments by participants. The MMAS-4 provides a score of self-reported adherence to
6 medication regimen. Scores range from 0 (low adherence) to 4 (high adherence).
7
8
9

10 11 12 *Follow-up interviews with staff*

13 Post-intervention, all pharmacists and all GPs in participating practices were invited to take part
14 in semi-structured interviews, carried out face-to-face when possible, otherwise by telephone.
15 Interviews were taped, transcribed verbatim and content analysis was carried out.
16
17
18
19

20 21 *Sample size*

22 As this was an exploratory trial to estimate the effect size for a larger trial, no formal sample
23 size calculation was possible (26). We aimed to recruit 30 participants per practice (excluding
24 those recruited for training purposes) i.e. 180 in total. This was deemed sufficient to give
25 reliable effect size estimates for the primary outcome measures of chronic pain grade or health
26 status.
27
28
29
30
31

32 33 *Data management and analysis*

34 Data were entered into identical SPSS databases at each site and accuracy checks carried out
35 on 10% before databases were merged. Descriptive statistics included means and standard
36 deviations (SD) for normally distributed continuous data, medians (interquartile range (IQR))
37 for skewed continuous data and percentages (n) for categorical data. Analysis was conducted
38 on an intention-to-treat basis for participants with complete data on relevant measures using
39 SPSS version 18.
40
41
42
43
44
45

46 Exploratory analyses for parametric data included the paired t-test for within-arm comparisons
47 of mean difference between baseline and 6 months and one-way ANOVA for between arm
48 comparisons of mean difference. For non-parametric data it included the Wilcoxon Signed
49 Rank test for within-arm comparisons of median difference and the Kruskal Wallis test for
50 between arm comparisons of median difference. Categorical data was analysed using the
51 marginal homogeneity test for within-arm comparisons (with null hypothesis that the
52 distribution of CPG grade or HADS group does not change between baseline and 6 month
53
54
55
56
57
58
59
60

1 follow-up) and the Chi-squared test for between arm comparisons; analyses reported here are
2 based on 6 month follow-up data (other than for participant experiences). Within arm effect
3 sizes, expressed in terms of a Pearson correlation coefficient (r) have been calculated using the
4 formulas from Rosenthal (1991) (27). Effect sizes can be directly compared using Cohen's
5 (1988) (28) criteria of $r=0.1$ (small effect); $r=0.3$ (medium effect) and $r=0.5$ (large effect).
6
7
8
9

10 11 12 **Results**

13 *Response rates and demography*

14 Six of the seven practices approached participated. GPs excluded 12% (392/3281) of patients,
15 mostly those with dementia. There was no statistically significant difference between
16 participants and non-participants in terms of age, gender, and index of multiple deprivation.
17 Figure 1 shows the flow of participants through the study. Overall, the consent rate was 25%
18 (356/1397) and the recruitment rate was 14% (196/1397).
19
20
21
22
23
24

25 [INSERT FIGURE 1 HERE]
26
27

28 Eighty six percent of participants (251/289) returned baseline questionnaires, of whom 232
29 were randomised (36 participants were randomised to one of the two intervention arms for
30 training purposes and were not included in any further analysis and 19 were not included as
31 recruitment target had been met). The overall follow-up rate at 3 months was 86%
32 (161/187) and at 6 months 84% (152/180).
33
34
35
36
37

38 As shown in Table 1, groups were similar at baseline for demographic and socioeconomic
39 variables and pain data. Most participants were married, Caucasian and female, older (mean
40 (SD) age 65 (12.6) years), had an annual income of <£25,000 and had suffered from pain for at
41 least five years. Most (57%;103/181) reported being fully adherent to their medication
42 regimen (MMAS-4, median 4.0 (IQR 3.0- 4.0)) (15 missing MMAS scores).
43
44
45
46

47 [INSERT TABLE 1 HERE]
48
49

50 In the prescribing arm, 78% (53/68) attended an initial prescribing consultation, 31 had at least
51 one planned follow-up (of which 34/37 were conducted by phone) and 130 recommendations
52 were made for 92% (49/53) of participants seen. Examples are shown in Box 1. The median
53 time taken for the note-based record review was 35 minutes (IQR 20.0, 45.0), the consultation
54
55
56
57
58
59
60

1 was 30 minutes (IQR 20.0, 40.0), careplan preparation 10 minutes (IQR 10.0, 20.0) and median
2 duration of follow-ups was 10 minutes (IQR 5.0- 15.0).
3
4

5
6 [INSERT BOX 1 HERE]
7

8
9 In the review arm 97% (60/62) of participants' records were reviewed (note there was one post
10 randomisation exclusion) for whom 197 recommendations were made. Where GP feedback
11 was provided (n=48), they generally agreed with pharmacists' recommendations, which were
12 fully implemented for 20 participants (two by the pharmacist following request by GP), partially
13 for 19 participants and not at all for nine participants. The median time taken for the note-
14 based record review was 30 minutes (IQR 24.3, 45.0), and careplan preparation was 10
15 minutes (IQR 5.0, 20.0).
16
17
18
19
20
21

22 23 *Clinical outcome measures*

24 Table 2 shows the mean (SD) or median (IQR) of the CPG for each arm at baseline and 6 month
25 follow-up. Table 3 shows the SF-12 scores and Table 4 shows the HADS-A and HADS-D results.
26
27
28

29
30 [INSERT TABLE 2,3,4, HERE]
31

32 In the prescribing arm, there was a statistically significant within arm improvement for the CPG
33 intensity (p=0.002, effect size (r)=0.45) and disability (p=0.003, effect size (r)=0.43) subscales,
34 and between arms on the intensity sub-scale (p=0.02), but not the disability subscale (p=0.55)
35 (Table 2). There was a significant within-arm improvement in overall CPG grade in the
36 prescribing (p=0.003) and review arm (p=0.001), but not in the TAU arm. The SF-12 Physical
37 Component Score showed a statistically significant within arm improvement in the TAU arm
38 (p=0.02, effect size (r)=0.35) (Table 3), but not between trial arms. The SF-12 Mental
39 Component Score showed a statistically significant deterioration in the TAU arm (p=0.002,
40 effect size (r)=0.45)(Table 3), as did the HADS-D (p=0.03, Table 4). Analysis was also carried out
41 on the non-categorised HADS scores which showed a statistically significant improvement
42 within the prescribing arm for Depression (p=0.022) and Anxiety (p=0.007). These were both
43 significant between groups (p=0.022 and p=0.045 respectively) (Table 5).
44
45
46
47
48
49
50
51
52
53

54 *Acceptability of the pharmacist prescribing intervention*

55 All six pharmacists and 56% of the GPs (23/41) were interviewed. All pharmacists and most GPs
56 were positive about the intervention, although some GPs suggested that the pharmacists'
57
58
59
60

1 recommendations had been minor and questioned the cost-effectiveness of the service.
2
3 Patient participants were generally positive about the pharmacist prescribing service although
4
5 some concerns were identified, as illustrated by the quotes shown in Box 2.
6
7

8 [INSERT BOX 2 HERE]
9

10 Discussion

11 *Principal findings*

12 This exploratory RCT of pharmacist-led management of patients with chronic pain suggests that
13
14 pharmacist prescribing (and possibly pharmacist review alone) may be effective in improving
15
16 pain-related outcomes and be acceptable to both patients and most professionals. There was
17
18 an indication of a positive effect on emotional health, but no measurable effect on general
19
20 health.
21
22

23 *Strengths and weaknesses*

24 This was the first RCT to assess clinical and humanistic outcomes after pharmacist prescribing
25
26 for any clinical condition compared to usual GP care, and the first RCT to specifically assess
27
28 pharmacist-led management of chronic pain, compared with usual GP care. It was based on
29
30 extensive development and feasibility work (14,15) in line with MRC framework for
31
32 development and evaluation of complex interventions (29). A range of validated outcome
33
34 measures was included, as well as a parallel qualitative process evaluation which assessed
35
36 satisfaction and acceptability. The inclusion of six practices and their associated pharmacists
37
38 from both Scotland and England increased the generalisability of the findings. Pharmacists
39
40 received formal training and agreed and used a common treatment algorithm which should
41
42 have increased standardisation of treatment. The preponderance of females (overall 62%) and
43
44 average age of 65 years reflects the wider chronic pain population (1) as does the distribution
45
46 of pain site (30, 31,)
47

48 There were, however limitations. Although high follow-up response rates were achieved at
49
50 both three (86%) and six months (85%) only 25% of eligible patients entered the trial. This low
51
52 initial consent rate is in line with other studies (32, 33), but may cause unknown biases
53
54 including problems of generalisability, as does the solely Caucasian ethnicity. Concerns
55
56 identified by participants during the formal feedback e.g. having too many people involved in
57
58 one's care may have contributed to poor response rates and rewording of participant
59
60

1 recruitment documentation to reassure participants of the role of the pharmacist could
2 address this. More participants withdrew in the prescribing arm compared with the other two
3 arms, which might be attributed to the need for an additional practice visit. The study was an
4 exploratory trial so no formal power calculation was undertaken. However, because there were
5 no published MIDs available to estimate effect size for the outcomes in this population, it was important
6 to present the actual clinical magnitude of change in outcome at 6 months alongside a statistical
7 assessment of this change (p-value). This allows an assessment of both clinical and statistical
8 significance simultaneously with the caveat that this is an exploratory study. With around 50 patients
9 per arm, this was deemed sufficient numbers to examine the change in outcome measures with
10 appropriate within and between group univariate statistical tests. Due to the nature of the
11 intervention, no participants were blind to their group allocation, and so some outcomes,
12 especially the qualitative components, may have been affected by social desirability bias.

13
14
15
16
17
18
19
20
21
22
23
24 Our main outcome measures were self-reported, but this is the norm in pain studies as pain is a
25 subjective experience (18). Furthermore we do not know how important the observed
26 differences were to participants. Following precedents set in previous research (25), and
27 because there is no consensus on an alternative measure (34) we used the HADS as a tool to
28 classify people by severity of depression and anxiety. However it is strictly a screening tool, and
29 the four levels of severity have not been formally validated. We therefore also compared
30 outcomes using it as a continuous scale.

31 *Relationship with other studies*

32 This study is important because no other RCT has evaluated pharmacist prescribing and few
33 studies, and importantly no RCTs, have evaluated pharmacist interventions for pain. In
34 pharmacist prescribing most research has focussed on reported experiences of professionals
35 and patients, and not used validated outcome measures. Yet pharmacist prescribing is now
36 widely practised. For pain, there have been a few small studies. Briggs et al (2008) (35)
37 conducted a small before-and-after evaluation (involving 65 patients) of a nurse and
38 pharmacist-led chronic pain clinic in primary care. Pain intensity Visual Analogue Scale scores
39 reduced significantly over six months. Another evaluation of 26 patients using a medication
40 review service provided jointly by a physiotherapist and pharmacist in the UK, reported
41 improvement in pain control for 88% of patients (36).

1
2 The CPG was found to show a graded effect across the three arms, showing discrimination with
3 both direction and strength of improvement, suggesting maximum benefit for those in the
4 pharmacist prescribing arm. However, the reduction in overall score appears to be mediated by
5 a change in the intensity of pain subscale rather than in pain-related disability. The effect size
6 of 0.45 suggests this could be an important difference. In contrast, the SF-12, a measure of
7 general health and functionality showed no significant difference between intervention arms,
8 reflecting either no effect or or lack of power to detect an effect.
9
10
11
12
13

14
15 Whilst most participants in this study were already within the normal range on the HADS scale,
16 and therefore had minimal chance of improvement, there were nonetheless suggestions of
17 better outcomes in participants in the prescribing arm. Including a range of instruments is in
18 line with IMMPACT recommendations (37), which state that focus should be on the whole
19 person, not just about pain. However, this needs to be balanced with minimising participant
20 burden.
21
22
23
24

25 26 *Explanations, implications, and future research*

27
28 The number of pharmacists' recommendations per participant was higher in the review arm
29 than in the prescribing arm. This might seem contradictory to the possible greater benefit
30 found in the prescribing arm. However, in the prescribing arm pharmacists met the participant
31 and may have more readily identified and dismissed suggestions previously tried. The interview
32 feedback highlighted that some recommendations for change, whilst sensible, had been tried
33 already. This might also be the reason why there were only 60% of pharmacist
34 recommendations with which the GP fully agreed. Self-reported adherence to medication at
35 baseline was good. Despite this, the pharmacists still improved pain outcomes in the
36 prescribing arm. This could have been due to changes in medications and/or participant
37 education about optimal timing for administration of analgesic medicines. Further research is
38 needed to confirm the beneficial effect of pharmacist prescribing and its sustainability.
39
40
41
42
43
44
45
46
47

48 **Conclusion**

49
50 Our results suggest that pharmacist prescribing (and possibly pharmacist review alone) for
51 patients with chronic pain is feasible, acceptable and may lead to improvements in pain and
52 other measures. A larger fully-powered trial is now needed to confirm these findings.
53
54

55 56 **Data sharing statement**

1
2 Consent was not obtained from participants for data sharing; the presented data are
3 anonymised and there is no risk of individual identification. Requests for data should be made to
4 the contact author who will provide this in a format in which risk of patient identification will be
5 minimal.
6
7

8 9 **Conflict of interest statement**

10 All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf
11 (available on request from the corresponding author) and declare: no support from any organisation for
12 the submitted work; no financial relationships with any organisations that might have an interest in the
13 submitted work in the previous 3 years; no other relationships or activities that could appear to have
14 influenced the submitted work.
15
16
17
18

19 **Authors' contributions**

20 HB and CB drafted the manuscript.
21

22 All authors:

- 23
24
25
26
27 1) made substantial contributions to conception and design, or acquisition of data, or analysis and
28 interpretation of data;
29
30
31 2) were involved in drafting the manuscript or revising it critically for important intellectual content; and
32
33
34 3) have given final approval of the version to be published.
35

36 **Acknowledgements**

37 We thank the participating patients, practices and pharmacists. We would also like to thank
38 Kirsten Harrild (Medical Statistics, UOA) for statistical support. Rick Adams (School of
39 Pharmacy, UEA) helped design and deliver the pharmacist training and Lesley Thomson (NHS
40 Grampian) helped design the pharmacist data collection forms. The patient postal
41 questionnaire was based on work by Nicola Cooper and the Norfolk Arthritis Register (NOAR)
42 research team. The Pharmacy-Led Management of Chronic Pain Study Team acknowledges the
43 financial support of NHS Research Scotland (NRS), through Scottish Primary Care Research
44 Network Northeast. The work was conducted as part of the Aberdeen Pain Research
45 Collaboration. The project was funded by the Medical Research Council. They had no further
46 involvement in any aspect of study conduct; all researchers were independent of the funding
47 body.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 All authors had access to all of the study data and can take responsibility for the integrity of the
3 data and the accuracy of the data analysis.
4

5 6 **References**

- 7
8 (1) Elliott AM, Smith BH, Penny KI, Smith WC, Chambers WA. The epidemiology of chronic pain
9 in the community. *Lancet* 1999;354:1248-1252.
10
11 (2) Elliott AM, Smith BH, Hannaford P, Smith WC, Chambers WA. The course of chronic pain in
12 the community: results of a 4-year follow-up study. *Pain* 2002;99:299-307.
13
14 (3) Becker N, Bondegaard Thomsen A, Olsen AK, Sjøgren P, Bech P, Eriksen J. Pain epidemiology
15 and health related quality of life in chronic non-malignant pain center patients referred to
16 a Danish multidisciplinary. *Pain* 1997;73:393-400.
17
18 (4) Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe:
19 prevalence, impact on daily life, and treatment. *Eur J Pain* 2006;10:287-333.
20
21 (5) Gureje O, Von Korff M, Simon GE, Gater R. Persistent pain and well-being: a World Health
22 Organization Study in Primary Care. *JAMA* 1998;280:147-151.
23
24 (6) Magni G, Marchetti M, Moreschi C, Merskey H, Luchini SR. Chronic musculoskeletal pain and
25 depressive symptoms in the National Health and Nutrition Examination. I. Epidemiologic
26 follow-up study. *Pain* 1993;53:163-168.
27
28 (7) Sullivan MD, Turner JA, Romano J. Chronic pain in primary care: identification and
29 management of psychological factors. *J Fam Pract* 1991;32:193-199.
30
31 (8) Green S, Buchbinder R, Hetrick SE. Physiotherapy interventions for shoulder pain. *Cochrane*
32 *Database of Syst Rev* 2010(9):Art. No.: CD004258. DOI: 10.1002/14651858.CD004258.
33
34 (9) Eccleston C, Williams, A. C. D. C., Morley S. Psychological therapies for the management of
35 chronic pain (excluding headache)
36 in adults. *Cochrane Database Syst Rev* 2009 Apr 15;(2):CD007407. DOI:
37 10.1002/14651858.CD007407.pub2.
38
39 (10) Haetzman M, Elliott AM, Smith BH, Hannaford P, Chambers WA. Chronic pain and the use
40 of conventional and alternative therapy. *Family Practice* 2003;20(2):147-154.
41
42 (11) Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug
43 reactions as cause of admission to hospital: prospective analysis of 18 820 patients. *BMJ*
44 2004;329:15.
45
46 (12) Krska J, Cromarty JA, Arris F, Jamieson D, Hansford D, Duffus PR, et al. Pharmacist-led
47 medication review in patients over 65: a randomized, controlled trial in primary care. *Age and*
48 *Ageing* 2001;30:205-211.
49
50
51
52
53
54
55
56
57
58
59
60

1
2 (13) Department of Health. Improving patients' access to medicines: A guide to implementing
3 nurse and pharmacist independent prescribing within the NHS England. Department of Health
4 2006.

5
6 (14) McDermott ME, Smith BH, Elliott AM, Bond CM, Hannaford P, Chambers WA. The use of
7 medication for chronic pain in primary care, and the potential for intervention by practice-
8 based pharmacist. *Family Practice* 2006;23:46-52.

9
10 (15) Bruhn H, Bond CM, Elliott AM, Hannaford PC, Lee AJ, McNamee P, et al. Developing an RCT
11 of general practice-based, pharmacist-led, management of chronic pain: the PIPPC study. *IJPP*
12 2010;18(Supplement 2).

13
14 (16) Smith BH, Read JRM, Chambers WAC, Watt B, Grimshaw JM. Researching chronic pain:
15 identification of a community based sample. *The Pain Clinic* 1996;9:73-76.

16
17 (17) Department of Health. Supplementary prescribing by nurses and pharmacists within the
18 NHS in England: A guide for implementation. Department of Health 2003.

19
20 (18) Turk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB, et al. Core outcome
21 domains for chronic pain clinical trials: IMMPACT recommendations. *Pain* 2003 12;106(3):337-
22 345.

23
24 (19) Von Korff M, Ormel J, Keefe FJ, Dworkin SF. Grading the severity of chronic pain. *Pain*
25 1992;50:133-149.

26
27 (20) Ware JE, Kosinski M, Turner-Bowker DM, Sundaram M, Gandek B, Maruish ME. User's
28 Manual for the SF-12v2 Health Survey. Second edition ed.: QualityMetric, Incorporated, 2009;
29 2009.

30
31 (21) Nicholl BI, Macfarlane GJ, Davies KA, Morriss R, Dickens C, McBeth J. Premorbid
32 psychosocial factors are associated with poor health-related quality of life in subjects with new
33 onset of chronic widespread pain - results from the EPIFUND study. *Pain* 2009;141:119-126.

34
35 (22) Carmona L, Ballina J, Gabriel R, Laffon A. The burden of musculoskeletal diseases in the
36 general population of Spain: results from a national survey. *Ann Rheum Dis* 2001;60:1040-1045.

37
38 (23) Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand*
39 1983 Jun;67(6):361-370.


40
41 (24) Snaith RP, Zigmond AS. HADS: Hospital Anxiety and Depression Scale. Windsor: NFER
42 Nelson; 1994.

43
44 (25) Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported
45 measure of medication adherence. *Med Care* 1986 Jan;24(1):67-74.

46
47 (26) Lancaster GA, Dood S, Williamson PR. Design and analysis of pilot studies:
48 recommendations for good practice. *J Eval Clin Pract* 2004;10(2):307-312.

- 1
2 (27) Rosenthal R. Meta-analytic procedures for social research (revised). Newbury Park, CA.
3 Sage 1991.
4
- 5 (28) Cohen J. Statistical power analysis for the behavioural sciences (2nd edition). New York.
6 Academic Press. (29) Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M.
7 Developing and evaluating complex interventions: the new Medical Research Council guidance.
8 BMJ 2008;337:a1655.
9
- 10 (30) Magni M, Caldieron C, Rigatti-Luchini S, Merskey H. Chronic musculo-skeletal pain and
11 depressive symptoms in the general population. An analysis of the 1st National Health and
12 Nutrition Examination Survey data. Pain 1990; 43: 299-307
13
- 14 (31) Gureje O, Von Korff M, Simon GE, Gater R. Persistent pain and well-being. A World Health
15 Organization study in primary care. Journal of the American Medical Association 1998; 280:
16 147-151.
17
- 18 (32) Community Pharmacy Medicines Management Project Evaluation Team. The MEDMAN
19 study: a randomized controlled trial of community pharmacy-led medicines management for
20 patients with coronary heart disease. Family Practice 2007;24:189-200.
21
- 22 (33) Treweek S, Mitchell E, Pitkethly M, Cook J, Kjeldstrøm M, Johansen M, et al. Strategies to
23 improve recruitment to randomised controlled trials. Cochrane Database Syst Rev
24 2010;(4):MR000013 2011.
25
- 26 (34) Cameron IM, Cardy A, Crawford JR, du Toit Schalk W, Hay S, Lawton K, et al. Measuring
27 depression severity in general practice: discriminatory performance of the PHQ-9, HADS-D, and
28 BDI-II. Br J Gen Pract 2011;61:e419-e426(8).
29
- 30 (35) Briggs M, Closs SJ, Marczewski K, Barratt J. A feasibility study of a combined
31 nurse/pharmacist-led chronic pain clinic in primary care. Qual Prim Care 2008;16:91-94.
32
- 33 (36) Anonymous. Pharmacist and physiotherapist-led community outreach pain programme
34 improve quality of life. The Pharmaceutical Journal 2005;275:14.
35
- 36 (37) Turk DC, Dworkin RH, Revicki D, Harding G, Burke LB, Cella D, et al. Identifying important
37 outcome domains for chronic pain clinical trials: An IMMPACT survey of people with pain.
38 2008;137:276-285.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1: CONSORT Flow Diagram



1
2 *In the **Grampian Health Board area**, on the basis of response rates in the earlier feasibility study (241
3 screened patients resulted in 22 recruited) only a random sample of eligible participants were screened
4 (15). In East Anglia all eligible patients were screened.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1: Baseline demographic, socio-economic and pain data of patients by study arm, prescribing, review and treatment as usual (TAU)

	Prescribing*	Review*	TAU*
	(n = 68)	(n = 62)	(n = 63)
Age: mean (SD)	66.1 (12.1)	65.7 (14.2)	64.9 (11.6)
Missing	1	1	0
Gender (% female)	54.4 (37)	74.2 (46)	58.7 (37)
<i>Marital status</i>			
Married	43	30	41
Single	6	6	3
Divorced/widow	10	21	13
Other	6	4	6
Missing	3	1	0
<i>Highest educational level achieved</i>			
No qualifications	30	27	21
O grade or equivalent	12	6	14
Higher/A-level/NVQ3/SVQ3	6	8	7
Tertiary education/NVQ4/NVQ5	18	17	14
Other	2	1	4
Missing	0	3	3
<i>Employment status</i>			
Employed	16	14	9
Unemployed	3	5	1
Retired	38	35	34
Long term sick/disabled	7	5	9
Other	3	2	7
Missing	1	1	3
<i>Household annual income before tax</i>			
Less than £9,999	13	15	10
£10,000 - £14,999	14	18	22
£15,000 - £24,999	14	12	12
£25,000 – or more	22	11	8
Missing	5	6	11
<i>Ethnic group</i>			
Caucasian	67	62	61
Other	1		
Missing	0	0	2
<i>Pain duration</i>			
< 1 year	3	2	4
1 – 3 years	12	12	7
3 – 5 years	10	13	9
5 – 10 years	17	13	15
> 10 years	26	22	28
<i>Pain localisation (% , n)</i>			
Back	27.9 (19)	32.3 (20)	20.6 (13)
Neck, shoulders	7.4 (5)	9.7 (6)	9.5 (6)
Limbs or hips	42.6 (29)	30.6 (19)	50.8 (32)
Other	8.8 (6)	4.8 (3)	7.9 (5)
Missing	9	14	7

*Denominator based on numbers allocated to the specific arms, minus any exclusions due to protocol violations.

Table 2: Mean (standard deviation, SD) CPG intensity, median (interquartile range, IQR) CPG disability, and count CPG grade at baseline, 6 months follow-up and difference between the two assessment points for each arm, prescribing, review and treatment as usual (TAU). P-values for within and between arm differences are also reported.

	Prescribing		Review		TAU		P (between groups ^{***})
	n*	Mean (SD)	n*	Mean (SD)	n*	Mean (SD)	
Baseline CPG intensity	47	66.1 (16.0)	45	68.4 (17.6)	54	65.4 (18.0)	
6 month follow-up CPG intensity		58.1 (19.5)		67.4 (21.7)		65.6 (19.6)	
Difference CPG intensity		-8.0 (16.3)		-1.0 (16.0)		0.2 (14.9)	
P (within groups ^{**})		0.002		0.67		0.93	0.02
Effect size (r)		0.45		0.07		0.01	
		Median [IQR]		Median [IQR]		Median [IQR]	
Baseline CPG disability	48	60.0 [30.0; 75.8]	46	66.7 [45.0; 80.0]	53	56.7 [36.7; 80.0]	
6 Month follow-up CPG disability		40.0 [20.0; 60.0]		53.3 [29.2; 73.3]		50.0 [25.0; 80.0]	
Difference CPG disability		-8.3 [-23.3; 0.0]		-3.3 [-16.7; 10.0]		-3.3 [-21.7; 5.0]	
P (within groups ^{**})		0.003		0.15		0.05	0.55
Effect size (r)		0.43		0.20		0.26	
Baseline CPG grade	44	Count (%)	44	Count (%)	48	Count (%)	
	I	5 (11.4)		3 (6.8)		5 (10.4)	
	II	16 (36.4)		9 (20.5)		13 (27.1)	
	III	7 (15.9)		10 (22.7)		13 (27.1)	
	VI	16 (36.4)		22 (50.0)		17 (35.4)	
6 month follow-up CPG grade							
	I	13 (29.5)		8 (18.2)		6 (12.5)	
	II	13 (29.5)		15 (34.1)		17 (35.4)	
	III	8 (18.2)		8 (18.2)		11 (22.9)	
	IV	10 (22.7)		13 (29.5)		14 (29.2)	
Difference CPG grade							
	≤-1	21 (47.7)		17 (38.6)		15 (31.2)	
	0	17 (38.6)		25 (56.8)		25 (52.1)	
	≥1	6 (13.6)		2 (4.5)		8 (2.1)	0.16
P (within groups ^{***})		0.003		0.001		0.17	

*Number of participants in each group who completed the appropriate part of the CPG at both baseline and follow-up.

** From paired t-test, Wilcoxon signed rank test or marginal homogeneity test as appropriate

*** From ANOVA on mean difference, Kruskal-Wallis on median difference or chi-squared test on difference in CPG grade as appropriate

Table 3: Mean (standard deviation, SD) SF12 Physical Component Score (PCS) and median (interquartile range, IQR) Mental Component Score (MCS) at baseline and 6 month follow-up and difference between the two assessment points for each arm, prescribing, review and treatment as usual (TAU). Within and between arm p-values are also reported.

	Prescribing		Review		TAU		P (between groups ^{***})
	n*	Mean (SD)	n*	Mean (SD)	n*	Mean (SD)	
Baseline SF12 PCS	41	33.5 (10.8)	43	32.59(11.38)	45	29.60 (9.71)	0.75
6 month follow-up SF12 PCS		35.3 (10.8)		34.62 (11.26)		32.59 (9.14)	
Difference SF12 PCS		1.8 (7.5)		2.02 (7.56)		2.99 (8.11)	
P (within groups ^{**})		0.12		0.09		0.02	
Effect size (r)		0.24		0.26		0.35	
		Median [IQR]		Median (IQR)	45	Median (IQR)	
Baseline SF12 MCS	42	52.4 [42.0; 58.8]	43	47.9 [38.5; 59.9]		51.5 [41.3; 60.7]	0.04
6 month follow-up SF12 MCS		49.6 [42.8; 58.1]		47.9 [38.9; 56.2]		44.7 [37.6; 55.8]	
Difference SF12 MCS		-0.4 [-3.7; 6.0]		-1.2 [-6.6; 4.2]		-3.0 [-10.0; 1.3]	
P (within groups ^{**})		0.64		0.37		0.002	
Effect size (r)		0.07		0.14		0.46	

* Number of participants in each group who completed the appropriate part of the SF-12 at both baseline and follow-up.

** From paired t-test or Wilcoxon signed rank test as appropriate

*** From ANOVA on mean difference or Kruskal-Wallis test on median difference as appropriate

Table 4: The HADS-Depression (HADS-D) and HADS-Anxiety (HADS-A) count of patients according to severity (normal, mild, moderate or severe) and the difference in severity category between the two assessment points for each arm, prescribing, review and treatment as usual (TAU). Within and between arm p-values are also reported.*

	n	Prescribing	n	Review	n	TAU	P (between groups***)
Baseline HADS-D	44	Count (%)	45	Count (%)	53	Count (%)	
Normal		32 (72.7)		31 (68.9)		38 (71.7)	
Mild		8 (18.2)		11 (24.4)		7 (13.2)	
Moderate		3 (6.8)		3 (6.7)		8 (15.1)	
Severe		1 (2.3)		0		0	
6 month follow-up HADS-D							
Normal		32 (72.7)		32 (71.1)		32 (60.4)	
Mild		7 (15.9)		6 (13.3)		10 (18.9)	
Moderate		5 (11.4)		6 (13.3)		8 (15.1)	
Severe		0		1 (2.2)		3 (5.7)	
Difference HADS-D							
≤-1		5 (11.4)		4 (8.9)		2 (3.8)	
0		34 (77.3)		37 (82.0)		40 (75.5)	
≥1		5 (11.4)		4 (8.9)		11 (20.8)	0.32
P (within groups**)		1.0		0.71		0.03	
Baseline HADS-A	44	Count (%)	43	Count (%)	48	Count (%)	
Normal		25 (56.8)		30 (69.8)		29 (60.4)	
Mild		8 (18.2)		7 (16.3)		9 (18.8)	
Moderate		8 (18.2)		5 (11.6)		8 (16.7)	
Severe		3 (6.8)		1 (2.3)		2 (4.2)	
6 month follow-up HADS-A							
Normal		27 (61.4)		29 (67.4)		32 (66.7)	
Mild		7 (15.9)		6 (14.0)		5 (10.4)	
Moderate		8 (18.2)		6 (14.0)		10 (20.8)	
Severe		2 (4.5)		2 (4.7)		1 (2.1)	
Difference HADS-A							
≤-1		6 (13.6)		3 (7.0)		10 (20.8)	
0		35 (79.5)		33 (76.7)		29 (60.4)	
≥1		3 (6.8)		7 (16.3)		9 (18.8)	0.14
P (within groups**)		0.25		0.21		0.55	

* Number of participants in each group who completed the appropriate part of the HADS at both baseline and follow-up.

** From marginal homogeneity test

*** From chi-squared test on difference in HADS

Table 5: Median HADS-Depression (HADS-D) and HADS-Anxiety (HADS-A) scores (interquartile range, IQR) at baseline and 6 month follow-up and difference between the two assessment point for each arm, prescribing, review and treatment as usual (TAU). Within and between arm p-values are also reported.

	Prescribing		Review		TAU		P (between groups)
	n	Median [IQR]	n	Median [IQR]	n	Median [IQR]	
Baseline HADS-D	42	5.0 [3.0; 8.0]	44	4.5 [2.3; 8.0]	51	5.0 [3.0; 8.0]	0.02
6 month follow-up HADS-D		4.0 [2.0; 8.0]		5.0 [2.0; 8.8]		5.0 [2.0; 10.0]	
Difference HADS-D		-1.0 [-2.0; 0.0]		0.0 [-1.0; 1.8]		0.0 [-1.0; 2.0]	
P (within groups)		0.02		0.33		0.22	
Baseline HADS-A	44	7.0 [3.3; 10.8]	43	5.0 [3.0; 10.0]	48	6.0 [4.0; 10.0]	0.05
6 month follow-up HADS-A		5.0 [2.3; 9.8]		6.0 [3.0; 9.0]		7.0 [4.0; 10.0]	
Difference HADS-A		-1.0 [-2.0; 0.0]		0.0 [-2.0; 2.0]		0.5 [-3.0; 2.0]	
P (within groups)		0.01		0.45		0.81	

* Number of participants in each group who completed the appropriate part of the HADS at both baseline and follow-up.

Box 1 Examples of pharmacist interventions in the prescribing arm

Changes to pain management: 'use paracetamol regularly', 'take tramadol if needed' 'add piroxicam gel PRN', 'given web links to self help groups'

Compliance aid: ' gave written times that this drug could be taken'

Addressing side effects/safety: 'take paracetamol after initial NSAID', 'take senna', 'ordered blood monitoring', 'stop use of two NSAIDS'

General health: 'discussed weight loss', 'invited to practice nurse for BP', 'glucose, lipids and lifestyle update',

Cost minimisation: 'change aspirin EC to plain',

1
2 BOX 2 Examples of quotes from Pharmacists (n=6), GPs (n=23) and patient participants (n=40)
3 on the prescribing intervention
4

5
6 **Pharmacists (from interviews):**

7 **Satisfying** (n=6): 'contact with patients', 'being able to help patients', 'being able to make a
8 difference to long-standing pain'...'even in small ways'
9

10
11 **Interesting** (n=6): 'learning about pain'

12
13 **Challenging** (n=6): 'complex, chronically ill patients'

14
15 **GPs (from interviews):**

16
17 **Support for the service** (n=17): 'it's been a very positive thing'

18
19 **Agreement with pharmacists' recommendations** (n=23): 'oh very reasonable suggestions',
20 'tinkering round the edges', 'had been tried already'.
21

22
23 **Trust in the practice pharmacist** (n=23): 'I respect his professional judgement'

24
25 **Cost effectiveness** (n=6): 'if there's limited resources do we want to spend the money on a
26 pharmacist'.
27

28
29 **Patients (from 3 month questionnaire):**

30
31 **Closed questions:**

32 Proportion agreeing that:

33 The pharmacist was interested in them (89%; 39/44)

34 They were totally satisfied (85%; 39/46)

35 They were told about their treatment (82%; 38/46)

36 Their consultation was thorough (79%; 34/44)

37 They would have liked more time (9%; 4/44)

38 They would have preferred to see their GP (9%; 4/44)

39 Too many people were now involved in their treatment (11%; 5/44).
40

41
42 **Open text questions:**

43
44 Positive (n=39): 'She was professional, relaxed, pleasant and interested. Excellent!'
45

46
47 Negative (n=1): 'A waste of time, altered my tablets which made my pain worse'.
48
49
50
51
52
53
54
55
56
57
58
59
60

Title page

Pharmacist-led management of chronic pain in primary care: results from a randomised controlled exploratory trial

Hanne Bruhn, Christine M Bond, Alison M Elliott, Philip C Hannaford, Amanda J Lee, Paul McNamee, Blair H Smith, Margaret C Watson, Annie Blyth, Richard Holland, David Wright

Centre for Healthcare Randomised Trials, Health Services Research Unit, University of Aberdeen, 3rd floor Health Sciences Building, Foresterhill, Aberdeen, AB25 2ZD, UK Hanne Bruhn, Trial Manager

Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Polwarth West Block, Foresterhill, Aberdeen, AB25 2ZD, UK, Christine M Bond, Professor of Primary Care: Pharmacy

Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Polwarth West Block, Foresterhill, Aberdeen, AB25 2ZD, UK, Alison M Elliott, Senior Research Fellow

Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Polwarth West Block, Foresterhill, Aberdeen, AB25 2ZD, UK, Philip C Hannaford, NHS Grampian Chair of Primary Care

Medical Statistics Team, Division of Applied Health Sciences~~Population Health, 1st floor,~~
Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, UK, Amanda J Lee, Professor of Medical Statistics

Health Economics Research Unit, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, UK, Paul McNamee, Reader

Mackenzie Building, Kirsty Semple Way, Ninewells Hospital and Medical School, Dundee, DD2 4RB, UK, Blair H Smith, Professor of Population Science

Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Polwarth West Block, Foresterhill, Aberdeen, AB25 2ZD, UK, Margaret C Watson, Senior Research Fellow

Norwich Medical School, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK, Annie Blyth, Research Associate

Norwich Medical School, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK, Richard Holland, Professor of Public Health Medicine

School of Pharmacy, University of East Anglia, Norwich Research Park, NR4 7TJ, UK, David Wright, Chair in Pharmacy Practice

1
2
3
4
5
6 Correspondence to: Professor CM Bond c.m.bond@abdn.ac.uk, Centre of Academic Primary
7 Care, Division of Applied Health Sciences, University of Aberdeen, Polwarth West Block,
8 Foresterhill, Aberdeen, AB25 2ZD, UK
9

10 The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all
11 authors, [a worldwide licence](#) to the Publishers and its licensees in perpetuity, in all forms, formats and
12 media (whether known now or created in the future), to i) publish, reproduce, distribute, display and
13 store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints,
14 include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii)
15 create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the
16 Contribution, v) the inclusion of electronic links from the Contribution to third party material where-
17 ever it may be located; and, vi) licence any third party to do any or all of the above.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives

To compare the effectiveness of pharmacist medication-review, with or without [pharmacist](#) prescribing, with standard care, for patients with chronic pain.

Design

An exploratory randomised controlled trial.

Setting

Six general practices with prescribing pharmacists in Grampian (3) and East Anglia (3).

Participants

Patients on repeat prescribed pain medication (4815) were screened by GPs, and mailed invitations (1397). 196 were randomised and 180 (92%) completed. Exclusion criteria included: severe mental illness, terminally ill, cancer related pain, history of addiction

Randomisation and intervention

Patients were randomised using a remote telephone service to: (i) pharmacist medication-review with face-to-face pharmacist prescribing; or (ii) pharmacist medication-review with feedback to GP and no planned patient contact; or (iii) treatment as usual (TAU). Blinding was not possible.

Outcome measures

Primary outcomes were the Chronic Pain Grade (CPG) and the SF-12v2, together with Hospital Anxiety and Depression Scale (HADS). Outcomes were collected at 0, 3, and 6 months. Ethical approval was obtained.

Results

In the prescribing arm (n=70) two patients were excluded/nine withdrew. In the review arm (n=63) one was excluded/three withdrew. In the TAU arm (n=63) four withdrew. Compared with baseline, patients had an improved CPG in the prescribing arm, 47.7% (21/44; p=0.003), and in the review arm, 38.6% (17/44; p=0.001), but not the TAU group, 31.3% (15/48; ns). The SF-12 PCS showed no effect in the prescribing or review arms but improvement in TAU

1
2
3
4
5
6 (p=0.02). The SF-12 MCS showed no effect for the prescribing or review arms and deterioration
7 in the TAU arm (p=0.002). HADS scores improved within the prescribing arm for Depression
8 (p=0.022) and Anxiety (p=0.007), between groups (p=0.022 and p=0.045 respectively)
9

10
11 **-Conclusion**

12 This is the first RCT of pharmacist-prescribing in the UK, and suggests [a-~~there may be a~~-benefit](#)
13 for patients with chronic pain. A larger trial is required.
14

15
16 Trial registration: www.isrctn.org/ISRCTN06131530. Medical Research Council funding.
17
18
19

20 *Focus:*

- 21 • Chronic pain, (lasting >3 months) affects up to half the adult population, most
22 of whom are primarily managed in primary care but prescribing is often sub-
23 optimal.
- 24 • Pharmacists now have prescribing rights but no published research has
25 compared the effectiveness of their prescribing with that of GPs.
- 26 • The ~~theory~~ hypothesis was that pharmacist advice (with or without pharmacist
27 prescribing) would lead to better outcomes than usual care
28

29 *Key messages:*

- 30 • The findings suggest [there may be](#) improved pain related outcomes for patients
31 receiving pain related care from a pharmacist prescriber
- 32 • A larger trial is called for.
33

34 *Strengths and Limitations*

- 35 • This the first randomised controlled trial of pharmacist prescribing in the UK
36 looking at patient reported clinical outcomes
- 37 • The study was designed as an exploratory trial so no power calculation was
38 done
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Chronic pain (pain lasting more than three months) affects up to half the adult United Kingdom (UK) population, and is considered severely limiting in about 15% of cases (1). Recovery is uncommon with nearly 80% of those identified with chronic pain at baseline still reporting chronic pain four years later (2). It adversely affects many aspects of a person's physical and psychological health, and social and economic well being (3-6).

In the UK, most patients with chronic pain present, and are managed, in primary care (7).

Although non-pharmacological treatments are available, these are accessed by few patients, with mixed success (e.g. (8-10)). Analgesics prescribed in primary care remain the mainstay of treatment (4), representing substantial workload and cost. Sub-optimal prescribing may lead to poor pain control and other adverse patient outcomes. One study found that the most common medications involved in adverse drug reaction-related emergency admissions involved non-steroidal anti-inflammatory drugs (NSAIDs) (11) [which are commonly used to manage pain](#). Improved prescribing could result in better outcomes and remove the need for more costly, scarce, alternatives.

Pharmacists working in UK general practices are well-placed to improve pain pharmacotherapy because of their expertise in therapeutics, understanding of the poly-pharmacy regimens (12) frequently used in chronic pain management, and established relationships with other primary care colleagues. In the UK National Health Service (NHS), recent regulatory changes now allow accredited pharmacists (as well as some other health care professionals such as nurses) to prescribe prescription-only medicines (POMs) (13). [Pharmacists can either be qualified as supplementary prescribers, in which case they operate within an agree-d clinical management plan \(CMP\) in partnership with the doctor and patient, or as an independent prescriber, in which case they can either prescribe completely independently or within a CMP.-](#)

However, despite the increasing number of non-medical prescribers, including pharmacists, there has been no rigorous comparisons of the outcomes of non-medical versus GP prescribing. This information is needed to assess the clinical effectiveness of different care models.

This paper reports findings from an exploratory randomised controlled trial (RCT) comparing pharmacist medication review, with or without pharmacist prescribing, with standard care for

1
2
3
4
5 patients with chronic pain. Development of the trial was informed by earlier feasibility work
6 (14,15).
7
8

9 The *a priori theory hypothesis* was that, in patients with chronic pain, pharmacist advice (with
10 or without pharmacist prescribing) would lead to better patient functioning and/or better pain
11 control at six months than treatment as usual (TAU). *The hypothesis was developed prior to*
12 *data collection.*
13
14
15
16
17
18
19

20 **Methods**

21 *Regulatory Issues*

22 Ethical approval was granted by the National Research Ethics Service Committee – North of
23 Scotland (reference number 09/S0801/107). NHS Research and Development approval was
24 granted by NHS Grampian and East Norfolk & Waveney Research Governance Committees.
25 Patients gave informed consent before taking part.
26
27
28

29 *Design*

30 An open, exploratory RCT in which patients were randomised to one of three study arms.
31 Participants were not blind to allocated treatment arm due to the nature of the intervention.
32
33

34 *Recruitment of practices and independent prescribing pharmacists*

35 Practices in [the Grampian Health Board area](#), Scotland (n=18) and East Anglia [region of](#),
36 England (n=4) known to have an attached Royal Pharmaceutical Society of Great Britain
37 registered independent pharmacist prescriber, were eligible to take part. From those indicating
38 a willingness to participate, convenience sampling was used to identify six general practices:
39 three in Grampian and three in East Anglia.
40
41
42
43

44 *Patient inclusion and exclusion criteria*

45 Patients registered with the recruited practices were eligible for inclusion if they were over 18
46 years of age, living in their own home, and receiving regular prescribed medication for pain.
47
48

49 Patients were identified by a computerised search [\(14\) \(5 McDermott, M. E. 2006\)](#) of the drug
50 records of all individuals registered with the practice, to identify those who had received either
51 two or more acute prescriptions, and/or one repeat prescription within the last 120 days, for
52 an analgesic (British National Formulary (BNF section 4.7) and/or non-steroidal anti-
53
54
55
56
57
58
59
60

Comment [g1]: Think we need to stay away from word hypothesis since it implies a powered study

Formatted: Font: Italic

1
2
3
4
5
6 inflammatory medication (NSAID) (BNF section 10.1.1). Medications which can be used for
7 analgesia but whose primary indication is not chronic pain (e.g. triptans, anti-epileptics or anti-
8 depressants) were excluded as these drugs identify few additional eligible patients (16). In
9 accordance with trial criteria, GPs excluded and recorded reasons for patients who had: a
10 concomitant severe mental health problem or terminal illness; had suffered recent
11 bereavement; had a known alcohol or drug addiction; suffered pain caused by cancer or other
12 malignancy; were unable to give informed consent; other (unspecified) reasons.
13
14
15

16 *Patient recruitment*

17
18 Eligible patients were sent an invitation pack (letter, information sheet, consent form) by
19 practice staff between March and June 2010. Consent forms were returned directly to the
20 researchers, who sent out a baseline questionnaire. Patients returning completed
21 questionnaires were randomised by the researcher using a telephone randomisation service
22 with a random number allocation which ensured allocation concealment. The allocation
23 sequence was 1:1:1.
24
25
26
27

28 *Intervention*

29
30 All participating pharmacists took part in a two-day course updating them about pain
31 management. As part of the training, participants defined and agreed the treatment algorithm
32 they would all use.
33
34

35 'Prescribing' arm: Pharmacists invited patients to a face-to-face consultation. Prior to the
36 consultation, pharmacists completed a paper-based medication review of each patient's
37 medical record and patients were asked to complete a pain diary to inform the consultation. A
38 pharmaceutical care plan was agreed between the pharmacist and the patient. The plan
39 assessed and documented relevant past medical history and current conditions; known
40 allergies and adverse drug reactions; relevant laboratory results; pain-related medications
41 prescribed in the previous 10 years; current pain related prescription medications; current
42 symptoms; lifestyle issues, including units of alcohol consumed per week; recommendations
43 for changes to medication (if any); whether non-pharmaceutical treatments had been
44 considered; and, any other relevant issues. [Copies of the pain diary and pharmaceutical care
45 plan are available -from the authors on request.](#) At the end of the consultation any required
46 prescriptions for medicines were issued by the pharmacist. Due to Controlled Drug (CD)
47 regulations in place at the time, prescribing for CDs was done using a supplementary
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 prescribing Clinical Management Plan (17), rather than independent prescribing. Patients were
7 followed up either by phone or face-to-face, at each pharmacist's discretion.
8

9
10 'Review arm': The pharmacists conducted a paper-based medication review focussed on pain-
11 related prescription medications, before creating a pharmaceutical care plan which detailed
12 any recommendations for medication changes. The plan was passed to the patient's GP for
13 implementation. The GPs were asked subsequently about actions taken as a result of the
14 recommendations. The GPs were asked subsequently about actions taken as a result of the
15 recommendations.
16

17
18 Treatment as usual (TAU): Patients received standard general practice care.
19

20 *Outcome measures*

21 There were two primary outcome measures: the Chronic Pain Grade (CPG) and the Medical
22 Outcomes Study 12-item short form version 2 (SF-12v2). Use of both a pain specific and generic
23 outcome measure was based on Initiative on Methods, Measurement, and Pain Assessment in
24 Clinical Trials (IMMPACT) recommendations (18) and an earlier (18,19) feasibility study (15).
25
26

27
28
29 The CPG (1920) is a seven item scale which assesses pain severity on two dimensions: disability
30 and intensity. The scale classifies pain according to level of intensity and disability (I (low
31 disability-low intensity) to IV (high disability-severely limiting)).
32
33

34
35 The SF-12v2 is a generic health and functioning scale (2021), previously used in population-
36 based studies of pain (21, 2222,23). A Physical (PCS) and Mental Component Score (MCS) was
37 calculated, ranging from 0 to 100; a higher score indicates better functioning.
38
39

40
41 A secondary outcome measure was the (4) Hospital Anxiety and Depression Scale (HADS
42 (2324), a 14-item screening instrument which identifies the possible and probable caseness of
43 anxiety (7 items (HADS-A)) and depression (7 items (HADS-D)); each item scored from 0 (not
44 present) to 3 (highly present). Standard thresholds and previously used labels (245) were
45 applied (no depression/anxiety (0-7), mild (8-10), moderate (11-15) or severe (>15)).
46
47
48
49

50 *Data collection*

51 *Participant questionnaires*

52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 Questionnaires were posted to participants at baseline (pre-randomisation), and 3 and 6
7 months post-randomisation (follow-up was conducted between July 2010 and January 2011).

8 Up to two reminders were sent. Questionnaire content included the outcome measures
9 described above together with items on: demographic status (baseline only); screening items
10 to confirm eligibility (baseline only); duration of pain condition (baseline only); location of pain;
11 Morisky Medication Adherence Scale 4 (MMAS-4) (256); participant satisfaction (11 statements
12 derived from the feasibility study for the prescribing arm (3 months only) and additional
13 comments by participants. The MMAS-4 provides a score of self-reported adherence to
14 medication regimen. Scores range from 0 (low adherence) to 4 (high adherence).
15
16
17
18
19

20 *Follow-up interviews with staff*

21 Post-intervention, all pharmacists and all GPs in participating practices were invited to take part
22 in semi-structured interviews, carried out face-to-face when possible, otherwise by telephone.
23 Interviews were taped, transcribed verbatim and content analysis was carried out.
24
25
26

27 *Sample size*

28 As this was an exploratory trial to estimate the effect size for a larger trial, no formal sample
29 size calculation was possible (267). We aimed to recruit 30 participants per practice (excluding
30 those recruited for training purposes) i.e. 180 in total. This was deemed sufficient to give
31 reliable effect size estimates for the primary outcome measures of chronic pain grade or health
32 status.
33
34
35
36

37 *Data management and analysis*

38 Data were entered into identical SPSS databases at each site and accuracy checks carried out
39 on 10% before databases were merged. Descriptive statistics included means and standard
40 deviations (SD) for normally distributed continuous data, medians (interquartile range (IQR))
41 for skewed continuous data and percentages (n) for categorical data. Analysis was conducted
42 on an intention-to-treat basis for participants with complete data on relevant measures using
43 SPSS version 18.
44
45
46
47
48

49 Exploratory analyses for parametric data included the paired t-test for within-arm comparisons
50 [of mean difference between baseline and 6 months](#) and one-way ANOVA for between arm
51 comparisons [of mean difference](#). For non-parametric data it included the Wilcoxon Signed
52 Rank test for within-arm comparisons [of median difference](#) and the Kruskal Wallis test for
53
54
55
56
57
58
59
60

1
2
3
4
5
6 between arm comparisons of median difference. Categorical data was analysed using the
7 marginal homogeneity test for within-arm comparisons of (with null hypothesis that the
8 distribution of CPG grade or HADS group does not change between baseline and 6 month
9 follow-up) and the Chi-squared test for between arm comparisons; analyses reported here are
10 based on 6 month follow-up data (other than for participant experiences). Within arm effect
11 sizes, expressed in terms of a Pearson correlation coefficient (r) have been calculated using the
12 formulas from Rosenthal (1991) (27). Effect sizes can be directly compared using Cohen's
13 (1988) (28) criteria of r=0.1 (small effect); r=0.3 (medium effect) and r=0.5 (large effect).

Formatted: Not Highlight

Formatted: Not Highlight

19 Results

20 *Response rates and demography*

21 Six of the seven practices approached participated. GPs excluded 12% (392/3281) of patients,
22 mostly those with dementia. There was no statistically significant difference between
23 participants and non-participants in terms of age, gender, and index of multiple deprivation.
24 Figure 1 shows the flow of participants through the study. Overall, the consent rate was 25%
25 (356/1397) and the recruitment rate was 14% (196/1397).
26
27
28
29

30 [INSERT FIGURE 1 HERE]

31
32 Eighty six percent of participants (251/289) returned baseline questionnaires, of whom 232
33 were randomised (36 participants were randomised to one of the two intervention arms for
34 training purposes and were not included in any further analysis and 19 were not included as
35 recruitment target had been met). The overall follow-up rate at 3 months was 86%
36 (161/187) and at 6 months 84% (152/180).
37
38
39

40 As shown in Table 1, groups were similar at baseline for demographic and socioeconomic
41 variables and pain data. Most participants were married, Caucasian and female, older (mean
42 (SD) age 65 (12.6) years), had an annual income of <£25,000 and had suffered from pain for at
43 least five years. Most (57%;103/181) reported being fully adherent to their medication
44 regimen (MMAS-4, median 4.0 (IQR 3.0- 4.0)) (15 missing MMAS scores).
45
46
47
48

49 [INSERT TABLE 1 HERE]

50
51 In the prescribing arm, 78% (53/68) attended an initial prescribing consultation, 31 had at least
52 one planned follow-up (of which 34/37 were generally conducted by phone) and 130
53
54
55

1
2
3
4
5
6 recommendations were made for 92% (49/53) of participants seen. Examples are shown in Box
7 1. The median time taken for the note-based record review was 35 minutes (IQR 20.0, 45.0),
8 the consultation was 30 minutes (IQR 20.0, 40.0), careplan preparation 10 minutes (IQR 10.0,
9 20.0) and median duration of follow-ups was 10 minutes (IQR 5.0- 15.0).

10
11
12 [INSERT BOX 1 HERE]

13
14 In the review arm 97% (60/62) of participants' records were reviewed (note there was one post
15 randomisation exclusion) for whom 197 recommendations were made. Where GP feedback
16 was provided (n=48), they generally agreed with pharmacists' recommendations, which were
17 fully implemented for 20 participants (two by the pharmacist following request by GP), partially
18 for 19 participants and not at all for nine participants. The median time taken for the note-
19 based record review was 30 minutes (IQR 24.3, 45.0), and careplan preparation was 10
20 minutes (IQR 5.0, 20.0).

21 22 23 24 25 26 27 *Clinical outcome measures*

28 Table 2 shows the mean (SD) or median (IQR) of the CPG for each arm at baseline and 6 month
29 follow-up. Table 3 shows the SF-12 scores and Table 4 shows the HADS-A and HADS-D results.

30
31
32 [INSERT TABLE 2,3,4, HERE]

33
34 In the prescribing arm, there was a statistically significant within arm improvement for the CPG
35 intensity ($p=0.002$, [effect size \(r\)=0.45](#)) and disability ($p=0.003$, [effect size \(r\)=0.43](#)) subscales,
36 and between arms on the intensity sub-scale ($p=0.02$), but not the disability subscale ($p=0.55$)
37 (Table 2). There was a significant within-arm improvement in overall CPG grade in the
38 prescribing ($p=0.003$) and review arm ($p=0.001$), but not in the TAU arm. The SF-12 Physical
39 Component Score showed a statistically significant within arm improvement in the TAU arm
40 ($p=0.02$, [effect size \(r\)=0.35](#)) (Table 3), but not between trial arms. The SF-12 Mental
41 Component Score showed a statistically significant deterioration in the TAU arm ($p=0.002$,
42 [effect size \(r\)=0.45](#)) (Table 3), as did the HADS-D ($p=0.03$, Table 4). Analysis was also carried out
43 on the non-categorised HADS scores which showed a statistically significant improvement
44 within the prescribing arm for Depression ($p=0.022$) and Anxiety ($p=0.007$). These were both
45 significant between groups ($p=0.022$ and $p=0.045$ respectively) (Table 5).

46 47 48 49 50 51 52 53 54 *Acceptability of the pharmacist prescribing intervention*

1
2
3
4
5 All six pharmacists and 56% of the GPs (23/41) were interviewed. All pharmacists and most GPs
6 were positive about the intervention, although some GPs suggested that the pharmacists'
7 recommendations had been minor and questioned the cost-effectiveness of the service.
8
9 Patient participants were generally positive about the pharmacist prescribing service although
10 some concerns were identified, as illustrated by the quotes shown in Box 2.
11
12

13
14 [INSERT BOX 2 HERE]
15

16 Discussion

17 *Principal findings*

18 This exploratory RCT of pharmacist-led management of patients with chronic pain suggests that
19 pharmacist prescribing (and possibly pharmacist review alone) may be effective in improving
20 pain-related outcomes and be acceptable to both patients and [most](#) professionals. There was
21 an indication of a positive effect on emotional health, but no measurable effect on general
22 health.
23
24
25
26
27

28 *Strengths and weaknesses*

29 This was the first RCT to assess clinical and humanistic outcomes after pharmacist prescribing
30 for any clinical condition compared to usual GP care, and the first RCT to specifically assess
31 pharmacist-led management of chronic pain, compared with usual GP care. It was based on
32 extensive development and feasibility work (14,15) in line with MRC framework for
33 development and evaluation of complex interventions ([2829](#)). A range of validated outcome
34 measures was included, as well as a parallel qualitative process evaluation which [demonstrated](#)
35 [assessed](#) satisfaction and acceptability. The inclusion of six practices and their associated
36 pharmacists from both Scotland and England increased the generalisability of the findings.
37
38
39
40
41

42 Pharmacists [received formal training and](#) agreed and used a common treatment algorithm
43 which should have increased standardisation of treatment. [The preponderance of females](#)
44 [\(overall 62%\) and average age of 65 years reflects the wider chronic pain population \(1\) as](#)
45 [does the distribution of pain site \(30, 31,29,30\)](#)
46
47
48

49 There were, however limitations. Although high follow-up response rates were achieved at
50 both three (86%) and six months (85%) only 25% of eligible patients entered the trial. This low
51 initial consent rate is in line with other studies ([32, 3331,3229,30](#)), but may cause unknown
52 biases including problems of generalisability, [as does the solely Caucasian- ethnicity. Concerns](#)
53
54
55
56
57
58
59
60

1
2
3
4
5
6 [identified by participants during the formal feedback e.g. having too many people involved in](#)
7 [one's care may have contributed to poor response rates and r](#)ewording of participant
8 recruitment documentation [to reassure participants of the role of the pharmacist](#) could
9 address [this. some of the concerns identified by participant feedback e.g. having too many](#)
10 [people involved in one's care.](#) More participants withdrew in the prescribing arm compared
11 with the other two arms, which might be attributed to the need for an additional practice visit.
12
13 The study was an exploratory trial so no formal power calculation was undertaken. ~~However,~~
14 ~~because there were no published MIDs available to estimate effect size for the outcomes in this~~
15 ~~population, it was important to present the actual clinical magnitude of change in outcome at 6 months~~
16 ~~alongside a statistical assessment of this change (p-value). This allows an assessment of both clinical~~
17 ~~and statistical significance simultaneously with the caveat that this is an exploratory study. With around~~
18 ~~50 patients per arm, this was deemed sufficient numbers to examine the change in outcome measures~~
19 ~~with appropriate within and between group univariate statistical tests. because of no prior~~
20 ~~knowledge of effect size.~~ Due to the nature of the intervention, no participants were blind to
21 their group allocation, and so some outcomes, especially the qualitative components, may have
22 been affected by social desirability bias.
23
24
25
26
27
28
29
30

31 Our main outcome measures were self-reported, but this is the norm in pain studies as pain is a
32 subjective experience (18). Furthermore we do not know how important the observed
33 differences were to participants. Following precedents set in previous research (25), and
34 because there is no consensus on an alternative measure (3431) we used the HADS as a tool to
35 classify people by severity of depression and anxiety. However it is strictly a screening tool, and
36 the four levels of severity have not been formally validated. We therefore also compared
37 outcomes using it as a continuous scale.
38
39
40
41

42 *Relationship with other studies*

43 This study is important because no other RCT has evaluated pharmacist prescribing and few
44 studies, and importantly no RCTs, have evaluated pharmacist interventions for pain. In
45 pharmacist prescribing most research has focussed on reported experiences of professionals
46 and patients, and not used validated outcome measures. Yet pharmacist prescribing is now
47 widely practised. For pain, there have been a few small studies. Briggs et al (2008) (3542)
48 conducted a small before-and-after evaluation (involving 65 patients) of a nurse and
49 pharmacist-led chronic pain clinic in primary care. Pain intensity Visual Analogue Scale scores
50
51
52
53
54

1
2
3
4
5 reduced significantly over six months. Another evaluation of 26 patients using a medication
6 review service provided jointly by a physiotherapist and pharmacist [in the UK](#), reported
7 improvement in pain control for 88% of patients ([3653](#)).
8
9

10 The CPG was found to show a graded effect across the three arms, showing discrimination with
11 both direction and strength of improvement, suggesting maximum benefit for those in the
12 pharmacist prescribing arm. However, the reduction in overall score appears to be mediated by
13 a change in the intensity of pain subscale rather than in pain-related disability. [The effect size
14 of 0.45 suggests this could be an important difference.](#) In contrast, the SF-12, a measure of
15 general health and functionality showed no significant difference between intervention arms,
16 reflecting either no effect or or lack of power to detect an effect.
17
18
19
20
21

22 Whilst most participants in this study were already within the normal range on the HADS scale,
23 and therefore had minimal chance of improvement, there were nonetheless suggestions of
24 better outcomes in participants in the prescribing arm. Including a range of instruments is in
25 line with IMMPACT recommendations ([3764](#)), which state that focus should be on the whole
26 person, not just about pain. However, this needs to be balanced with minimising participant
27 burden.
28
29
30
31

32 *Explanations, implications, and future research*

33 The number of pharmacists' recommendations per participant was higher in the review arm
34 than in the prescribing arm. This might seem contradictory to the possible greater benefit
35 found in the prescribing arm. However, in the prescribing arm pharmacists met the participant
36 and may have more readily identified and dismissed suggestions previously -tried. The
37 interview feedback highlighted that some recommendations for change, whilst sensible, had
38 been tried already. This might also be the reason why there were only 60% of pharmacist
39 recommendations with which the GP fully agreed. Self-reported adherence to medication at
40 baseline was good. Despite this, the pharmacists still improved pain outcomes in the
41 prescribing arm. This could have been due to changes in medications and/or participant
42 education about optimal timing for administration of analgesic medicines. Further research is
43 needed to confirm the beneficial effect of pharmacist prescribing and its sustainability.
44
45
46
47
48
49
50

51 **Conclusion**

1
2
3
4
5
6 Our results suggest that pharmacist prescribing -(and possibly pharmacist review alone) -for
7 patients with chronic pain is feasible, acceptable and may lead to improvements...acceptable
8 and leads to improvements_ in pain and other measures. A larger fully-powered trial is now
9 needed to confirm these findings.
10

Formatted: Font: (Default) +Body (Calibri),
12 pt, Not Bold, Not Italic

11 **Data sharing statement**

12 Consent was not obtained from participants for data sharing; the presented data are
13 anonymised and there is no risk of individual -identification. Requests for data- should be made to
14 the contact author who will provide this in a format in which risk of patient identification will be
15 minimal.
16

17 **Conflict of interest statement**

18 All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf
19 (available on request from the corresponding author) and declare: no support from any organisation for
20 the submitted work; no financial relationships with any organisations that might have an interest in the
21 submitted work in the previous 3 years; no other relationships or activities that could appear to have
22 influenced the submitted work.
23

24 **Authors' contributions**

25 HB and CB drafted the manuscript.

26 All authors:

- 27 1) made substantial contributions to conception and design, or acquisition of data, or analysis and
28 interpretation of data;
- 29 2) were involved in drafting the manuscript or revising it critically for important intellectual content; and
- 30 3) have given final approval of the version to be published.
31

32 **Acknowledgements**

33 We thank the participating patients, practices and pharmacists. We would also like to thank
34 Kirsten Harrild (Medical Statistics, UOA) for statistical support. Rick Adams (School of
35 Pharmacy, UEA) helped design and deliver the pharmacist training and Lesley Thomson (NHS
36 Grampian) helped design the pharmacist data collection forms. The patient postal
37 questionnaire was based on work by Nicola Cooper and the Norfolk Arthritis Register (NOAR)
38 research team. The Pharmacy-Led Management of Chronic Pain Study Team acknowledges the
39
40
41
42
43

1
2
3
4
5 financial support of NHS Research Scotland (NRS), through Scottish Primary Care Research
6 Network Northeast. The work was conducted as part of the Aberdeen Pain Research
7 Collaboration. The project was funded by the Medical Research Council. They had no further
8 involvement in any aspect of study conduct; all researchers were independent of the funding
9 body.
10
11
12

13 All authors had access to all of the study data and can take responsibility for the integrity of the
14 data and the accuracy of the data analysis.
15
16

17 References

18
19 (1) Elliott AM, Smith BH, Penny KI, Smith WC, Chambers WA. The epidemiology of chronic pain
20 in the community. *Lancet* 1999;354:1248-1252.
21

22 (2) Elliott AM, Smith BH, Hannaford P, Smith WC, Chambers WA. The course of chronic pain in
23 the community: results of a 4-year follow-up study. *Pain* 2002;99:299-307.
24

25 (3) Becker N, Bondegaard Thomsen A, Olsen AK, Sjøgren P, Bech P, Eriksen J. Pain epidemiology
26 and health related quality of life in chronic non-malignant pain center patients referred to
27 a Danish multidisciplinary. *Pain* 1997;73:393-400.
28

29 (4) Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe:
30 prevalence, impact on daily life, and treatment. *Eur J Pain* 2006;10:287-333.
31

32 (5) Gureje O, Von Korff M, Simon GE, Gater R. Persistent pain and well-being: a World Health
33 Organization Study in Primary Care. *JAMA* 1998;280:147-151.
34

35 (6) Magni G, Marchetti M, Moreschi C, Merskey H, Luchini SR. Chronic musculoskeletal pain and
36 depressive symptoms in the National Health and Nutrition Examination. I. Epidemiologic
37 follow-up study. *Pain* 1993;53:163-168.
38

39 (7) Sullivan MD, Turner JA, Romano J. Chronic pain in primary care: identification and
40 management of psychological factors. *J Fam Pract* 1991;32:193-199.
41

42 (8) Green S, Buchbinder R, Hetrick SE. Physiotherapy interventions for shoulder pain. *Cochrane*
43 *Database of Syst Rev* 2010(9):Art. No.: CD004258. DOI: 10.1002/14651858.CD004258.
44

45 (9) Eccleston C, Williams, A. C. D. C., Morley S. Psychological therapies for the management of
46 chronic pain (excluding headache)
47 in adults. *Cochrane Database Syst Rev* 2009 Apr 15;(2):CD007407. DOI:
48 10.1002/14651858.CD007407.pub2.
49

50 (10) Haetzman M, Elliott AM, Smith BH, Hannaford P, Chambers WA. Chronic pain and the use
51 of conventional and alternative therapy. *Family Practice* 2003;20(2):147-154.
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6 (11) Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug
7 reactions as cause of admission to hospital: prospective analysis of 18 820 patients. *BMJ*
8 2004;329:15.
- 9
10 (12) Krska J, Cromarty JA, Arris F, Jamieson D, Hansford D, Duffus PR, et al. Pharmacist-led
11 medication review in patients over 65: a randomized, controlled trial in primary care. *Age and*
12 *Ageing* 2001;30:205-211.
- 13
14 (13) Department of Health. Improving patients' access to medicines: A guide to implementing
15 nurse and pharmacist independent prescribing within the NHS England. Department of Health
16 2006.
- 17
18 (14) McDermott ME, Smith BH, Elliott AM, Bond CM, Hannaford P, Chambers WA. The use of
19 medication for chronic pain in primary care, and the potential for intervention by practice-
20 based pharmacist. *Family Practice* 2006;23:46-52.
- 21
22 (15) Bruhn H, Bond CM, Elliott AM, Hannaford PC, Lee AJ, McNamee P, et al. Developing an RCT
23 of general practice-based, pharmacist-led, management of chronic pain: the PIPPC study. *IJPP*
24 2010;18(Supplement 2).
- 25
26 (16) Smith BH, Read JRM, Chambers WAC, Watt B, Grimshaw JM. Researching chronic pain:
27 identification of a community based sample. *The Pain Clinic* 1996;9:73-76.
- 28
29 (17) Department of Health. Supplementary prescribing by nurses and pharmacists within the
30 NHS in England: A guide for implementation. Department of Health 2003.
- 31
32 (18) Turk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB, et al. Core outcome
33 domains for chronic pain clinical trials: IMMEDIATE recommendations. *Pain* 2003 12;106(3):337-
34 345.
- 35
36 ~~(19) The Community Pharmacy Medicines Management Project Evaluation Team. The~~
37 ~~MEDMAN study: a randomized controlled trial of community pharmacy led medicines~~
38 ~~management for patients with coronary heart disease. *Family Practice* 2007;24:189-200.~~
- 39
40 (1920) Von Korff M, Ormel J, Keefe FJ, Dworkin SF. Grading the severity of chronic pain. *Pain*
41 1992;50:133-149.
- 42
43 (2024) Ware JE, Kosinski M, Turner-Bowker DM, Sundaram M, Gandek B, Maruish ME. User's
44 Manual for the SF-12v2 Health Survey. Second edition ed.: QualityMetric, Incorporated, 2009;
45 2009.
- 46
47 (2122) Nicholl BI, Macfarlane GJ, Davies KA, Morriss R, Dickens C, McBeth J. Premorbid
48 psychosocial factors are associated with poor health-related quality of life in subjects with new
49 onset of chronic widespread pain - results from the EPIFUND study. *Pain* 2009;141:119-126.
- 50
51 (2223) Carmona L, Ballina J, Gabriel R, Laffon A. The burden of musculoskeletal diseases in the
52 general population of Spain: results from a national survey. *Ann Rheum Dis* 2001;60:1040-1045.
- 53
54
55
56
57
58
59
60

(2324) Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983 Jun;67(6):361-370.

(2425) Snaith RP, Zigmond AS. HADS: Hospital Anxiety and Depression Scale. Windsor: NFER Nelson; 1994.

(2526) Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986 Jan;24(1):67-74.

(2627) Lancaster GA, Dood S, Williamson PR. Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract 2004;10(2):307-312.

(27) Rosenthal R. Meta-analytic procedures for social research (revised). Newbury Park, CA. Sage 1991.

(28) Cohen J. Statistical power analysis for the behavioural sciences (2nd edition). New York. Academic Press.

(2928) Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ 2008;337:a1655.

(3029) Magni M, Caldieron C, Rigatti-Luchini S, Merskey H. Chronic musculo-skeletal pain and depressive symptoms in the general population. An analysis of the 1st National Health and Nutrition Examination Survey data. Pain 1990; 43: 299-307

(3130) Gureje O, Von Korff M, Simon GE, Gater R. Persistent pain and well-being. A World Health Organization study in primary care. Journal of the American Medical Association 1998; 280: 147-151.

(322931) Community Pharmacy Medicines Management Project Evaluation Team. The MEDMAN study: a randomized controlled trial of community pharmacy-led medicines management for patients with coronary heart disease. Family Practice 2007;24:189-200.

(333032) Treweek S, Mitchell E, Pitkethly M, Cook J, Kjeldstrøm M, Johansen M, et al. Strategies to improve recruitment to randomised controlled trials. Cochrane Database Syst Rev 2010;(4):MR000013 2011.

(343133) Cameron IM, Cardy A, Crawford JR, du Toit Schalk W, Hay S, Lawton K, et al. Measuring depression severity in general practice: discriminatory performance of the PHQ-9, HADS-D, and BDI-II. Br J Gen Pract 2011;61:e419-e426(8).

(353234) Briggs M, Closs SJ, Marczewski K, Barratt J. A feasibility study of a combined nurse/pharmacist-led chronic pain clinic in primary care. Qual Prim Care 2008;16:91-94.

(363335) Anonymous. Pharmacist and physiotherapist-led community outreach pain programme improve quality of life. The Pharmaceutical Journal 2005;275:14.

Formatted: Space After: 0 pt

Formatted: Normal

Formatted: Space Before: 0 pt, After: 0 pt

Formatted: Font: Calibri, 12 pt, Not Bold, Font color: Auto

Formatted: Font: Calibri, 12 pt, Not Bold, Font color: Auto

Formatted: Font: Calibri, Not Bold, Font color: Auto

Formatted: Font: Calibri, Not Bold, Font color: Auto

1
2
3
4
5
6 | (373436) Turk DC, Dworkin RH, Revicki D, Harding G, Burke LB, Cella D, et al. Identifying
7 important outcome domains for chronic pain clinical trials: An IMMPACT survey of people with
8 pain. 2008;137:276-285.


9
10 ~~Rosenthal R. Meta-analytic procedures for social research (revised). Newbury Park, CA. Sage~~
11 ~~1991.~~

12 ~~Cohen J. Statistical power analysis for the behavioural sciences (2nd edition). New York.~~
13 ~~Academic Press.~~
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Formatted: Font: +Body (Calibri), Superscript

Figure 1: CONSORT Flow Diagram

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



1
2
3
4
5
6 | *In [the Grampian Health Board area](#) Grampian, on the basis of response rates in the earlier feasibility
7 study (241 screened patients resulted in 22 recruited) only a random sample of eligible participants
8 were screened (15). In East Anglia all eligible patients were screened.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1: Baseline demographic, socio-economic and pain data of patients by study arm, prescribing, review and treatment as usual (TAU)

	Prescribing* (n = 68)	Review* (n = 62)	TAU* (n = 63)
Age: mean (SD)	66.1 (12.1)	65.7 (14.2)	64.9 (11.6)
Missing	1	1	0
Gender (% female)	54.4 (37)	74.2 (46)	58.7 (37)
<i>Marital status</i>			
Married	43	30	41
Single	6	6	3
Divorced/widow	10	21	13
Other	6	4	6
Missing	3	1	0
<i>Highest educational level achieved</i>			
No qualifications	30	27	21
O grade or equivalent	12	6	14
Higher/A-level/NVQ3/SVQ3	6	8	7
Tertiary education/NVQ4/NVQ5	18	17	14
Other	2	1	4
Missing	0	3	3
<i>Employment status</i>			
Employed	16	14	9
Unemployed	3	5	1
Retired	38	35	34
Long term sick/disabled	7	5	9
Other	3	2	7
Missing	1	1	3
<i>Household annual income before tax</i>			
Less than £9,999	13	15	10
£10,000 - £14,999	14	18	22
£15,000 - £24,999	14	12	12
£25,000 – or more	22	11	8
Missing	5	6	11
<i>Ethnic group</i>			
Caucasian	67	62	61
Other	1		
Missing	0	0	2
<i>Pain duration</i>			
< 1 year	3	2	4
1 – 3 years	12	12	7
3 – 5 years	10	13	9
5 – 10 years	17	13	15
> 10 years	26	22	28
<i>Pain localisation (% , n)</i>			
Back	27.9 (19)	32.3 (20)	20.6 (13)
Neck, shoulders	7.4 (5)	9.7 (6)	9.5 (6)
Limbs or hips	42.6 (29)	30.6 (19)	50.8 (32)
Other	8.8 (6)	4.8 (3)	7.9 (5)
Missing	9	14	7

*Denominator based on numbers allocated to the specific arms, minus any exclusions due to protocol violations.

Table 2: Mean (standard deviation, SD) CPG intensity , median (interquartile range, IQR) CPG disability, and count CPG grade at baseline, 6 months follow-up and difference between the two assessment points for each arm, prescribing, review and treatment as usual (TAU). P-values for within and between arm differences are also reported.

	Prescribing		Review		TAU		P (between groups ^{***})
	n*	Mean (SD)	n*	Mean (SD)	n*	Mean (SD)	
Baseline CPG intensity	47	66.1 (16.0)	45	68.4 (17.6)	54	65.4 (18.0)	
6 month follow-up CPG intensity		58.1 (19.5)		67.4 (21.7)		65.6 (19.6)	
Difference CPG intensity		-8.0 (16.3)		-1.0 (16.0)		0.2 (14.9)	0.02
P (within groups ^{**})		0.002		0.67		0.93	0.02
Effect size (r)		0.45x		0.07x		0.01x	
		Median [IQR]		Median [IQR]		Median [IQR]	
Baseline CPG disability	48	60.0 [30.0; 75.8]	46	66.7 [45.0; 80.0]	53	56.7 [36.7; 80.0]	
6 Month follow-up CPG disability		40.0 [20.0; 60.0]		53.3 [29.2; 73.3]		50.0 [25.0; 80.0]	
Difference CPG disability		-8.3 [-23.3; 0.0]		-3.3 [-16.7; 10.0]		-3.3 [-21.7; 5.0]	0.55
P (within groups ^{**})		0.003		0.15		0.05	0.55
Effect size (r)		0.43x		0.20x		0.26x	
Baseline CPG grade	44	Count (%)	44	Count (%)	48	Count (%)	
	I	5 (11.4)		3 (6.8)		5 (10.4)	
	II	16 (36.4)		9 (20.5)		13 (27.1)	
	III	7 (15.9)		10 (22.7)		13 (27.1)	
	VI	16 (36.4)		22 (50.0)		17 (35.4)	
6 month follow-up CPG grade							
	I	13 (29.5)		8 (18.2)		6 (12.5)	
	II	13 (29.5)		15 (34.1)		17 (35.4)	
	III	8 (18.2)		8 (18.2)		11 (22.9)	
	IV	10 (22.7)		13 (29.5)		14 (29.2)	
Difference CPG grade							
	≤-1	21 (47.7)		17 (38.6)		15 (31.2)	
	0	17 (38.6)		25 (56.8)		25 (52.1)	
	≥1	6 (13.6)		2 (4.5)		8 (2.1)	0.16
P (within groups ^{***})		0.003		0.001		0.17	

*Number of participants in each group who completed the appropriate part of the CPG at both baseline and follow-up.

** From paired t-test, Wilcoxon signed rank test or marginal homogeneity test as appropriate

*** From ANOVA on mean difference, Kruskal-Wallis on median difference or chi-squared test on difference in CPG grade as appropriate

Table 3: Mean (standard deviation, SD) SF12 Physical Component Score (PCS) and median (interquartile range, IQR) Mental Component Score (MCS) at baseline and 6 month follow-up and difference between the two assessment points for each arm, prescribing, review and treatment as usual (TAU). Within and between arm p-values are also reported.

	Prescribing		Review		TAU		P (between groups ^{***})
	n*	Mean (SD)	n*	Mean (SD)	n*	Mean (SD)	
Baseline SF12 PCS	41	33.5 (10.8)	43	32.59(11.38)	45	29.60 (9.71)	
6 month follow-up SF12 PCS		35.3 (10.8)		34.62 (11.26)		32.59 (9.14)	
Difference SF12 PCS		1.8 (7.5)		2.02 (7.56)		2.99 (8.11)	0.75
P (within groups ^{**})		0.12		0.09		0.02	0.75
Effect size (r)		<u>0.24x</u>		<u>0.26x</u>		<u>0.35x</u>	
		Median [IQR]		Median (IQR)	45	Median (IQR)	
Baseline SF12 MCS	42	52.4 [42.0; 58.8]	43	47.9 [38.5; 59.9]		51.5 [41.3; 60.7]	
6 month follow-up SF12 MCS		49.6 [42.8; 58.1]		47.9 [38.9; 56.2]		44.7 [37.6; 55.8]	
Difference SF12 MCS		-0.4 [-3.7; 6.0]		-1.2 [-6.6; 4.2]		-3.0 [-10.0; 1.3]	0.04
P (within groups ^{**})		0.64		0.37		0.002	0.04
Effect size (r)		<u>0.07x</u>		<u>0.14x</u>		<u>0.46x</u>	

* Number of participants in each group who completed the appropriate part of the SF-12 at both baseline and follow-up.

** From paired t-test or Wilcoxon signed rank test as appropriate

*** From ANOVA on mean difference or Kruskal-Wallis test on median difference as appropriate

Table 4: The HADS-Depression (HADS-D) and HADS-Anxiety (HADS-A) count of patients according to severity (normal, mild, moderate or severe) and the difference in severity category between the two assessment points for each arm, prescribing, review and treatment as usual (TAU). Within and between arm p-values are also reported.*

	n	Prescribing	n	Review	n	TAU	P (between groups ^{***})
Baseline HADS-D	44	Count (%)	45	Count (%)	53	Count (%)	
Normal		32 (72.7)		31 (68.9)		38 (71.7)	
Mild		8 (18.2)		11 (24.4)		7 (13.2)	
Moderate		3 (6.8)		3 (6.7)		8 (15.1)	
Severe		1 (2.3)		0		0	
6 month follow-up HADS-D							
Normal		32 (72.7)		32 (71.1)		32 (60.4)	
Mild		7 (15.9)		6 (13.3)		10 (18.9)	
Moderate		5 (11.4)		6 (13.3)		8 (15.1)	
Severe		0		1 (2.2)		3 (5.7)	
Difference HADS-D							
≤-1		5 (11.4)		4 (8.9)		2 (3.8)	
0		34 (77.3)		37 (82.0)		40 (75.5)	
≥1		5 (11.4)		4 (8.9)		11 (20.8)	0.32 ^{Net valid**}
P (within groups ^{**})		1.0		0.71		0.03	
Baseline HADS-A	44	Count (%)	43	Count (%)	48	Count (%)	
Normal		25 (56.8)		30 (69.8)		29 (60.4)	
Mild		8 (18.2)		7 (16.3)		9 (18.8)	
Moderate		8 (18.2)		5 (11.6)		8 (16.7)	
Severe		3 (6.8)		1 (2.3)		2 (4.2)	
6 month follow-up HADS-A							
Normal		27 (61.4)		29 (67.4)		32 (66.7)	
Mild		7 (15.9)		6 (14.0)		5 (10.4)	
Moderate		8 (18.2)		6 (14.0)		10 (20.8)	
Severe		2 (4.5)		2 (4.7)		1 (2.1)	
Difference HADS-A							
≤-1		6 (13.6)		3 (7.0)		10 (20.8)	
0		35 (79.5)		33 (76.7)		29 (60.4)	
≥1		3 (6.8)		7 (16.3)		9 (18.8)	0.14
P (within groups ^{**})		0.25		0.21		0.55	

* Number of participants in each group who completed the appropriate part of the HADS at both baseline and follow-up.

**** Between arms p-value not valid due to low numbers in multiple cells, even after collapsing to the**

**** From marginal homogeneity test**

***** From chi-squared test on difference in HADS**

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ree categories.

For peer review only




Table 5: Median HADS-Depression (HADS-D) and HADS-Anxiety (HADS-A) scores (interquartile range, IQR) at baseline and 6 month follow-up and difference between the two assessment point for each arm, prescribing, review and treatment as usual (TAU). Within and between arm p-values are also reported.

	Prescribing		Review		TAU		P (between groups)
	n	Median [IQR]	n	Median [IQR]	n	Median [IQR]	
Baseline HADS-D	42	5.0 [3.0;8.0]	44	4.5 [2.3; 8.0]	51	5.0 [3.0; 8.0]	0.02
6 month follow-up HADS-D		4.0 [2.0; 8.0]		5.0 [2.0; 8.8]		5.0 [2.0; 10.0]	
Difference HADS-D		-1.0 [-2.0; 0.0]		0.0 [-1.0; 1.8]		0.0 [-1.0; 2.0]	
P (within groups)		0.02		0.33		0.22	
Baseline HADS-A	44	7.0 [3.3; 10.8]	43	5.0 [3.0; 10.0]	48	6.0[4.0; 10.0]	0.05
6 month follow-up HADS-A		5.0 [2.3; 9.8]		6.0 [3.0; 9.0]		7.0 [4.0; 10.0]	
Difference HADS-A		-1.0 [-2.0; 0.0]		0.0 [-2.0; 2.0]		0.5 [-3.0; 2.0]	
P (within groups)		0.01		0.45		0.81	

* Number of participants in each group who completed the appropriate part of the HADS at both baseline and follow-up.

Box 1 Examples of pharmacist interventions in the prescribing arm

Changes to pain management: 'use paracetamol regularly', 'take tramadol if needed' 'add piroxicam gel PRN', 'given web links to self help groups'

Compliance aid: 'gave written times that this drug could be taken'

Addressing side effects/safety: 'take paracetamol after initial NSAID', 'take senna', 'ordered blood monitoring', 'stop use of two NSAIDS'

General health: 'discussed weight loss', 'invited to practice nurse for BP', 'glucose, lipids and lifestyle update',

Cost minimisation: 'change aspirin EC to plain',

BOX 2 Examples of quotes from Pharmacists (n=6), GPs (n=23) and patient participants (n=40) on the prescribing intervention

Pharmacists (from interviews):

Satisfying (n=6): 'contact with patients', 'being able to help patients', 'being able to make a difference to long-standing pain'... 'even in small ways'

Interesting (n=6): 'learning about pain'

Challenging (n=6): 'complex, chronically ill patients'

GPs (from interviews):

Support for the service (n=17): 'it's been a very positive thing'

Agreement with pharmacists' recommendations (n=23): 'oh very reasonable suggestions', 'tinkering round the edges', 'had been tried already'.

Trust in the practice pharmacist (n=23): 'I respect his professional judgement'

Cost effectiveness (n=6): 'if there's limited resources do we want to spend the money on a pharmacist'.

Patients (from 3 month questionnaire):

Closed questions:

Proportion agreeing that:

The pharmacist was interested in them (89%; 39/44)

They were totally satisfied (85%; 39/46)

They were told about their treatment (82%; 38/46)

Their consultation was thorough (79%; 34/44)

They would have liked more time (9%; 4/44)

They would have preferred to see their GP (9%; 4/44)

Too many people were now involved in their treatment (11%; 5/44).

Open text questions:

Positive (n=39): 'She was professional, relaxed, pleasant and interested. Excellent!'

Negative (n=1): 'A waste of time, altered my tablets which made my pain worse'.



CONSORT 2010 checklist of information to include when reporting a randomised trial*

Section/Topic	Item No	Checklist item	Reported on page No
Title and abstract			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	3-4
Introduction			
Background and objectives	2a	Scientific background and explanation of rationale	5
	2b	Specific objectives or hypotheses	5-6
Methods			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	6
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	N/A
Participants	4a	Eligibility criteria for participants	6
	4b	Settings and locations where the data were collected	6
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	7-8
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	8
	6b	Any changes to trial outcomes after the trial commenced, with reasons	N/A
Sample size	7a	How sample size was determined	9
	7b	When applicable, explanation of any interim analyses and stopping guidelines	N/A
Randomisation:			
Sequence generation	8a	Method used to generate the random allocation sequence	7
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	N/A
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	7
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	7
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those	N/A

		assessing outcomes) and how	
	11b	If relevant, description of the similarity of interventions	N/A
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	9
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	N/A
Results			
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	10, figure 1(p.18)
	13b	For each group, losses and exclusions after randomisation, together with reasons	10, figure 1(p.18)
Recruitment	14a	Dates defining the periods of recruitment and follow-up	7-8
	14b	Why the trial ended or was stopped	N/A
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	10, Table 1 (p20)
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	See Tables 2,3,4,5 and page 9 (ITT)
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	See pages 10/11, and Tables 2,3,4,5. P values reported
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	N/A
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	N/A
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	N/A
Discussion			
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	12
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	12-13
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	13
Other information			
Registration	23	Registration number and name of trial registry	4

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Protocol	24	Where the full trial protocol can be accessed, if available	N/A
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	14

*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.

For peer review only



Pharmacist-led management of chronic pain in primary care: results from a randomised controlled exploratory trial

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-002361.R2
Article Type:	Research
Date Submitted by the Author:	06-Feb-2013
Complete List of Authors:	Bruhn, Hanne; University of Aberdeen, Health Services Research Unit Bond, Christine; University of Aberdeen, Elliott, Alison; University of Aberdeen, General Practice and Primary Care Hannaford, Phil; University of Aberdeen Lee, Amanda; University of Aberdeen, Division of Applied Health Sciences McNamee, Paul; University of Aberdeen Smith, Blair; University of Dundee, Watson, Margaret; University of Aberdeen, General Practice and Primary Care Blyth, Annie; University of East Anglia, Norwich Medical School Wright, David; University of East Anglia, Infection Holland, Richard; University of East Anglia,
Primary Subject Heading:	General practice / Family practice
Secondary Subject Heading:	General practice / Family practice, Health services research
Keywords:	PAIN MANAGEMENT, PRIMARY CARE, Clinical trials < THERAPEUTICS

SCHOLARONE™
Manuscripts

only

Title page

Pharmacist-led management of chronic pain in primary care: results from a randomised controlled exploratory trial

Hanne Bruhn, Christine M Bond, Alison M Elliott, Philip C Hannaford, Amanda J Lee, Paul McNamee, Blair H Smith, Margaret C Watson, Annie Blyth, Richard Holland, David Wright

Centre for Healthcare Randomised Trials, Health Services Research Unit, University of Aberdeen, 3rd floor Health Sciences Building, Foresterhill, Aberdeen, AB25 2ZD, UK Hanne Bruhn, Trial Manager

Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Polwarth West Block, Foresterhill, Aberdeen, AB25 2ZD, UK, Christine M Bond, Professor of Primary Care: Pharmacy

Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Polwarth West Block, Foresterhill, Aberdeen, AB25 2ZD, UK, Alison M Elliott, Senior Research Fellow

Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Polwarth West Block, Foresterhill, Aberdeen, AB25 2ZD, UK, Philip C Hannaford, NHS Grampian Chair of Primary Care

Medical Statistics Team, Division of Applied Health Sciences, Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, UK, Amanda J Lee, Professor of Medical Statistics

Health Economics Research Unit, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, UK, Paul McNamee, Reader

Division of Population Health Sciences, University of Dundee, Ninewells Hospital and Medical School, Dundee, DD2 4RB, UK, Blair H Smith, Professor of Population Science

Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Polwarth West Block, Foresterhill, Aberdeen, AB25 2ZD, UK, Margaret C Watson, Senior Research Fellow

Norwich Medical School, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK, Annie Blyth, Research Associate

Norwich Medical School, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK, Richard Holland, Professor of Public Health Medicine

School of Pharmacy, University of East Anglia, Norwich Research Park, NR4 7TJ, UK, David Wright, Chair in Pharmacy Practice

1
2 Correspondence to: Professor CM Bond c.m.bond@abdn.ac.uk, Centre of Academic Primary
3 Care, Division of Applied Health Sciences, University of Aberdeen, Polwarth West Block,
4 Foresterhill, Aberdeen, AB25 2ZD, UK
5

6
7 The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all
8 authors, [a worldwide licence](#) to the Publishers and its licensees in perpetuity, in all forms, formats and
9 media (whether known now or created in the future), to i) publish, reproduce, distribute, display and
10 store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints,
11 include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii)
12 create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the
13 Contribution, v) the inclusion of electronic links from the Contribution to third party material where-
14 ever it may be located; and, vi) licence any third party to do any or all of the above.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives

To compare the effectiveness of pharmacist medication-review, with or without pharmacist prescribing, with standard care, for patients with chronic pain.

Design

An exploratory randomised controlled trial.

Setting

Six general practices with prescribing pharmacists in Grampian (3) and East Anglia (3).

Participants

Patients on repeat prescribed pain medication(4815) were screened by GPs, and mailed invitations (1397). 196 were randomised and 180 (92%) completed. Exclusion criteria included: severe mental illness, terminally ill, cancer related pain, history of addiction

Randomisation and intervention

Patients were randomised using a remote telephone service to: (i) pharmacist medication-review with face-to-face pharmacist prescribing; or (ii) pharmacist medication-review with feedback to GP and no planned patient contact; or (iii) treatment as usual (TAU). Blinding was not possible.

Outcome measures

Outcomes were the SF-12v2, the Chronic Pain Grade (CPG), the HUI3 and the Hospital Anxiety and Depression Scale (HADS). Outcomes were collected at 0,3,and 6 months.

Ethical approval was obtained.

Results

In the prescribing arm (n=70) two patients were excluded/nine withdrew. In the review arm (n=63) one was excluded/three withdrew. In the TAU arm (n=63) four withdrew. Compared with baseline, patients had an improved CPG in the prescribing arm, 47.7% (21/44; p=0.003), and in the review arm, 38.6% (17/44; p=0.001), but not the TAU group, 31.3% (15/48; ns). The

1 SF-12 PCS showed no effect in the prescribing or review arms but improvement in TAU
2 (p=0.02). The SF-12 MCS showed no effect for the prescribing or review arms and deterioration
3 in the TAU arm (p=0.002). HADS scores improved within the prescribing arm for Depression
4 (p=0.022) and Anxiety (p=0.007), between groups (p=0.022 and p=0.045 respectively).
5
6
7
8

9 Conclusion

10 This is the first RCT of pharmacist-prescribing in the UK, and suggests there may be a benefit
11 for patients with chronic pain. A larger trial is required.
12
13

14 Trial registration: www.isrctn.org/ISRCTN06131530. Medical Research Council funding.
15
16
17
18
19

20 *Focus:*

- 21 • Chronic pain, (lasting >3 months) affects up to half the adult population, most
22 of whom are primarily managed in primary care but prescribing is often sub-
23 optimal.
- 24 • Pharmacists now have prescribing rights but no published research has
25 compared the effectiveness of their prescribing with that of GPs.
- 26 • The hypothesis was that pharmacist advice (with or without pharmacist
27 prescribing) would lead to better outcomes than usual care
28
29
30

31 *Key messages:*

- 32 • The findings suggest there may be improved pain related outcomes for patients
33 receiving pain related care from a pharmacist prescriber
- 34 • A larger trial is called for.
35
36

37 *Strengths and Limitations*

- 38 • This the first randomised controlled trial of pharmacist prescribing in the UK
39 looking at patient reported clinical outcomes
- 40 • The study was designed as an exploratory trial so no power calculation was
41 done
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Chronic pain (pain lasting more than three months) affects up to half the adult United Kingdom (UK) population, and is considered severely limiting in about 15% of cases (1). Recovery is uncommon with nearly 80% of those identified with chronic pain at baseline still reporting chronic pain four years later (2). It adversely affects many aspects of a person's physical and psychological health, and social and economic well being (3-6).

In the UK, most patients with chronic pain present, and are managed, in primary care (7). Although non-pharmacological treatments are available, these are accessed by few patients, with mixed success (e.g. (8-10)). Analgesics prescribed in primary care remain the mainstay of treatment (4), representing substantial workload and cost. Sub-optimal prescribing may lead to poor pain control and other adverse patient outcomes. One study found that the most common medications involved in adverse drug reaction-related emergency admissions involved non-steroidal anti-inflammatory drugs (NSAIDs) (11) which are commonly used to manage pain. Improved prescribing could result in better outcomes and remove the need for more costly, scarce, alternatives.

Pharmacists working in UK general practices are well-placed to improve pain pharmacotherapy because of their expertise in therapeutics, understanding of the poly-pharmacy regimens (12) frequently used in chronic pain management, and established relationships with other primary care colleagues. In the UK National Health Service (NHS), recent regulatory changes now allow accredited pharmacists (as well as some other health care professionals such as nurses) to prescribe prescription-only medicines (POMs) (13). Pharmacists can either be qualified as supplementary prescribers, in which case they operate within an agreed clinical management plan (CMP) in partnership with the doctor and patient, or as an independent prescriber, in which case they can either prescribe completely independently or within a CMP.

However, despite the increasing number of non-medical prescribers, including pharmacists, there has been no rigorous comparisons of the outcomes of non-medical versus GP prescribing. This information is needed to assess the clinical effectiveness of different care models.

This paper reports findings from an exploratory randomised controlled trial (RCT) comparing pharmacist medication review, with or without pharmacist prescribing, with standard care for

1 patients with chronic pain. Development of the trial was informed by earlier feasibility work
2
3 (14,15).
4

5
6 The *a priori* hypothesis was that, in patients with chronic pain, pharmacist advice (with or
7
8 without pharmacist prescribing) would lead to better patient functioning and/or better pain
9
10 control at six months than treatment as usual (TAU).
11

12 **Methods**

13 *Regulatory Issues*

14
15 Ethical approval was granted by the National Research Ethics Service Committee – North of
16
17 Scotland (reference number 09/S0801/107). NHS Research and Development approval was
18
19 granted by NHS Grampian and East Norfolk & Waveney Research Governance Committees.
20
21 Patients gave informed consent before taking part.
22
23

24 *Design*

25
26 An open, exploratory RCT in which patients were randomised to one of three study arms.
27
28 Participants were not blind to allocated treatment arm due to the nature of the intervention.
29
30

31 *Recruitment of practices and independent prescribing pharmacists*

32
33 Practices in the Grampian Health Board area, Scotland (n=18) and East Anglia region of England
34
35 (n=4) known to have an attached Royal Pharmaceutical Society of Great Britain registered
36
37 independent pharmacist prescriber, were eligible to take part. From those indicating a
38
39 willingness to participate, convenience sampling was used to identify six general practices:
40
41 three in Grampian and three in East Anglia.
42

43 *Patient inclusion and exclusion criteria*

44
45 Patients registered with the recruited practices were eligible for inclusion if they were over 18
46
47 years of age, living in their own home, and receiving regular prescribed medication for pain.
48
49 Patients were identified by a computerised search (14) of the drug records of all individuals
50
51 registered with the practice, to identify those who had received either two or more acute
52
53 prescriptions, and/or one repeat prescription within the last 120 days, for an analgesic (British
54
55 National Formulary (BNF section 4.7) and/or non-steroidal anti-inflammatory medication
56
57 (NSAID) (BNF section 10.1.1). Medications which can be used for analgesia but whose primary
58
59 indication is not chronic pain (e.g. triptans, anti-epileptics or anti-depressants) were excluded
60

1 as these drugs identify few additional eligible patients (16). In accordance with trial criteria,
2 GPs excluded and recorded reasons for patients who had: a concomitant severe mental health
3 problem or terminal illness; had suffered recent bereavement; had a known alcohol or drug
4 addiction; suffered pain caused by cancer or other malignancy; were unable to give informed
5 consent; other (unspecified) reasons.
6
7
8
9

10 *Patient recruitment*

11 Eligible patients were sent an invitation pack (letter, information sheet, consent form) by
12 practice staff between March and June 2010. Consent forms were returned directly to the
13 researchers, who sent out a baseline questionnaire. Patients returning completed
14 questionnaires were randomised by the researcher using a telephone randomisation service
15 with a random number allocation which ensured allocation concealment. The allocation
16 sequence was 1:1:1.
17
18
19
20
21
22
23

24 *Intervention*

25 All participating pharmacists took part in a two-day course updating them about pain
26 management. As part of the training, participants defined and agreed the treatment algorithm
27 they would all use.
28
29
30
31

32 'Prescribing' arm: Pharmacists invited patients to a face-to-face consultation. Prior to the
33 consultation, pharmacists completed a paper-based medication review of each patient's
34 medical record and patients were asked to complete a pain diary to inform the consultation. A
35 pharmaceutical care plan was agreed between the pharmacist and the patient. The plan
36 assessed and documented relevant past medical history and current conditions; known
37 allergies and adverse drug reactions; relevant laboratory results; pain-related medications
38 prescribed in the previous 10 years; current pain related prescription medications; current
39 symptoms; lifestyle issues, including units of alcohol consumed per week; recommendations
40 for changes to medication (if any); whether non-pharmaceutical treatments had been
41 considered; and, any other relevant issues. Copies of the pain diary and pharmaceutical care
42 plan are available from the authors on request. At the end of the consultation any required
43 prescriptions for medicines were issued by the pharmacist. Due to Controlled Drug (CD)
44 regulations in place at the time, prescribing for CDs was done using a supplementary
45 prescribing Clinical Management Plan (17), rather than independent prescribing. Patients were
46 followed up either by phone or face-to-face, at each pharmacist's discretion.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 'Review arm': The pharmacists conducted a paper-based medication review focussed on pain-
3 related prescription medications, before creating a pharmaceutical care plan which detailed
4 any recommendations for medication changes. The plan was passed to the patient's GP for
5 implementation. The GPs were asked subsequently about actions taken as a result of the
6 recommendations.
7
8
9

10
11 Treatment as usual (TAU): Patients received standard general practice care.
12
13

14 *Outcome measures*

15 A core aim of this exploratory randomised controlled trial (RCT) was to finalise the selection of outcome
16 measures for a subsequent multi-centred RCT. In the Current Controlled Trials Registration
17 (ISRCTNO6131530) we specified both primary and secondary outcome measures (primary: SF12, HUI ;
18 secondary: CPG, HADS) based on our judgement following the earlier feasibility study (15). However in
19 practice, all outcomes were considered equal and no single measure was defined as the primary
20 outcome, for example, for the purpose of a sample size calculation (see below). These four outcome
21 measures are described below. Inclusion of both pain specific and generic outcome measures was
22 based on Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials
23 (IMMPACT) recommendations (18) and an earlier feasibility study (15).
24
25
26
27
28
29

30 The SF-12v2 is a generic health and functioning scale (19), previously used in population-based
31 studies of pain (20,21). A Physical (PCS) and Mental Component Score (MCS) was calculated,
32 ranging from 0 to 100; a higher score indicates better functioning.
33
34
35
36

37 The Health Utilities Index (HUI3) is a preference-based system for measuring comprehensive
38 health status and health-related quality of life (HRQL) (22). It provides descriptive evidence and
39 a score for each dimension of health (vision, hearing, speech, ambulation/mobility, pain,
40 dexterity, self-care, emotion and cognition) and a HRQL score for overall health. Each
41 dimension has 3- 6 levels. Owing to the cost of the additional license fee to score data from
42 this measure, this instrument was not subsequently analysed.
43
44
45
46

47 The CPG (23) is a seven item scale which assesses pain severity on two dimensions: disability
48 and intensity. The scale classifies pain according to level of intensity and disability (I (low
49 disability-low intensity) to IV (high disability-severely limiting)).
50
51
52
53
54
55
56
57
58
59
60

1
2 The Hospital Anxiety and Depression Scale (HADS) (24) is a 14-item screening instrument which
3 identifies the possible and probable caseness of anxiety (7 items (HADS-A)) and depression (7
4 items (HADS-D)); each item scored from 0 (not present) to 3 (highly present). Standard
5 thresholds and previously used labels (25) were applied (no depression/anxiety (0-7), mild (8-
6 10), moderate (11-15) or severe (>15)).
7
8
9

10 11 12 *Data collection*

13 14 *Participant questionnaires*

15 Questionnaires were posted to participants at baseline (pre-randomisation), and 3 and 6
16 months post-randomisation (follow-up was conducted between July 2010 and January 2011).
17 Up to two reminders were sent. Questionnaire content included the outcome measures
18 described above together with items on: demographic status (baseline only); screening items
19 to confirm eligibility (baseline only); duration of pain condition (baseline only); location of pain;
20 Morisky Medication Adherence Scale 4 (MMAS-4) (26); participant satisfaction (11 statements
21 derived from the feasibility study for the prescribing arm (3 months only) and additional
22 comments by participants. The MMAS-4 provides a score of self-reported adherence to
23 medication regimen. Scores range from 0 (low adherence) to 4 (high adherence).
24
25
26
27
28
29
30
31

32 33 *Follow-up interviews with staff*

34 Post-intervention, all pharmacists and all GPs in participating practices were invited to take part
35 in semi-structured interviews, carried out face-to-face when possible, otherwise by telephone.
36 Interviews were taped, transcribed verbatim and content analysis was carried out.
37
38
39

40 41 *Sample size*

42 As this was an exploratory trial to estimate the effect size for a larger trial, no formal sample
43 size calculation was possible (27). We aimed to recruit 30 participants per practice (n=180)
44 (with an additional six per practice for training purposes i.e. 216 in total. This was deemed
45 sufficient to give reliable effect size estimates for the outcome measures of health status or
46 chronic pain grade..
47
48
49
50

51 52 *Data management and analysis*

53 Data were entered into identical SPSS databases at each site and accuracy checks carried out
54 on 10% before databases were merged. Descriptive statistics included means and standard
55 deviations (SD) for normally distributed continuous data, medians (interquartile range (IQR))
56
57
58
59
60

1
2 for skewed continuous data and percentages (n) for categorical data. Analysis was conducted
3 on an intention-to-treat basis for participants with complete data on relevant measures using
4 SPSS version 18.
5
6

7
8
9 Exploratory analyses for parametric data included the paired t-test for within-arm comparisons
10 of mean difference between baseline and 6 months and one-way ANOVA for between arm
11 comparisons of mean difference. For non-parametric data it included the Wilcoxon Signed
12 Rank test for within-arm comparisons of median difference and the Kruskal Wallis test for
13 between arm comparisons of median difference. Categorical data was analysed using the
14 marginal homogeneity test for within-arm comparisons (with null hypothesis that the
15 distribution of CPG grade or HADS group does not change between baseline and 6 month
16 follow-up) and the Chi-squared test for between arm comparisons; analyses reported here are
17 based on 6 month follow-up data (other than for participant experiences). Within arm effect
18 sizes, expressed in terms of a Pearson correlation coefficient (r) have been calculated using the
19 formulas from Rosenthal (1991) (28). Effect sizes can be directly compared using Cohen's
20 (1988) (29) criteria of $r=0.1$ (small effect); $r=0.3$ (medium effect) and $r=0.5$ (large effect).
21
22
23
24
25
26
27
28
29
30

31 **Results**

32 *Response rates and demography*

33
34 Six of the seven practices approached participated. GPs excluded 12% (392/3281) of patients,
35 mostly those with dementia. There was no statistically significant difference between
36 participants and non-participants in terms of age, gender, and index of multiple deprivation.
37 Figure 1 shows the flow of participants through the study. Overall, the consent rate was 25%
38 (356/1397) and the recruitment rate was 14% (196/1397).
39
40
41
42
43
44

45 [INSERT FIGURE 1 HERE]

46
47 Eighty six percent of participants (251/289) returned baseline questionnaires, of whom 232
48 were randomised (36 participants were randomised to one of the two intervention arms for
49 training purposes and were not included in any further analysis and 19 were not included as
50 recruitment target had been met). The overall follow-up rate at 3 months was 86%
51 (161/187) and at 6 months 84% (152/180).
52
53
54
55
56
57
58
59
60

1
2 As shown in Table 1, groups were similar at baseline for demographic and socioeconomic
3 variables and pain data. Most participants were married, Caucasian and female, older (mean
4 (SD) age 65 (12.6) years), had an annual income of <£25,000 and had suffered from pain for at
5 least five years. Most (57%;103/181) reported being fully adherent to their medication
6 regimen (MMAS-4, median 4.0 (IQR 3.0- 4.0)) (15 missing MMAS scores).
7
8
9

10
11 [INSERT TABLE 1 HERE]
12

13
14 In the prescribing arm, 78% (53/68) attended an initial prescribing consultation, 31 had at least
15 one planned follow-up (of which 34/37 were conducted by phone) and 130 recommendations
16 were made for 92% (49/53) of participants seen. Examples are shown in Box 1. The median
17 time taken for the note-based record review was 35 minutes (IQR 20.0, 45.0), the consultation
18 was 30 minutes (IQR 20.0, 40.0), careplan preparation 10 minutes (IQR 10.0, 20.0) and median
19 duration of follow-ups was 10 minutes (IQR 5.0- 15.0).
20
21
22
23

24
25 [INSERT BOX 1 HERE]
26
27

28 In the review arm 97% (60/62) of participants' records were reviewed (note there was one post
29 randomisation exclusion) for whom 197 recommendations were made. Where GP feedback
30 was provided (n=48), they generally agreed with pharmacists' recommendations, which were
31 fully implemented for 20 participants (two by the pharmacist following request by GP), partially
32 for 19 participants and not at all for nine participants. The median time taken for the note-
33 based record review was 30 minutes (IQR24.3, 45.0), and careplan preparation was 10
34 minutes (IQR 5.0, 20.0).
35
36
37
38
39
40
41
42

43 *Clinical outcome measures*

44 Table 2 shows the mean (SD) or median (IQR) of the CPG for each arm at baseline and 6 month
45 follow-up. Table 3 shows the SF-12 scores and Table 4 shows the HADS-A and HADS-D results.
46
47
48

49 [INSERT TABLE 2,3,4, HERE]
50

51 In the prescribing arm, there was a statistically significant within arm improvement for the CPG
52 intensity (p=0.002, effect size (r)=0.45) and disability (p=0.003, effect size (r)=0.43) subscales,
53 and between arms on the intensity sub-scale (p=0.02), but not the disability subscale (p=0.55)
54 (Table 2). There was a significant within-arm improvement in overall CPG grade in the
55
56
57
58
59
60

1
2 prescribing (p=0.003) and review arm (p=0.001), but not in the TAU arm. The SF-12 Physical
3 Component Score showed a statistically significant within arm improvement in the TAU arm
4 (p=0.02, effect size (r)=0.35) (Table 3), but not between trial arms. The SF-12 Mental
5 Component Score showed a statistically significant deterioration in the TAU arm (p=0.002,
6 effect size (r)=0.45)(Table 3), as did the HADS-D (p=0.03, Table 4). Analysis was also carried out
7 on the non-categorised HADS scores which showed a statistically significant improvement
8 within the prescribing arm for Depression (p=0.022) and Anxiety (p=0.007). These were both
9 significant between groups (p=0.022 and p=0.045 respectively) (Table 5).

16 *Acceptability of the pharmacist prescribing intervention*

17 All six pharmacists and 56% of the GPs (23/41) were interviewed. All pharmacists and most GPs
18 were positive about the intervention, although some GPs suggested that the pharmacists'
19 recommendations had been minor and questioned the cost-effectiveness of the service.
20 Patient participants were generally positive about the pharmacist prescribing service although
21 some concerns were identified, as illustrated by the quotes shown in Box 2.

22 [INSERT BOX 2 HERE]

28 **Discussion**

30 *Principal findings*

31 This exploratory RCT of pharmacist-led management of patients with chronic pain suggests that
32 pharmacist prescribing (and possibly pharmacist review alone) may be effective in improving
33 pain-related outcomes and be acceptable to both patients and most professionals. There was
34 an indication of a positive effect on emotional health, but no measurable effect on general
35 health.

36 *Strengths and weaknesses*

37 This was the first RCT to assess clinical and humanistic outcomes after pharmacist prescribing
38 for any clinical condition compared to usual GP care, and the first RCT to specifically assess
39 pharmacist-led management of chronic pain, compared with usual GP care. It was based on
40 extensive development and feasibility work (14,15) in line with MRC framework for
41 development and evaluation of complex interventions (30). A range of validated outcome
42 measures was included, as well as a parallel qualitative process evaluation which assessed
43 satisfaction and acceptability. The inclusion of six practices and their associated pharmacists
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 from both Scotland and England increased the generalisability of the findings. Pharmacists
2 received formal training and agreed and used a common treatment algorithm which should
3 have increased standardisation of treatment. The preponderance of females (overall 62%) and
4 average age of 65 years reflects the wider chronic pain population (1) as does the distribution
5 of pain site (31,32)
6
7
8
9

10
11 There were, however limitations. Although high follow-up response rates were achieved at
12 both three (86%) and six months (85%) only 25% of eligible patients entered the trial. This low
13 initial consent rate is in line with other studies (33,34), but may cause unknown biases
14 including problems of generalisability, as does the solely Caucasian ethnicity. Concerns
15 identified by participants during the formal feedback e.g. having too many people involved in
16 one's care may have contributed to poor response rates and rewording of participant
17 recruitment documentation to reassure participants of the role of the pharmacist could
18 address this. More participants withdrew in the prescribing arm compared with the other two
19 arms, which might be attributed to the need for an additional practice visit. The study was an
20 exploratory trial so no formal power calculation was undertaken. However, because there
21 were no published MIDAs available to estimate effect size for the outcomes in this population, it
22 was important to present the actual clinical magnitude of change in outcome at 6 months
23 alongside a statistical assessment of this change (p-value). This allows an assessment of both
24 clinical and statistical significance simultaneously with the caveat that this is an exploratory
25 study. With around 50 patients per arm, this was deemed sufficient numbers to examine the
26 change in outcome measures with appropriate within and between group univariate statistical
27 tests. Due to the nature of the intervention, no participants were blind to their group
28 allocation, and so some outcomes, especially the qualitative components, may have been
29 affected by social desirability bias.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 Our outcome measures were self-reported, but this is the norm in pain studies as pain is a
47 subjective experience (18). Furthermore we do not know how important the observed
48 differences were to participants. Following precedents set in previous research (25), and
49 because there is no consensus on an alternative measure (35) we used the HADS as a tool to
50 classify people by severity of depression and anxiety. However it is strictly a screening tool, and
51 the four levels of severity have not been formally validated. We therefore also compared
52 outcomes using it as a continuous scale.
53
54
55
56
57
58
59
60

Relationship with other studies

This study is important because no other RCT has evaluated pharmacist prescribing and few studies, and importantly no RCTs, have evaluated pharmacist interventions for pain. In pharmacist prescribing most research has focussed on reported experiences of professionals and patients, and not used validated outcome measures. Yet pharmacist prescribing is now widely practised. For pain, there have been a few small studies. Briggs et al (2008) (36) conducted a small before-and-after evaluation (involving 65 patients) of a nurse and pharmacist-led chronic pain clinic in primary care. Pain intensity Visual Analogue Scale scores reduced significantly over six months. Another evaluation of 26 patients using a medication review service provided jointly by a physiotherapist and pharmacist in the UK, reported improvement in pain control for 88% of patients (37).

The CPG was found to show a graded effect across the three arms, showing discrimination with both direction and strength of improvement, suggesting maximum benefit for those in the pharmacist prescribing arm. However, the reduction in overall score appears to be mediated by a change in the intensity of pain subscale rather than in pain-related disability. The effect size of 0.45 suggests this could be an important difference. In contrast, the SF-12, a measure of general health and functionality showed no significant difference between intervention arms, reflecting either no effect or or lack of power to detect an effect.

Whilst most participants in this study were already within the normal range on the HADS scale, and therefore had minimal chance of improvement, there were nonetheless suggestions of better outcomes in participants in the prescribing arm. Including a range of instruments is in line with IMMPACT recommendations (38), which state that focus should be on the whole person, not just about pain. However, this needs to be balanced with minimising participant burden.

Explanations, implications, and future research

The number of pharmacists' recommendations per participant was higher in the review arm than in the prescribing arm. This might seem contradictory to the possible greater benefit found in the prescribing arm. However, in the prescribing arm pharmacists met the participant and may have more readily identified and dismissed suggestions previously tried. The interview feedback highlighted that some recommendations for change, whilst sensible, had been tried already. This might also be the reason why there were only 60% of pharmacist

1
2 recommendations with which the GP fully agreed. Self-reported adherence to medication at
3 baseline was good. Despite this, the pharmacists still improved pain outcomes in the
4 prescribing arm. This could have been due to changes in medications and/or participant
5 education about optimal timing for administration of analgesic medicines. Further research is
6 needed to confirm the beneficial effect of pharmacist prescribing and its sustainability.
7
8
9

11 **Conclusion**

12 Our results suggest that pharmacist prescribing (and possibly pharmacist review alone) for
13 patients with chronic pain is feasible, acceptable and may lead to improvements in pain and
14 other measures. A larger fully-powered trial is now needed to confirm these findings.
15
16
17

19 **Data sharing statement**

20 Consent was not obtained from participants for data sharing; the presented data are
21 anonymised and there is no risk of individual identification. Requests for data should be made to
22 the contact author who will provide this in a format in which risk of patient identification will be
23 minimal.
24
25
26
27

28 **Conflict of interest statement**

29 All authors have completed the Unified Competing Interest form at
30 www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and
31 declare: no support from any organisation for the submitted work; no financial relationships
32 with any organisations that might have an interest in the submitted work in the previous 3
33 years; no other relationships or activities that could appear to have influenced the submitted
34 work.
35
36
37
38
39

41 **Authors' contributions**

42 HB and CB drafted the manuscript.
43
44

45 **All authors:**

- 46
47
48
49 1) made substantial contributions to conception and design, or acquisition of data, or analysis
50 and interpretation of data;
51
52
53 2) were involved in drafting the manuscript or revising it critically for important intellectual
54 content; and
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

3) have given final approval of the version to be published.

Acknowledgements

We thank the participating patients, practices and pharmacists. We would also like to thank Kirsten Harrild (Medical Statistics, UOA) for statistical support. Rick Adams (School of Pharmacy, UEA) helped design and deliver the pharmacist training and Lesley Thomson (NHS Grampian) helped design the pharmacist data collection forms. The patient postal questionnaire was based on work by Nicola Cooper and the Norfolk Arthritis Register (NOAR) research team. The Pharmacy-Led Management of Chronic Pain Study Team acknowledges the financial support of NHS Research Scotland (NRS), through Scottish Primary Care Research Network Northeast. The work was conducted as part of the Aberdeen Pain Research Collaboration. The project was funded by the Medical Research Council. They had no further involvement in any aspect of study conduct; all researchers were independent of the funding body.

All authors had access to all of the study data and can take responsibility for the integrity of the data and the accuracy of the data analysis.

References

- (1) Elliott AM, Smith BH, Penny KI, et al. The epidemiology of chronic pain in the community. *Lancet* 1999;354:1248-1252.
- (2) Elliott AM, Smith BH, Hannaford P, et al. The course of chronic pain in the community: results of a 4-year follow-up study. *Pain* 2002;99:299-307.
- (3) Becker N, Bondegaard Thomsen A, Olsen AK, et al. Pain epidemiology and health related quality of life in chronic non-malignant pain center patients referred to a Danish multidisciplinary. *Pain* 1997;73:393-400.
- (4) Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. *Eur J Pain* 2006;10:287-333.
- (5) Gureje O, Von Korff M, Simon GE, et al. Persistent pain and well-being: a World Health Organization Study in Primary Care. *JAMA* 1998;280:147-151.
- (6) Magni G, Marchetti M, Moreschi C, et al. Chronic musculoskeletal pain and depressive symptoms in the National Health and Nutrition Examination. I. Epidemiologic follow-up study. *Pain* 1993;53:163-168.
- (7) Sullivan MD, Turner JA, Romano J. Chronic pain in primary care: identification and management of psychological factors. *J Fam Pract* 1991;32:193-199.

- 1
2 (8) Green S, Buchbinder R, Hetrick SE. Physiotherapy interventions for shoulder pain. Cochrane
3 Database of Syst Rev 2010(9):Art. No.: CD004258. DOI: 10.1002/14651858.CD004258.
4
- 5 (9) Eccleston C, Williams, A. C. D. C., Morley S. Psychological therapies for the management of
6 chronic pain (excluding headache)
7 in adults. Cochrane Database Syst Rev 2009 Apr 15;(2):CD007407. DOI:
8 10.1002/14651858.CD007407.pub2.
9
- 10 (10) Haetzman M, Elliott AM, Smith BH, et al. Chronic pain and the use of conventional and
11 alternative therapy. Family Practice 2003;20(2):147-154.
12
- 13 (11) Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to
14 hospital: prospective analysis of 18 820 patients. BMJ 2004;329:15.
15
- 16 (12) Krska J, Cromarty JA, Arris F, et al. Pharmacist-led medication review in patients over 65: a
17 randomized, controlled trial in primary care. Age and Ageing 2001;30:205-211.
18
- 19 (13) Department of Health. Improving patients' access to medicines: A guide to implementing
20 nurse and pharmacist independent prescribing within the NHS England. Department of Health
21 2006.
22
- 23 (14) McDermott ME, Smith BH, Elliott AM, et al. The use of medication for chronic pain in
24 primary care, and the potential for intervention by practice-based pharmacist. Family Practice
25 2006;23:46-52.
26
- 27 (15) Bruhn H, Bond CM, Elliott AM, et al. Developing an RCT of general practice-based,
28 pharmacist-led, management of chronic pain: the PIPPC study. IJPP 2010;18(Supplement 2).
29
- 30 (16) Smith BH, Read JRM, Chambers WAC, et al. Researching chronic pain: identification of a
31 community based sample. The Pain Clinic 1996;9:73-76.
32
- 33 (17) Department of Health. Supplementary prescribing by nurses and pharmacists within the
34 NHS in England: A guide for implementation. Department of Health 2003.
35
- 36 (18) Turk DC, Dworkin RH, Allen RR, et al. Core outcome domains for chronic pain clinical trials:
37 IMMPACT recommendations. Pain 2003 12;106(3):337-345.
38
- 39 (19) Ware JE, Kosinski M, Turner-Bowker DM, et al. User's Manual for the SF-12v2 Health
40 Survey. Second edition ed.: QualityMetric, Incorporated, 2009; 2009.
41
- 42 (20) Nicholl BI, Macfarlane GJ, Davies KA, et al. Premorbid psychosocial factors are associated
43 with poor health-related quality of life in subjects with new onset of chronic widespread pain -
44 results from the EPIFUND study. Pain 2009;141:119-126.
45
- 46 (21) Carmona L, Ballina J, Gabriel R, et al. The burden of musculoskeletal diseases in the
47 general population of Spain: results from a national survey. Ann Rheum Dis 2001;60:1040-1045.
48
49
50
51
52
53
54
55
56
57
58
59
60


- 1
2 (22) Feeny, David, "Preference-Based Measures: Utility and Quality-Adjusted Life Years,"
3 Chapter 6.2 in Peter Fayers and Ron Hays, eds., *Assessing Quality of Life in Clinical Trials*,
4 Second Edition, Oxford, Oxford University Press, 2005, pp 405-429.
5
- 6 (23) Von Korff M, Ormel J, Keefe FJ, et al. Grading the severity of chronic pain. *Pain*
7 1992;50:133-149.
8
- 9 (24) Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand*
10 1983 Jun;67(6):361-370.
11
- 12 (25) Snaith RP, Zigmond AS. *HADS: Hospital Anxiety and Depression Scale*. Windsor: NFER
13 Nelson; 1994.
14
- 15 (26) Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported
16 measure of medication adherence. *Med Care* 1986 Jan;24(1):67-74.
17
- 18 (27) Lancaster GA, Dood S, Williamson PR. Design and analysis of pilot studies:
19 recommendations for good practice. *J Eval Clin Pract* 2004;10(2):307-312.
20
- 21 (28) Rosenthal R. *Meta-analytic procedures for social research (revised)*. Newbury Park, CA.
22 Sage 1991.
23
- 24 (29) Cohen J. *Statistical power analysis for the behavioural sciences (2nd edition)*. New York.
25 Academic Press. (30) Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M.
26 *Developing and evaluating complex interventions: the new Medical Research Council guidance*.
27 *BMJ* 2008;337:a1655.
28
- 29 (31) Magni M, Caldieron C, Rigatti-Luchini S, et al. Chronic musculo-skeletal pain and depressive
30 symptoms in the general population. An analysis of the 1st National Health and Nutrition
31 Examination Survey data. *Pain* 1990; 43: 299-307
32
- 33 (32) Gureje O, Von Korff M, Simon GE, et al. Persistent pain and well-being. A World Health
34 Organization study in primary care. *Journal of the American Medical Association* 1998; 280:
35 147-151.
36
- 37 (33) Community Pharmacy Medicines Management Project Evaluation Team. The MEDMAN
38 study: a randomized controlled trial of community pharmacy-led medicines management for
39 patients with coronary heart disease. *Family Practice* 2007;24:189-200.
40
- 41 (34) Treweek S, Mitchell E, Pitkethly M, et al. Strategies to improve recruitment to randomised
42 controlled trials. *Cochrane Database Syst Rev* 2010;(4):MR000013 2011.
43
- 44 (35) Cameron IM, Cardy A, Crawford JR, et al. Measuring depression severity in general
45 practice: discriminatory performance of the PHQ-9, HADS-D, and BDI-II. *Br J Gen Pract*
46 2011;61:e419-e426(8).
47
- 48 (36) Briggs M, Closs SJ, Marczewski K, et al. A feasibility study of a combined nurse/pharmacist-
49 led chronic pain clinic in primary care. *Qual Prim Care* 2008;16:91-94.
50
51
52
53
54
55
56
57
58
59
60

1
2 (37) Anonymous. Pharmacist and physiotherapist-led community outreach pain programme
3 improve quality of life. The Pharmaceutical Journal 2005;275:14.
4

5 (38) Turk DC, Dworkin RH, Revicki D, et al. Identifying important outcome domains for chronic
6 pain clinical trials: An IMMPACT survey of people with pain. 2008;137:276-285.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Figure 1: CONSORT Flow Diagram



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

*In the **Grampian Health Board area**, on the basis of response rates in the earlier feasibility study (241 screened patients resulted in 22 recruited) only a random sample of eligible participants were screened (15). In East Anglia all eligible patients were screened.

For peer review only

Table 1: Baseline demographic, socio-economic and pain data of patients by study arm, prescribing, review and treatment as usual (TAU)

	Prescribing*	Review*	TAU*
	(n = 68)	(n = 62)	(n = 63)
Age: mean (SD)	66.1 (12.1)	65.7 (14.2)	64.9 (11.6)
Missing	1	1	0
Gender (% female)	54.4 (37)	74.2 (46)	58.7 (37)
<i>Marital status</i>			
Married	43	30	41
Single	6	6	3
Divorced/widow	10	21	13
Other	6	4	6
Missing	3	1	0
<i>Highest educational level achieved</i>			
No qualifications	30	27	21
O grade or equivalent	12	6	14
Higher/A-level/NVQ3/SVQ3	6	8	7
Tertiary education/NVQ4/NVQ5	18	17	14
Other	2	1	4
Missing	0	3	3
<i>Employment status</i>			
Employed	16	14	9
Unemployed	3	5	1
Retired	38	35	34
Long term sick/disabled	7	5	9
Other	3	2	7
Missing	1	1	3
<i>Household annual income before tax</i>			
Less than £9,999	13	15	10
£10,000 - £14,999	14	18	22
£15,000 - £24,999	14	12	12
£25,000 – or more	22	11	8
Missing	5	6	11
<i>Ethnic group</i>			
Caucasian	67	62	61
Other	1		
Missing	0	0	2
<i>Pain duration</i>			
< 1 year	3	2	4
1 – 3 years	12	12	7
3 – 5 years	10	13	9
5 – 10 years	17	13	15
> 10 years	26	22	28
<i>Pain localisation (% , n)</i>			
Back	27.9 (19)	32.3 (20)	20.6 (13)
Neck, shoulders	7.4 (5)	9.7 (6)	9.5 (6)
Limbs or hips	42.6 (29)	30.6 (19)	50.8 (32)
Other	8.8 (6)	4.8 (3)	7.9 (5)
Missing	9	14	7

*Denominator based on numbers allocated to the specific arms, minus any exclusions due to protocol violations.

Table 2: Mean (standard deviation, SD) CPG intensity, median (interquartile range, IQR) CPG disability, and count CPG grade at baseline, 6 months follow-up and difference between the two assessment points for each arm, prescribing, review and treatment as usual (TAU). P-values for within and between arm differences are also reported.

	Prescribing		Review		TAU		P (between groups***)
	n*	Mean (SD)	n*	Mean (SD)	n*	Mean (SD)	
Baseline CPG intensity	47	66.1 (16.0)	45	68.4 (17.6)	54	65.4 (18.0)	
6 month follow-up CPG intensity		58.1 (19.5)		67.4 (21.7)		65.6 (19.6)	
Difference CPG intensity		-8.0 (16.3)		-1.0 (16.0)		0.2 (14.9)	
P (within groups**)		0.002		0.67		0.93	0.02
Effect size (r)		0.45		0.07		0.01	
		Median [IQR]		Median [IQR]		Median [IQR]	
Baseline CPG disability	48	60.0 [30.0; 75.8]	46	66.7 [45.0; 80.0]	53	56.7 [36.7; 80.0]	
6 Month follow-up CPG disability		40.0 [20.0; 60.0]		53.3 [29.2; 73.3]		50.0 [25.0; 80.0]	
Difference CPG disability		-8.3 [-23.3; 0.0]		-3.3 [-16.7; 10.0]		-3.3 [-21.7; 5.0]	
P (within groups**)		0.003		0.15		0.05	0.55
Effect size (r)		0.43		0.20		0.26	
Baseline CPG grade	44	Count (%)	44	Count (%)	48	Count (%)	
	I	5 (11.4)		3 (6.8)		5 (10.4)	
	II	16 (36.4)		9 (20.5)		13 (27.1)	
	III	7 (15.9)		10 (22.7)		13 (27.1)	
	VI	16 (36.4)		22 (50.0)		17 (35.4)	
6 month follow-up CPG grade							
	I	13 (29.5)		8 (18.2)		6 (12.5)	
	II	13 (29.5)		15 (34.1)		17 (35.4)	
	III	8 (18.2)		8 (18.2)		11 (22.9)	
	IV	10 (22.7)		13 (29.5)		14 (29.2)	
Difference CPG grade							
	≤-1	21 (47.7)		17 (38.6)		15 (31.2)	
	0	17 (38.6)		25 (56.8)		25 (52.1)	
	≥1	6 (13.6)		2 (4.5)		8 (2.1)	0.16
P (within groups***)		0.003		0.001		0.17	

*Number of participants in each group who completed the appropriate part of the CPG at both baseline and follow-up.

** From paired t-test, Wilcoxon signed rank test or marginal homogeneity test as appropriate

*** From ANOVA on mean difference, Kruskal-Wallis on median difference or chi-squared test on difference in CPG grade as appropriate

Table 3: Mean (standard deviation, SD) SF12 Physical Component Score (PCS) and median (interquartile range, IQR) Mental Component Score (MCS) at baseline and 6 month follow-up and difference between the two assessment points for each arm, prescribing, review and treatment as usual (TAU). Within and between arm p-values are also reported.

	Prescribing		Review		TAU		P (between groups ^{***})
	n*	Mean (SD)	n*	Mean (SD)	n*	Mean (SD)	
Baseline SF12 PCS	41	33.5 (10.8)	43	32.59(11.38)	45	29.60 (9.71)	0.75
6 month follow-up SF12 PCS		35.3 (10.8)		34.62 (11.26)		32.59 (9.14)	
Difference SF12 PCS		1.8 (7.5)		2.02 (7.56)		2.99 (8.11)	
P (within groups ^{**})		0.12		0.09		0.02	
Effect size (r)		0.24		0.26		0.35	
		Median [IQR]		Median (IQR)	45	Median (IQR)	
Baseline SF12 MCS	42	52.4 [42.0; 58.8]	43	47.9 [38.5; 59.9]		51.5 [41.3; 60.7]	0.04
6 month follow-up SF12 MCS		49.6 [42.8; 58.1]		47.9 [38.9; 56.2]		44.7 [37.6; 55.8]	
Difference SF12 MCS		-0.4 [-3.7; 6.0]		-1.2 [-6.6; 4.2]		-3.0 [-10.0; 1.3]	
P (within groups ^{**})		0.64		0.37		0.002	
Effect size (r)		0.07		0.14		0.46	

* Number of participants in each group who completed the appropriate part of the SF-12 at both baseline and follow-up.

** From paired t-test or Wilcoxon signed rank test as appropriate

*** From ANOVA on mean difference or Kruskal-Wallis test on median difference as appropriate

Table 4: The HADS-Depression (HADS-D) and HADS-Anxiety (HADS-A) count of patients according to severity (normal, mild, moderate or severe) and the difference in severity category between the two assessment points for each arm, prescribing, review and treatment as usual (TAU). Within and between arm p-values are also reported.*

	n	Prescribing	n	Review	n	TAU	P (between groups***)
Baseline HADS-D	44	Count (%)	45	Count (%)	53	Count (%)	
Normal		32 (72.7)		31 (68.9)		38 (71.7)	
Mild		8 (18.2)		11 (24.4)		7 (13.2)	
Moderate		3 (6.8)		3 (6.7)		8 (15.1)	
Severe		1 (2.3)		0		0	
6 month follow-up HADS-D							
Normal		32 (72.7)		32 (71.1)		32 (60.4)	
Mild		7 (15.9)		6 (13.3)		10 (18.9)	
Moderate		5 (11.4)		6 (13.3)		8 (15.1)	
Severe		0		1 (2.2)		3 (5.7)	
Difference HADS-D							
≤-1		5 (11.4)		4 (8.9)		2 (3.8)	
0		34 (77.3)		37 (82.0)		40 (75.5)	
≥1		5 (11.4)		4 (8.9)		11 (20.8)	0.32
P (within groups**)		1.0		0.71		0.03	
Baseline HADS-A	44	Count (%)	43	Count (%)	48	Count (%)	
Normal		25 (56.8)		30 (69.8)		29 (60.4)	
Mild		8 (18.2)		7 (16.3)		9 (18.8)	
Moderate		8 (18.2)		5 (11.6)		8 (16.7)	
Severe		3 (6.8)		1 (2.3)		2 (4.2)	
6 month follow-up HADS-A							
Normal		27 (61.4)		29 (67.4)		32 (66.7)	
Mild		7 (15.9)		6 (14.0)		5 (10.4)	
Moderate		8 (18.2)		6 (14.0)		10 (20.8)	
Severe		2 (4.5)		2 (4.7)		1 (2.1)	
Difference HADS-A							
≤-1		6 (13.6)		3 (7.0)		10 (20.8)	
0		35 (79.5)		33 (76.7)		29 (60.4)	
≥1		3 (6.8)		7 (16.3)		9 (18.8)	0.14
P (within groups**)		0.25		0.21		0.55	

* Number of participants in each group who completed the appropriate part of the HADS at both baseline and follow-up.

** From marginal homogeneity test

*** From chi-squared test on difference in HADS

Table 5: Median HADS-Depression (HADS-D) and HADS-Anxiety (HADS-A) scores (interquartile range, IQR) at baseline and 6 month follow-up and difference between the two assessment point for each arm, prescribing, review and treatment as usual (TAU). Within and between arm p-values are also reported.

	Prescribing		Review		TAU		P (between groups)
	n	Median [IQR]	n	Median [IQR]	n	Median [IQR]	
Baseline HADS-D	42	5.0 [3.0; 8.0]	44	4.5 [2.3; 8.0]	51	5.0 [3.0; 8.0]	0.02
6 month follow-up HADS-D		4.0 [2.0; 8.0]		5.0 [2.0; 8.8]		5.0 [2.0; 10.0]	
Difference HADS-D		-1.0 [-2.0; 0.0]		0.0 [-1.0; 1.8]		0.0 [-1.0; 2.0]	
P (within groups)		0.02		0.33		0.22	
Baseline HADS-A	44	7.0 [3.3; 10.8]	43	5.0 [3.0; 10.0]	48	6.0 [4.0; 10.0]	0.05
6 month follow-up HADS-A		5.0 [2.3; 9.8]		6.0 [3.0; 9.0]		7.0 [4.0; 10.0]	
Difference HADS-A		-1.0 [-2.0; 0.0]		0.0 [-2.0; 2.0]		0.5 [-3.0; 2.0]	
P (within groups)		0.01		0.45		0.81	

* Number of participants in each group who completed the appropriate part of the HADS at both baseline and follow-up.

Box 1 Examples of pharmacist interventions in the prescribing arm

Changes to pain management: 'use paracetamol regularly', 'take tramadol if needed' 'add piroxicam gel PRN', 'given web links to self help groups'

Compliance aid: ' gave written times that this drug could be taken'

Addressing side effects/safety: 'take paracetamol after initial NSAID', 'take senna', 'ordered blood monitoring', 'stop use of two NSAIDS'

General health: 'discussed weight loss', 'invited to practice nurse for BP', 'glucose, lipids and lifestyle update',

Cost minimisation: 'change aspirin EC to plain',

1
2 BOX 2 Examples of quotes from Pharmacists (n=6), GPs (n=23) and patient participants (n=40)
3 on the prescribing intervention
4

5
6 **Pharmacists (from interviews):**

7
8 **Satisfying** (n=6): 'contact with patients', 'being able to help patients', 'being able to make a
9 difference to long-standing pain'...'even in small ways'

10
11 **Interesting** (n=6): 'learning about pain'

12
13 **Challenging** (n=6): 'complex, chronically ill patients'

14
15 **GPs (from interviews):**

16
17 **Support for the service** (n=17): 'it's been a very positive thing'

18
19 **Agreement with pharmacists' recommendations** (n=23): 'oh very reasonable suggestions',
20 'tinkering round the edges', 'had been tried already'.
21

22
23 **Trust in the practice pharmacist** (n=23): 'I respect his professional judgement'

24
25 **Cost effectiveness** (n=6): 'if there's limited resources do we want to spend the money on a
26 pharmacist'.
27

28
29 **Patients (from 3 month questionnaire):**

30
31 **Closed questions:**

32
33 Proportion agreeing that:

34 The pharmacist was interested in them (89%; 39/44)

35 They were totally satisfied (85%; 39/46)

36 They were told about their treatment (82%; 38/46)

37 Their consultation was thorough (79%; 34/44)

38 They would have liked more time (9%; 4/44)

39 They would have preferred to see their GP (9%; 4/44)

40 Too many people were now involved in their treatment (11%; 5/44).
41

42
43 **Open text questions:**

44
45 Positive (n=39): 'She was professional, relaxed, pleasant and interested. Excellent!'
46

47
48 Negative (n=1): 'A waste of time, altered my tablets which made my pain worse'.
49
50
51
52
53
54
55
56
57
58
59
60

Title page

Pharmacist-led management of chronic pain in primary care: results from a randomised controlled exploratory trial

Hanne Bruhn, Christine M Bond, Alison M Elliott, Philip C Hannaford, Amanda J Lee, Paul McNamee, Blair H Smith, Margaret C Watson, Annie Blyth, Richard Holland, David Wright

Centre for Healthcare Randomised Trials, Health Services Research Unit, University of Aberdeen, 3rd floor Health Sciences Building, Foresterhill, Aberdeen, AB25 2ZD, UK Hanne Bruhn, Trial Manager

Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Polwarth West Block, Foresterhill, Aberdeen, AB25 2ZD, UK, Christine M Bond, Professor of Primary Care: Pharmacy

Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Polwarth West Block, Foresterhill, Aberdeen, AB25 2ZD, UK, Alison M Elliott, Senior Research Fellow

Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Polwarth West Block, Foresterhill, Aberdeen, AB25 2ZD, UK, Philip C Hannaford, NHS Grampian Chair of Primary Care

~~Medical Statistics Team, Division of Applied Health Sciences~~~~Population Health, 1st floor,~~
Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, UK, Amanda J Lee, Professor of Medical Statistics

Health Economics Research Unit, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, UK, Paul McNamee, Reader

~~Mackenzie Building, Kirsty Semple Way~~[Division of Population Health Sciences, University of Dundee](#), Ninewells Hospital and Medical School, Dundee, DD2 4RB, UK, Blair H Smith, Professor of Population Science

Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Polwarth West Block, Foresterhill, Aberdeen, AB25 2ZD, UK, Margaret C Watson, Senior Research Fellow

Norwich Medical School, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK, Annie Blyth, Research Associate

Norwich Medical School, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK, Richard Holland, Professor of Public Health Medicine

School of Pharmacy, University of East Anglia, Norwich Research Park, NR4 7TJ, UK, David Wright, Chair in Pharmacy Practice

1
2
3
4
5 Correspondence to: Professor CM Bond c.m.bond@abdn.ac.uk, Centre of Academic Primary
6 Care, Division of Applied Health Sciences, University of Aberdeen, Polwarth West Block,
7 Foresterhill, Aberdeen, AB25 2ZD, UK
8

9
10 The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all
11 authors, [a worldwide licence](#) to the Publishers and its licensees in perpetuity, in all forms, formats and
12 media (whether known now or created in the future), to i) publish, reproduce, distribute, display and
13 store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints,
14 include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii)
15 create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the
16 Contribution, v) the inclusion of electronic links from the Contribution to third party material where-
17 ever it may be located; and, vi) licence any third party to do any or all of the above.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives

To compare the effectiveness of pharmacist medication-review, with or without [pharmacist](#) prescribing, with standard care, for patients with chronic pain.

Design

An exploratory randomised controlled trial.

Setting

Six general practices with prescribing pharmacists in Grampian (3) and East Anglia (3).

Participants

Patients on repeat prescribed pain medication(4815) were screened by GPs, and mailed invitations (1397). 196 were randomised and 180 (92%) completed. Exclusion criteria included: severe mental illness, terminally ill, cancer related pain, history of addiction

Randomisation and intervention

Patients were randomised using a remote telephone service to: (i) pharmacist medication-review with face-to-face pharmacist prescribing; or (ii) pharmacist medication-review with feedback to GP and no planned patient contact; or (iii) treatment as usual (TAU). Blinding was not possible.

Outcome measures

Primary Outcomes were the [SF-12v2](#), the Chronic Pain Grade (CPG), the [HUI3](#) and the [SF-12v2, together with](#) Hospital Anxiety and Depression Scale (HADS). Outcomes were collected at 0,3,and 6 months.

Ethical approval was obtained.

Results

In the prescribing arm (n=70) two patients were excluded/nine withdrew. In the review arm (n=63) one was excluded/three withdrew. In the TAU arm (n=63) four withdrew. Compared with baseline, patients had an improved CPG in the prescribing arm, 47.7% (21/44; p=0.003),

Formatted: Highlight

Formatted: Highlight

1
2
3
4
5 and in the review arm, 38.6% (17/44; p=0.001), but not the TAU group, 31.3% (15/48; ns). The
6 SF-12 PCS showed no effect in the prescribing or review arms but improvement in TAU
7 (p=0.02). The SF-12 MCS showed no effect for the prescribing or review arms and deterioration
8 in the TAU arm (p=0.002). HADS scores improved within the prescribing arm for Depression
9 (p=0.022) and Anxiety (p=0.007), between groups (p=0.022 and p=0.045 respectively).

10
11
12
13
14 -Conclusion

15 This is the first RCT of pharmacist-prescribing in the UK, and suggests a there may be a benefit
16 for patients with chronic pain. A larger trial is required.

17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Trial registration: www.isrctn.org/ISRCTN06131530. Medical Research Council funding.

Focus:

- Chronic pain, (lasting >3 months) affects up to half the adult population, most of whom are primarily managed in primary care but prescribing is often sub-optimal.
- Pharmacists now have prescribing rights but no published research has compared the effectiveness of their prescribing with that of GPs.
- The theoryhypothesis hypothesis was that pharmacist advice (with or without pharmacist prescribing) would lead to better outcomes than usual care

Key messages:

- The findings suggest there may be improved pain related outcomes for patients receiving pain related care from a pharmacist prescriber
- A larger trial is called for.

Strengths and Limitations

- This the first randomised controlled trial of pharmacist prescribing in the UK looking at patient reported clinical outcomes
- The study was designed as an exploratory trial so no power calculation was done

Introduction

Chronic pain (pain lasting more than three months) affects up to half the adult United Kingdom (UK) population, and is considered severely limiting in about 15% of cases (1). Recovery is uncommon with nearly 80% of those identified with chronic pain at baseline still reporting chronic pain four years later (2). It adversely affects many aspects of a person's physical and psychological health, and social and economic well being (3-6).

In the UK, most patients with chronic pain present, and are managed, in primary care (7).

Although non-pharmacological treatments are available, these are accessed by few patients, with mixed success (e.g. (8-10)). Analgesics prescribed in primary care remain the mainstay of treatment (4), representing substantial workload and cost. Sub-optimal prescribing may lead to poor pain control and other adverse patient outcomes. One study found that the most common medications involved in adverse drug reaction-related emergency admissions involved non-steroidal anti-inflammatory drugs (NSAIDs) (11) [which are commonly used to manage pain](#). Improved prescribing could result in better outcomes and remove the need for more costly, scarce, alternatives.

Pharmacists working in UK general practices are well-placed to improve pain pharmacotherapy because of their expertise in therapeutics, understanding of the poly-pharmacy regimens (12) frequently used in chronic pain management, and established relationships with other primary care colleagues. In the UK National Health Service (NHS), recent regulatory changes now allow accredited pharmacists (as well as some other health care professionals such as nurses) to prescribe prescription-only medicines (POMs) (13). [Pharmacists can either be qualified as supplementary prescribers, in which case they operate within an agree-d clinical management plan \(CMP\) in partnership with the doctor and patient, or as an independent prescriber, in which case they can either prescribe completely independently or within a CMP.-](#)

However, despite the increasing number of non-medical prescribers, including pharmacists, there has been no rigorous comparisons of the outcomes of non-medical versus GP prescribing. This information is needed to assess the clinical effectiveness of different care models.

This paper reports findings from an exploratory randomised controlled trial (RCT) comparing pharmacist medication review, with or without pharmacist prescribing, with standard care for

1
2
3
4
5 patients with chronic pain. Development of the trial was informed by earlier feasibility work
6 (14,15).
7

8
9 The *a priori theory hypothesis* hypothesis was that, in patients with chronic pain, pharmacist
10 advice (with or without pharmacist prescribing) would lead to better patient functioning and/or
11 better pain control at six months than treatment as usual (TAU). ~~The hypothesis was developed
12 prior to data collection.~~
13
14
15

Formatted: Font: Italic

Formatted: Highlight

16 17 18 19 **Methods**

20 *Regulatory Issues*

21 Ethical approval was granted by the National Research Ethics Service Committee – North of
22 Scotland (reference number 09/S0801/107). NHS Research and Development approval was
23 granted by NHS Grampian and East Norfolk & Waveney Research Governance Committees.
24
25 Patients gave informed consent before taking part.
26
27

28 29 *Design*

30 An open, exploratory RCT in which patients were randomised to one of three study arms.
31
32 Participants were not blind to allocated treatment arm due to the nature of the intervention.
33

34 35 *Recruitment of practices and independent prescribing pharmacists*

36 Practices in [the Grampian Health Board area](#), Scotland (n=18) and East Anglia [region of](#),
37
38 England (n=4) known to have an attached Royal Pharmaceutical Society of Great Britain
39 registered independent pharmacist prescriber, were eligible to take part. From those indicating
40 a willingness to participate, convenience sampling was used to identify six general practices:
41
42 three in Grampian and three in East Anglia.
43

44 45 *Patient inclusion and exclusion criteria*

46 Patients registered with the recruited practices were eligible for inclusion if they were over 18
47 years of age, living in their own home, and receiving regular prescribed medication for pain.
48

49 Patients were identified by a computerised search [\(14\) \(5 McDermott, M. E. 2006\)](#) of the drug
50 records of all individuals registered with the practice, to identify those who had received either
51
52 two or more acute prescriptions, and/or one repeat prescription within the last 120 days, for
53
54 an analgesic (British National Formulary (BNF section 4.7) and/or non-steroidal anti-
55

1
2
3
4
5
6 inflammatory medication (NSAID) (BNF section 10.1.1). Medications which can be used for
7 analgesia but whose primary indication is not chronic pain (e.g. triptans, anti-epileptics or anti-
8 depressants) were excluded as these drugs identify few additional eligible patients (16). In
9 accordance with trial criteria, GPs excluded and recorded reasons for patients who had: a
10 concomitant severe mental health problem or terminal illness; had suffered recent
11 bereavement; had a known alcohol or drug addiction; suffered pain caused by cancer or other
12 malignancy; were unable to give informed consent; other (unspecified) reasons.
13
14
15

16 *Patient recruitment*

17
18 Eligible patients were sent an invitation pack (letter, information sheet, consent form) by
19 practice staff between March and June 2010. Consent forms were returned directly to the
20 researchers, who sent out a baseline questionnaire. Patients returning completed
21 questionnaires were randomised by the researcher using a telephone randomisation service
22 with a random number allocation which ensured allocation concealment. The allocation
23 sequence was 1:1:1.
24
25
26
27

28 *Intervention*

29
30 All participating pharmacists took part in a two-day course updating them about pain
31 management. As part of the training, participants defined and agreed the treatment algorithm
32 they would all use.
33
34

35 'Prescribing' arm: Pharmacists invited patients to a face-to-face consultation. Prior to the
36 consultation, pharmacists completed a paper-based medication review of each patient's
37 medical record and patients were asked to complete a pain diary to inform the consultation. A
38 pharmaceutical care plan was agreed between the pharmacist and the patient. The plan
39 assessed and documented relevant past medical history and current conditions; known
40 allergies and adverse drug reactions; relevant laboratory results; pain-related medications
41 prescribed in the previous 10 years; current pain related prescription medications; current
42 symptoms; lifestyle issues, including units of alcohol consumed per week; recommendations
43 for changes to medication (if any); whether non-pharmaceutical treatments had been
44 considered; and, any other relevant issues. [Copies of the pain diary and pharmaceutical care
45 plan are available -from the authors on request.](#) At the end of the consultation any required
46 prescriptions for medicines were issued by the pharmacist. Due to Controlled Drug (CD)
47 regulations in place at the time, prescribing for CDs was done using a supplementary
48
49
50
51
52
53
54
55
56
57
58
59
60

prescribing Clinical Management Plan (17), rather than independent prescribing. Patients were followed up either by phone or face-to-face, at each pharmacist’s discretion.

‘Review arm’: The pharmacists conducted a paper-based medication review focussed on pain-related prescription medications, before creating a pharmaceutical care plan which detailed any recommendations for medication changes. The plan was passed to the patient’s GP for implementation. The GPs were asked subsequently about actions taken as a result of the recommendations.

Treatment as usual (TAU): Patients received standard general practice care.

Outcome measures

A core aim of this exploratory randomised controlled trial (RCT) was to finalise the selection of outcome measures for a subsequent multi-centred RCT. In the Current Controlled Trials Registration (ISRCTN06131530) we specified both primary and secondary outcome measures (primary: SF12, HUI ; secondary: CPG, HADS) based on our judgement following the earlier feasibility study (15). However in practice, all outcomes were considered equal and no single measure was defined as the primary outcome, for example, for the purpose of a sample size calculation (see below). These four outcome measures are described below.

There were two primary outcome measures: the Chronic Pain-Grade (CPG) and the Medical Outcomes Study 12-item short form version 2 (SF-12v2). Use-Inclusion of both a pain specific and generic outcome measures was based on Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) recommendations (18) and an earlier (18,19) feasibility study (15).

The SF-12v2 is a generic health and functioning scale (19), previously used in population-based studies of pain (20,21). A Physical (PCS) and Mental Component Score (MCS) was calculated, ranging from 0 to 100; a higher score indicates better functioning.

The Health Utilities Index (HUI3) is a preference-based system for measuring comprehensive health status and health-related quality of life (HRQL) (22). It provides descriptive evidence and a score for each dimension of health (vision, hearing, speech, ambulation/mobility, pain, dexterity, self-care, emotion and cognition) and a HRQL score for overall health. Each dimension has 3- 6 levels. Owing to the cost of the additional license fee to score data from this measure, this instrument was not subsequently analysed.

Formatted: Highlight

Formatted: Space Before: 0 pt, After: 10 pt, Line spacing: Multiple 1.15 li

Formatted: Highlight

Formatted: Space After: 10 pt, Line spacing: Multiple 1.15 li

Formatted: Highlight

Formatted: Highlight

Formatted: Highlight

Formatted: Highlight

Formatted: Highlight

Formatted: Highlight

Formatted: Highlight

Formatted: Highlight

Formatted: Highlight

Formatted: Highlight

Formatted: Highlight

Formatted: Highlight

Formatted: Highlight

Formatted: Highlight

Formatted: Highlight

Formatted: Highlight

1
2
3
4
5
6 The CPG (192230) is a seven item scale which assesses pain severity on two dimensions:
7 disability and intensity. The scale classifies pain according to level of intensity and disability (I
8 (low disability-low intensity) to IV (high disability-severely limiting)).
9

10
11 ~~The SF-12v2 is a generic health and functioning scale (2021), previously used in population-~~
12 ~~based studies of pain (21, 222,23). A Physical (PCS) and Mental Component Score (MCS) was~~
13 ~~calculated, ranging from 0 to 100; a higher score indicates better functioning.~~
14
15

16
17
18 ~~A secondary outcome measure was~~The the ({}))Hospital Anxiety and Depression Scale (HADS)
19 ~~(2324(24)), is~~ a 14-item screening instrument which identifies the possible and probable
20 caseness of anxiety (7 items (HADS-A)) and depression (7 items (HADS-D)); each item scored
21 from 0 (not present) to 3 (highly present). Standard thresholds and previously used labels
22 (~~2545~~) were applied (no depression/anxiety (0-7), mild (8-10), moderate (11-15) or severe
23 (>15)).
24
25
26
27

28 *Data collection*

29 *Participant questionnaires*

30
31 Questionnaires were posted to participants at baseline (pre-randomisation), and 3 and 6
32 months post-randomisation (follow-up was conducted between July 2010 and January 2011).
33 Up to two reminders were sent. Questionnaire content included the outcome measures
34 described above together with items on: demographic status (baseline only); screening items
35 to confirm eligibility (baseline only); duration of pain condition (baseline only); location of pain;
36 Morisky Medication Adherence Scale 4 (MMAS-4) (2566); participant satisfaction (11
37 statements derived from the feasibility study for the prescribing arm (3 months only) and
38 additional comments by participants. The MMAS-4 provides a score of self-reported adherence
39 to medication regimen. Scores range from 0 (low adherence) to 4 (high adherence).
40
41
42
43
44
45

46 *Follow-up interviews with staff*

47 Post-intervention, all pharmacists and all GPs in participating practices were invited to take part
48 in semi-structured interviews, carried out face-to-face when possible, otherwise by telephone.
49 Interviews were taped, transcribed verbatim and content analysis was carried out.
50
51
52

53 *Sample size*

54
55
56
57
58
59
60

As this was an exploratory trial to estimate the effect size for a larger trial, no formal sample size calculation was possible (27267). We aimed to recruit 30 participants per practice (n=180) (excluding those recruited for training purposes with an additional six per practice for training purposes) i.e. 180-216 in total. This was deemed sufficient to give reliable effect size estimates for the primary outcome measures of health status or chronic pain grade, or health status.

Formatted: Highlight

Formatted: Highlight

Data management and analysis

Data were entered into identical SPSS databases at each site and accuracy checks carried out on 10% before databases were merged. Descriptive statistics included means and standard deviations (SD) for normally distributed continuous data, medians (interquartile range (IQR)) for skewed continuous data and percentages (n) for categorical data. Analysis was conducted on an intention-to-treat basis for participants with complete data on relevant measures using SPSS version 18.

Exploratory analyses for parametric data included the paired t-test for within-arm comparisons of mean difference between baseline and 6 months and one-way ANOVA for between arm comparisons of mean difference. For non-parametric data it included the Wilcoxon Signed Rank test for within-arm comparisons of median difference and the Kruskal Wallis test for between arm comparisons of median difference. Categorical data was analysed using the marginal homogeneity test for within-arm comparisons of (with null hypothesis that the distribution of CPG grade or HADS group does not change between baseline and 6 month follow-up) and the Chi-squared test for between arm comparisons; analyses reported here are based on 6 month follow-up data (other than for participant experiences). Within arm effect sizes, expressed in terms of a Pearson correlation coefficient (r) have been calculated using the formulas from Rosenthal (1991) (287). Effect sizes can be directly compared using Cohen's (1988) (298) criteria of r=0.1 (small effect); r=0.3 (medium effect) and r=0.5 (large effect).

Formatted: Not Highlight

Formatted: Not Highlight

Results

Response rates and demography

Six of the seven practices approached participated. GPs excluded 12% (392/3281) of patients, mostly those with dementia. There was no statistically significant difference between participants and non-participants in terms of age, gender, and index of multiple deprivation.

1
2
3
4
5
6 Figure 1 shows the flow of participants through the study. Overall, the consent rate was 25%
7 (356/1397) and the recruitment rate was 14% (196/1397).
8

9 [INSERT FIGURE 1 HERE]
10

11 Eighty six percent of participants (251/289) returned baseline questionnaires, of whom 232
12 were randomised (36 participants were randomised to one of the two intervention arms for
13 training purposes and were not included in any further analysis and 19 were not included as
14 recruitment target had been met). The overall follow-up rate at 3 months was 86%
15 (161/187) and at 6 months 84% (152/180).
16
17

18 As shown in Table 1, groups were similar at baseline for demographic and socioeconomic
19 variables and pain data. Most participants were married, Caucasian and female, older (mean
20 (SD) age 65 (12.6) years), had an annual income of <£25,000 and had suffered from pain for at
21 least five years. Most (57%;103/181) reported being fully adherent to their medication
22 regimen (MMAS-4, median 4.0 (IQR 3.0- 4.0)) (15 missing MMAS scores).
23
24
25
26
27

28 [INSERT TABLE 1 HERE]
29

30 In the prescribing arm, 78% (53/68) attended an initial prescribing consultation, 31 had at least
31 one planned follow-up (of which 34/37 were generally conducted by phone) and 130
32 recommendations were made for 92% (49/53) of participants seen. Examples are shown in Box
33 1. The median time taken for the note-based record review was 35 minutes (IQR 20.0, 45.0),
34 the consultation was 30 minutes (IQR 20.0, 40.0), careplan preparation 10 minutes (IQR 10.0,
35 20.0) and median duration of follow-ups was 10 minutes (IQR 5.0- 15.0).
36
37
38
39

40 [INSERT BOX 1 HERE]
41

42 In the review arm 97% (60/62) of participants' records were reviewed (note there was one post
43 randomisation exclusion) for whom 197 recommendations were made. Where GP feedback
44 was provided (n=48), they generally agreed with pharmacists' recommendations, which were
45 fully implemented for 20 participants (two by the pharmacist following request by GP), partially
46 for 19 participants and not at all for nine participants. The median time taken for the note-
47 based record review was 30 minutes (IQR 24.3, 45.0), and careplan preparation was 10
48 minutes (IQR 5.0, 20.0).
49
50
51
52
53
54
55
56
57
58
59
60

Clinical outcome measures

Table 2 shows the mean (SD) or median (IQR) of the CPG for each arm at baseline and 6 month follow-up. Table 3 shows the SF-12 scores and Table 4 shows the HADS-A and HADS-D results.

[INSERT TABLE 2,3,4, HERE]

In the prescribing arm, there was a statistically significant within arm improvement for the CPG intensity ($p=0.002$, [effect size \(r\)=0.45](#)) and disability ($p=0.003$, [effect size \(r\)=0.43](#)) subscales, and between arms on the intensity sub-scale ($p=0.02$), but not the disability subscale ($p=0.55$) (Table 2). There was a significant within-arm improvement in overall CPG grade in the prescribing ($p=0.003$) and review arm ($p=0.001$), but not in the TAU arm. The SF-12 Physical Component Score showed a statistically significant within arm improvement in the TAU arm ($p=0.02$, [effect size \(r\)=0.35](#)) (Table 3), but not between trial arms. The SF-12 Mental Component Score showed a statistically significant deterioration in the TAU arm ($p=0.002$, [effect size \(r\)=0.45](#)) (Table 3), as did the HADS-D ($p=0.03$, Table 4). Analysis was also carried out on the non-categorised HADS scores which showed a statistically significant improvement within the prescribing arm for Depression ($p=0.022$) and Anxiety ($p=0.007$). These were both significant between groups ($p=0.022$ and $p=0.045$ respectively) (Table 5).

Acceptability of the pharmacist prescribing intervention

All six pharmacists and 56% of the GPs (23/41) were interviewed. All pharmacists and most GPs were positive about the intervention, although some GPs suggested that the pharmacists' recommendations had been minor and questioned the cost-effectiveness of the service. Patient participants were generally positive about the pharmacist prescribing service although some concerns were identified, as illustrated by the quotes shown in Box 2.

[INSERT BOX 2 HERE]

Discussion

Principal findings

This exploratory RCT of pharmacist-led management of patients with chronic pain suggests that pharmacist prescribing (and possibly pharmacist review alone) may be effective in improving pain-related outcomes and be acceptable to both patients and [most](#) professionals. There was an indication of a positive effect on emotional health, but no measurable effect on general health.

Strengths and weaknesses

This was the first RCT to assess clinical and humanistic outcomes after pharmacist prescribing for any clinical condition compared to usual GP care, and the first RCT to specifically assess pharmacist-led management of chronic pain, compared with usual GP care. It was based on extensive development and feasibility work (14,15) in line with MRC framework for development and evaluation of complex interventions (28,29,30). A range of validated outcome measures was included, as well as a parallel qualitative process evaluation which ~~demonstrated~~ assessed satisfaction and acceptability. The inclusion of six practices and their associated pharmacists from both Scotland and England increased the generalisability of the findings. Pharmacists received formal training and agreed and used a common treatment algorithm which should have increased standardisation of treatment. The preponderance of females (overall 62%) and average age of 65 years reflects the wider chronic pain population (1) as does the distribution of pain site (31,320, 31,29,30)

There were, however limitations. Although high follow-up response rates were achieved at both three (86%) and six months (85%) only 25% of eligible patients entered the trial. This low initial consent rate is in line with other studies (33,342, 3329,30), but may cause unknown biases including problems of generalisability, as does the solely Caucasian- ethnicity. Concerns identified by participants during the formal feedback e.g. having too many people involved in one's care may have contributed to poor response rates and rewording of participant recruitment documentation to reassure participants of the role of the pharmacist could address this. some of the concerns identified by participant feedback e.g. having too many people involved in one's care. More participants withdrew in the prescribing arm compared with the other two arms, which might be attributed to the need for an additional practice visit.

The study was an exploratory trial so no formal power calculation was undertaken. **However, because there were no published MID_s available to estimate effect size for the outcomes in this population, it was important to present the actual clinical magnitude of change in outcome at 6 months alongside a statistical assessment of this change (p-value). This allows an assessment of both clinical and statistical significance simultaneously with the caveat that this is an exploratory study. With around 50 patients per arm, this was deemed sufficient numbers to examine the change in outcome measures with appropriate within and between group univariate statistical tests. because of no prior knowledge of effect size.** Due to the nature of the intervention, no participants were blind to their group allocation, and so some

Formatted: Font: Bold

Formatted: Font: 12 pt, Bold

Formatted: Font: Bold

1
2
3
4
5 outcomes, especially the qualitative components, may have been affected by social desirability
6 bias.
7
8

9
10 Our **main** outcome measures were self-reported, but this is the norm in pain studies as pain is
11 a subjective experience (18). Furthermore we do not know how important the observed
12 differences were to participants. Following precedents set in previous research (25), and
13 because there is no consensus on an alternative measure (35434) we used the HADS as a tool
14 to classify people by severity of depression and anxiety. However it is strictly a screening tool,
15 and the four levels of severity have not been formally validated. We therefore also compared
16 outcomes using it as a continuous scale.
17
18
19
20

21 *Relationship with other studies*

22
23 This study is important because no other RCT has evaluated pharmacist prescribing and few
24 studies, and importantly no RCTs, have evaluated pharmacist interventions for pain. In
25 pharmacist prescribing most research has focussed on reported experiences of professionals
26 and patients, and not used validated outcome measures. Yet pharmacist prescribing is now
27 widely practised. For pain, there have been a few small studies. Briggs et al (2008) (3652)
28 conducted a small before-and-after evaluation (involving 65 patients) of a nurse and
29 pharmacist-led chronic pain clinic in primary care. Pain intensity Visual Analogue Scale scores
30 reduced significantly over six months. Another evaluation of 26 patients using a medication
31 review service provided jointly by a physiotherapist and pharmacist in the UK, reported
32 improvement in pain control for 88% of patients (3763).
33
34
35
36
37
38

39 The CPG was found to show a graded effect across the three arms, showing discrimination with
40 both direction and strength of improvement, suggesting maximum benefit for those in the
41 pharmacist prescribing arm. However, the reduction in overall score appears to be mediated by
42 a change in the intensity of pain subscale rather than in pain-related disability. The effect size
43 of 0.45 suggests this could be an important difference. In contrast, the SF-12, a measure of
44 general health and functionality showed no significant difference between intervention arms,
45 reflecting either no effect or or lack of power to detect an effect.
46
47
48
49

50 Whilst most participants in this study were already within the normal range on the HADS scale,
51 and therefore had minimal chance of improvement, there were nonetheless suggestions of
52 better outcomes in participants in the prescribing arm. Including a range of instruments is in
53
54
55
56

line with IMMPACT recommendations (3874), which state that focus should be on the whole person, not just about pain. However, this needs to be balanced with minimising participant burden.

Explanations, implications, and future research

The number of pharmacists' recommendations per participant was higher in the review arm than in the prescribing arm. This might seem contradictory to the possible greater benefit found in the prescribing arm. However, in the prescribing arm pharmacists met the participant and may have more readily identified and dismissed suggestions previously -tried. The interview feedback highlighted that some recommendations for change, whilst sensible, had been tried already. This might also be the reason why there were only 60% of pharmacist recommendations with which the GP fully agreed. Self-reported adherence to medication at baseline was good. Despite this, the pharmacists still improved pain outcomes in the prescribing arm. This could have been due to changes in medications and/or participant education about optimal timing for administration of analgesic medicines. Further research is needed to confirm the beneficial effect of pharmacist prescribing and its sustainability.

Conclusion

Our results suggest that pharmacist prescribing -(and possibly pharmacist review alone) -for patients with chronic pain is feasible, acceptable and may lead to improvements...acceptable and leads to improvements in pain and other measures. A larger fully-powered trial is now needed to confirm these findings.

Formatted: Font: (Default) +Body (Calibri), 12 pt, Not Bold, Not Italic

Data sharing statement

Consent was not obtained from participants for data sharing; the presented data are anonymised and there is no risk of individual -identification. Requests for data- should be made to the contact author who will provide this in a format in which risk of patient identification will be minimal.

Conflict of interest statement

All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous 3

Formatted: Font: 12 pt

years; no other relationships or activities that could appear to have influenced the submitted work.

Authors' contributions

Formatted: Font: 12 pt, Not Bold

HB and CB drafted the manuscript.

Formatted: Font: 12 pt

All authors:

- 1) made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data;
- 2) were involved in drafting the manuscript or revising it critically for important intellectual content; and
- 3) have given final approval of the version to be published.

Acknowledgements

We thank the participating patients, practices and pharmacists. We would also like to thank Kirsten Harrild (Medical Statistics, UOA) for statistical support. Rick Adams (School of Pharmacy, UEA) helped design and deliver the pharmacist training and Lesley Thomson (NHS Grampian) helped design the pharmacist data collection forms. The patient postal questionnaire was based on work by Nicola Cooper and the Norfolk Arthritis Register (NOAR) research team. The Pharmacy-Led Management of Chronic Pain Study Team acknowledges the financial support of NHS Research Scotland (NRS), through Scottish Primary Care Research Network Northeast. The work was conducted as part of the Aberdeen Pain Research Collaboration. The project was funded by the Medical Research Council. They had no further involvement in any aspect of study conduct; all researchers were independent of the funding body.

All authors had access to all of the study data and can take responsibility for the integrity of the data and the accuracy of the data analysis.

References

- (1) Elliott AM, Smith BH, Penny KI, Smith WC, Chambers WA. The epidemiology of chronic pain in the community. *Lancet* 1999;354:1248-1252.
- (2) Elliott AM, Smith BH, Hannaford P, Smith WC, Chambers WA. The course of chronic pain in the community: results of a 4-year follow-up study. *Pain* 2002;99:299-307.

- 1
2
3
4
5
6 (3) Becker N, Bondegaard Thomsen A, Olsen AK, Sjøgren P, Bech P, Eriksen J. Pain epidemiology
7 and health related quality of life in chronic non-malignant pain center patients referred to
8 a Danish multidisciplinary. *Pain* 1997;73:393-400.
- 9
10 (4) Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe:
11 prevalence, impact on daily life, and treatment. *Eur J Pain* 2006;10:287-333.
- 12
13 (5) Gureje O, Von Korff M, Simon GE, Gater R. Persistent pain and well-being: a World Health
14 Organization Study in Primary Care. *JAMA* 1998;280:147-151.
- 15
16 (6) Magni G, Marchetti M, Moreschi C, Merskey H, Luchini SR. Chronic musculoskeletal pain and
17 depressive symptoms in the National Health and Nutrition Examination. I. Epidemiologic
18 follow-up study. *Pain* 1993;53:163-168.
- 19
20 (7) Sullivan MD, Turner JA, Romano J. Chronic pain in primary care: identification and
21 management of psychological factors. *J Fam Pract* 1991;32:193-199.
- 22
23 (8) Green S, Buchbinder R, Hetrick SE. Physiotherapy interventions for shoulder pain. *Cochrane*
24 *Database of Syst Rev* 2010(9):Art. No.: CD004258. DOI: 10.1002/14651858.CD004258.
- 25
26 (9) Eccleston C, Williams, A. C. D. C., Morley S. Psychological therapies for the management of
27 chronic pain (excluding headache)
28 in adults. *Cochrane Database Syst Rev* 2009 Apr 15;(2):CD007407. DOI:
29 10.1002/14651858.CD007407.pub2.
- 30
31 (10) Haetzman M, Elliott AM, Smith BH, Hannaford P, Chambers WA. Chronic pain and the use
32 of conventional and alternative therapy. *Family Practice* 2003;20(2):147-154.
- 33
34 (11) Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug
35 reactions as cause of admission to hospital: prospective analysis of 18 820 patients. *BMJ*
36 2004;329:15.
- 37
38 (12) Krska J, Cromarty JA, Arris F, Jamieson D, Hansford D, Duffus PR, et al. Pharmacist-led
39 medication review in patients over 65: a randomized, controlled trial in primary care. *Age and*
40 *Ageing* 2001;30:205-211.
- 41
42 (13) Department of Health. Improving patients' access to medicines: A guide to implementing
43 nurse and pharmacist independent prescribing within the NHS England. Department of Health
44 2006.
- 45
46 (14) McDermott ME, Smith BH, Elliott AM, Bond CM, Hannaford P, Chambers WA. The use of
47 medication for chronic pain in primary care, and the potential for intervention by practice-
48 based pharmacist. *Family Practice* 2006;23:46-52.
- 49
50 (15) Bruhn H, Bond CM, Elliott AM, Hannaford PC, Lee AJ, McNamee P, et al. Developing an RCT
51 of general practice-based, pharmacist-led, management of chronic pain: the PIPPC study. *IJPP*
52 2010;18(Supplement 2).
- 53
54
55
56
57
58
59
60

1
2
3
4
5
6 (16) Smith BH, Read JRM, Chambers WAC, Watt B, Grimshaw JM. Researching chronic pain:
7 identification of a community based sample. The Pain Clinic 1996;9:73-76.

8
9 (17) Department of Health. Supplementary prescribing by nurses and pharmacists within the
10 NHS in England: A guide for implementation. Department of Health 2003.

11
12 (18) Turk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB, et al. Core outcome
13 domains for chronic pain clinical trials: IMMPACT recommendations. Pain 2003 12;106(3):337-
14 345.

15
16 (19) Ware JE, Kosinski M, Turner-Bowker DM, Sundaram M, Gandek B, Maruish ME. User's
17 Manual for the SF-12v2 Health Survey. Second edition ed.: QualityMetric, Incorporated, 2009;
18 2009.

19
20 ~~(19) The Community Pharmacy Medicines Management Project Evaluation Team. The~~
21 ~~MEDMAN study: a randomized controlled trial of community pharmacy led medicines~~
22 ~~management for patients with coronary heart disease. Family Practice 2007;24:189-200.~~

23
24 ~~(1920) Von Korff M, Ormel J, Keefe FJ, Dworkin SF. Grading the severity of chronic pain. Pain~~
25 ~~1992;50:133-149.~~

26
27 (20) Nicholl BI, Macfarlane GJ, Davies KA, Morriss R, Dickens C, McBeth J. Premorbid
28 psychosocial factors are associated with poor health-related quality of life in subjects with new
29 onset of chronic widespread pain - results from the EPIFUND study. Pain 2009;141:119-126.

30
31 ~~(2021) Ware JE, Kosinski M, Turner-Bowker DM, Sundaram M, Gandek B, Maruish ME. User's~~
32 ~~Manual for the SF-12v2 Health Survey. Second edition ed.: QualityMetric, Incorporated, 2009;~~
33 ~~2009.~~

34
35 ~~(2122) Nicholl BI, Macfarlane GJ, Davies KA, Morriss R, Dickens C, McBeth J. Premorbid~~
36 ~~psychosocial factors are associated with poor health-related quality of life in subjects with new~~
37 ~~onset of chronic widespread pain—results from the EPIFUND study. Pain 2009;141:119-126.~~

38
39 (21223) Carmona L, Ballina J, Gabriel R, Laffon A. The burden of musculoskeletal diseases in the
40 general population of Spain: results from a national survey. Ann Rheum Dis 2001;60:1040-1045.

41
42 (22) Feeny, David, "Preference-Based Measures: Utility and Quality-Adjusted Life Years,"
43 Chapter 6.2 in Peter Fayers and Ron Hays, eds., Assessing Quality of Life in Clinical Trials,
44 Second Edition, Oxford, Oxford University Press, 2005, pp 405-429.

45
46 (23) Von Korff M, Ormel J, Keefe FJ, Dworkin SF. Grading the severity of chronic pain. Pain
47 1992;50:133-149.

48
49 ~~(2424) Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand~~
50 ~~1983 Jun;67(6):361-370.~~

51
52 (25425) Snaith RP, Zigmond AS. HADS: Hospital Anxiety and Depression Scale. Windsor: NFER
53 Nelson; 1994.

Formatted: Font: (Default) Calibri, 12 pt

(26526) Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. *Med Care* 1986 Jan;24(1):67-74.

(27627) Lancaster GA, Dood S, Williamson PR. Design and analysis of pilot studies: recommendations for good practice. *J Eval Clin Pract* 2004;10(2):307-312.

(287) Rosenthal R. *Meta-analytic procedures for social research (revised)*. Newbury Park, CA. Sage 1991.

(298) Cohen J. *Statistical power analysis for the behavioural sciences (2nd edition)*. New York. Academic Press.

(302928) Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and evaluating complex interventions: the new Medical Research Council guidance. *BMJ* 2008;337:a1655.

(3109) Magni M, Caldieron C, Rigatti-Luchini S, Merskey H. Chronic musculo-skeletal pain and depressive symptoms in the general population. An analysis of the 1st National Health and Nutrition Examination Survey data. *Pain* 1990; 43: 299-307

(3210) Gureje O, Von Korff M, Simon GE, Gater R. Persistent pain and well-being. A World Health Organization study in primary care. *Journal of the American Medical Association* 1998; 280: 147-151.

(3322931) Community Pharmacy Medicines Management Project Evaluation Team. The MEDMAN study: a randomized controlled trial of community pharmacy-led medicines management for patients with coronary heart disease. *Family Practice* 2007;24:189-200.

(3433032) Treweek S, Mitchell E, Pitkethly M, Cook J, Kjeldstrøm M, Johansen M, et al. Strategies to improve recruitment to randomised controlled trials. *Cochrane Database Syst Rev* 2010;(4):MR000013 2011.

(3543133) Cameron IM, Cardy A, Crawford JR, du Toit Schalk W, Hay S, Lawton K, et al. Measuring depression severity in general practice: discriminatory performance of the PHQ-9, HADS-D, and BDI-II. *Br J Gen Pract* 2011;61:e419-e426(8).

(3653234) Briggs M, Closs SJ, Marczewski K, Barratt J. A feasibility study of a combined nurse/pharmacist-led chronic pain clinic in primary care. *Qual Prim Care* 2008;16:91-94.

(3763335) Anonymous. Pharmacist and physiotherapist-led community outreach pain programme improve quality of life. *The Pharmaceutical Journal* 2005;275:14.

(3873436) Turk DC, Dworkin RH, Revicki D, Harding G, Burke LB, Cella D, et al. Identifying important outcome domains for chronic pain clinical trials: An IMMPACT survey of people with pain. 2008;137:276-285.

~~Rosenthal R. *Meta-analytic procedures for social research (revised)*. Newbury Park, CA. Sage 1991.~~

Formatted: Space After: 0 pt

Formatted: Normal

Formatted: Space Before: 0 pt, After: 0 pt

Formatted: Font: Calibri, 12 pt, Not Bold, Font color: Auto

Formatted: Font: Calibri, 12 pt, Not Bold, Font color: Auto

Formatted: Font: Calibri, Not Bold, Font color: Auto

Formatted: Font: Calibri, Not Bold, Font color: Auto

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


~~Cohen J. Statistical power analysis for the behavioural sciences (2nd edition). New York:
Academic Press.~~

Formatted: Font: +Body (Calibri), Superscript

For peer review only

Figure 1: CONSORT Flow Diagram

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



1
2
3
4
5
6 | *In the Grampian Health Board areaGrampian, on the basis of response rates in the earlier feasibility
7 study (241 screened patients resulted in 22 recruited) only a random sample of eligible participants
8 were screened (15). In East Anglia all eligible patients were screened.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1: Baseline demographic, socio-economic and pain data of patients by study arm, prescribing, review and treatment as usual (TAU)

	Prescribing* (n = 68)	Review* (n = 62)	TAU* (n = 63)
Age: mean (SD)	66.1 (12.1)	65.7 (14.2)	64.9 (11.6)
Missing	1	1	0
Gender (% female)	54.4 (37)	74.2 (46)	58.7 (37)
<i>Marital status</i>			
Married	43	30	41
Single	6	6	3
Divorced/widow	10	21	13
Other	6	4	6
Missing	3	1	0
<i>Highest educational level achieved</i>			
No qualifications	30	27	21
O grade or equivalent	12	6	14
Higher/A-level/NVQ3/SVQ3	6	8	7
Tertiary education/NVQ4/NVQ5	18	17	14
Other	2	1	4
Missing	0	3	3
<i>Employment status</i>			
Employed	16	14	9
Unemployed	3	5	1
Retired	38	35	34
Long term sick/disabled	7	5	9
Other	3	2	7
Missing	1	1	3
<i>Household annual income before tax</i>			
Less than £9,999	13	15	10
£10,000 - £14,999	14	18	22
£15,000 - £24,999	14	12	12
£25,000 – or more	22	11	8
Missing	5	6	11
<i>Ethnic group</i>			
Caucasian	67	62	61
Other	1		
Missing	0	0	2
<i>Pain duration</i>			
< 1 year	3	2	4
1 – 3 years	12	12	7
3 – 5 years	10	13	9
5 – 10 years	17	13	15
> 10 years	26	22	28
<i>Pain localisation (% , n)</i>			
Back	27.9 (19)	32.3 (20)	20.6 (13)
Neck, shoulders	7.4 (5)	9.7 (6)	9.5 (6)
Limbs or hips	42.6 (29)	30.6 (19)	50.8 (32)
Other	8.8 (6)	4.8 (3)	7.9 (5)
Missing	9	14	7

*Denominator based on numbers allocated to the specific arms, minus any exclusions due to protocol violations.

Table 2: Mean (standard deviation, SD) CPG intensity , median (interquartile range, IQR) CPG disability, and count CPG grade at baseline, 6 months follow-up and difference between the two assessment points for each arm, prescribing, review and treatment as usual (TAU). P-values for within and between arm differences are also reported.

	Prescribing		Review		TAU		P (between groups ^{***})
	n*	Mean (SD)	n*	Mean (SD)	n*	Mean (SD)	
Baseline CPG intensity	47	66.1 (16.0)	45	68.4 (17.6)	54	65.4 (18.0)	
6 month follow-up CPG intensity		58.1 (19.5)		67.4 (21.7)		65.6 (19.6)	
Difference CPG intensity		-8.0 (16.3)		-1.0 (16.0)		0.2 (14.9)	0.02
P (within groups ^{**})		0.002		0.67		0.93	0.02
Effect size (r)		0.45x		0.07x		0.01x	
		Median [IQR]		Median [IQR]		Median [IQR]	
Baseline CPG disability	48	60.0 [30.0; 75.8]	46	66.7 [45.0; 80.0]	53	56.7 [36.7; 80.0]	
6 Month follow-up CPG disability		40.0 [20.0; 60.0]		53.3 [29.2; 73.3]		50.0 [25.0; 80.0]	
Difference CPG disability		-8.3 [-23.3; 0.0]		-3.3 [-16.7; 10.0]		-3.3 [-21.7; 5.0]	0.55
P (within groups ^{**})		0.003		0.15		0.05	0.55
Effect size (r)		0.43x		0.20x		0.26x	
Baseline CPG grade	44	Count (%)	44	Count (%)	48	Count (%)	
	I	5 (11.4)		3 (6.8)		5 (10.4)	
	II	16 (36.4)		9 (20.5)		13 (27.1)	
	III	7 (15.9)		10 (22.7)		13 (27.1)	
	VI	16 (36.4)		22 (50.0)		17 (35.4)	
6 month follow-up CPG grade							
	I	13 (29.5)		8 (18.2)		6 (12.5)	
	II	13 (29.5)		15 (34.1)		17 (35.4)	
	III	8 (18.2)		8 (18.2)		11 (22.9)	
	IV	10 (22.7)		13 (29.5)		14 (29.2)	
Difference CPG grade							
	≤-1	21 (47.7)		17 (38.6)		15 (31.2)	
	0	17 (38.6)		25 (56.8)		25 (52.1)	
	≥1	6 (13.6)		2 (4.5)		8 (2.1)	0.16
P (within groups ^{***})		0.003		0.001		0.17	

*Number of participants in each group who completed the appropriate part of the CPG at both baseline and follow-up.

** From paired t-test, Wilcoxon signed rank test or marginal homogeneity test as appropriate

*** From ANOVA on mean difference, Kruskal-Wallis on median difference or chi-squared test on difference in CPG grade as appropriate

Table 3: Mean (standard deviation, SD) SF12 Physical Component Score (PCS) and median (interquartile range, IQR) Mental Component Score (MCS) at baseline and 6 month follow-up and difference between the two assessment points for each arm, prescribing, review and treatment as usual (TAU). Within and between arm p-values are also reported.

	Prescribing		Review		TAU		P (between groups ^{***})
	n*	Mean (SD)	n*	Mean (SD)	n*	Mean (SD)	
Baseline SF12 PCS	41	33.5 (10.8)	43	32.59(11.38)	45	29.60 (9.71)	
6 month follow-up SF12 PCS		35.3 (10.8)		34.62 (11.26)		32.59 (9.14)	
Difference SF12 PCS		1.8 (7.5)		2.02 (7.56)		2.99 (8.11)	0.75
P (within groups ^{**})		0.12		0.09		0.02	0.75
Effect size (r)		<u>0.24x</u>		<u>0.26x</u>		<u>0.35x</u>	
		Median [IQR]		Median (IQR)	45	Median (IQR)	
Baseline SF12 MCS	42	52.4 [42.0; 58.8]	43	47.9 [38.5; 59.9]		51.5 [41.3; 60.7]	
6 month follow-up SF12 MCS		49.6 [42.8; 58.1]		47.9 [38.9; 56.2]		44.7 [37.6; 55.8]	
Difference SF12 MCS		-0.4 [-3.7; 6.0]		-1.2 [-6.6; 4.2]		-3.0 [-10.0; 1.3]	0.04
P (within groups ^{**})		0.64		0.37		0.002	0.04
Effect size (r)		<u>0.07x</u>		<u>0.14x</u>		<u>0.46x</u>	

* Number of participants in each group who completed the appropriate part of the SF-12 at both baseline and follow-up.

** From paired t-test or Wilcoxon signed rank test as appropriate

*** From ANOVA on mean difference or Kruskal-Wallis test on median difference as appropriate

Table 4: The HADS-Depression (HADS-D) and HADS-Anxiety (HADS-A) count of patients according to severity (normal, mild, moderate or severe) and the difference in severity category between the two assessment points for each arm, prescribing, review and treatment as usual (TAU). Within and between arm p-values are also reported.*

	n	Prescribing	n	Review	n	TAU	P (between groups ^{***})
Baseline HADS-D	44	Count (%)	45	Count (%)	53	Count (%)	
Normal		32 (72.7)		31 (68.9)		38 (71.7)	
Mild		8 (18.2)		11 (24.4)		7 (13.2)	
Moderate		3 (6.8)		3 (6.7)		8 (15.1)	
Severe		1 (2.3)		0		0	
6 month follow-up HADS-D							
Normal		32 (72.7)		32 (71.1)		32 (60.4)	
Mild		7 (15.9)		6 (13.3)		10 (18.9)	
Moderate		5 (11.4)		6 (13.3)		8 (15.1)	
Severe		0		1 (2.2)		3 (5.7)	
Difference HADS-D							
≤-1		5 (11.4)		4 (8.9)		2 (3.8)	
0		34 (77.3)		37 (82.0)		40 (75.5)	
≥1		5 (11.4)		4 (8.9)		11 (20.8)	0.32 ^{Net valid**}
P (within groups ^{**})		1.0		0.71		0.03	
Baseline HADS-A	44	Count (%)	43	Count (%)	48	Count (%)	
Normal		25 (56.8)		30 (69.8)		29 (60.4)	
Mild		8 (18.2)		7 (16.3)		9 (18.8)	
Moderate		8 (18.2)		5 (11.6)		8 (16.7)	
Severe		3 (6.8)		1 (2.3)		2 (4.2)	
6 month follow-up HADS-A							
Normal		27 (61.4)		29 (67.4)		32 (66.7)	
Mild		7 (15.9)		6 (14.0)		5 (10.4)	
Moderate		8 (18.2)		6 (14.0)		10 (20.8)	
Severe		2 (4.5)		2 (4.7)		1 (2.1)	
Difference HADS-A							
≤-1		6 (13.6)		3 (7.0)		10 (20.8)	
0		35 (79.5)		33 (76.7)		29 (60.4)	
≥1		3 (6.8)		7 (16.3)		9 (18.8)	0.14
P (within groups ^{**})		0.25		0.21		0.55	

* Number of participants in each group who completed the appropriate part of the HADS at both baseline and follow-up.

**** Between arms p-value not valid due to low numbers in multiple cells, even after collapsing to the**

**** From marginal homogeneity test**

***** From chi-squared test on difference in HADS**

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ree categories.

For peer review only




Table 5: Median HADS-Depression (HADS-D) and HADS-Anxiety (HADS-A) scores (interquartile range, IQR) at baseline and 6 month follow-up and difference between the two assessment point for each arm, prescribing, review and treatment as usual (TAU). Within and between arm p-values are also reported.

	Prescribing		Review		TAU		P (between groups)
	n	Median [IQR]	n	Median [IQR]	n	Median [IQR]	
Baseline HADS-D	42	5.0 [3.0; 8.0]	44	4.5 [2.3; 8.0]	51	5.0 [3.0; 8.0]	0.02
6 month follow-up HADS-D		4.0 [2.0; 8.0]		5.0 [2.0; 8.8]		5.0 [2.0; 10.0]	
Difference HADS-D		-1.0 [-2.0; 0.0]		0.0 [-1.0; 1.8]		0.0 [-1.0; 2.0]	
P (within groups)		0.02		0.33		0.22	
Baseline HADS-A	44	7.0 [3.3; 10.8]	43	5.0 [3.0; 10.0]	48	6.0 [4.0; 10.0]	0.05
6 month follow-up HADS-A		5.0 [2.3; 9.8]		6.0 [3.0; 9.0]		7.0 [4.0; 10.0]	
Difference HADS-A		-1.0 [-2.0; 0.0]		0.0 [-2.0; 2.0]		0.5 [-3.0; 2.0]	
P (within groups)		0.01		0.45		0.81	

* Number of participants in each group who completed the appropriate part of the HADS at both baseline and follow-up.

Box 1 Examples of pharmacist interventions in the prescribing arm

Changes to pain management: 'use paracetamol regularly', 'take tramadol if needed' 'add piroxicam gel PRN', 'given web links to self help groups'

Compliance aid: 'gave written times that this drug could be taken'

Addressing side effects/safety: 'take paracetamol after initial NSAID', 'take senna', 'ordered blood monitoring', 'stop use of two NSAIDS'

General health: 'discussed weight loss', 'invited to practice nurse for BP', 'glucose, lipids and lifestyle update',

Cost minimisation: 'change aspirin EC to plain',

BOX 2 Examples of quotes from Pharmacists (n=6), GPs (n=23) and patient participants (n=40) on the prescribing intervention

Pharmacists (from interviews):

Satisfying (n=6): 'contact with patients', 'being able to help patients', 'being able to make a difference to long-standing pain'...'even in small ways'

Interesting (n=6): 'learning about pain'

Challenging (n=6): 'complex, chronically ill patients'

GPs (from interviews):

Support for the service (n=17): 'it's been a very positive thing'

Agreement with pharmacists' recommendations (n=23): 'oh very reasonable suggestions', 'tinkering round the edges', 'had been tried already'.

Trust in the practice pharmacist (n=23): 'I respect his professional judgement'

Cost effectiveness (n=6): 'if there's limited resources do we want to spend the money on a pharmacist'.

Patients (from 3 month questionnaire):

Closed questions:

Proportion agreeing that:

The pharmacist was interested in them (89%; 39/44)

They were totally satisfied (85%; 39/46)

They were told about their treatment (82%; 38/46)

Their consultation was thorough (79%; 34/44)

They would have liked more time (9%; 4/44)

They would have preferred to see their GP (9%; 4/44)

Too many people were now involved in their treatment (11%; 5/44).

Open text questions:

Positive (n=39): 'She was professional, relaxed, pleasant and interested. Excellent!'

Negative (n=1): 'A waste of time, altered my tablets which made my pain worse'.



CONSORT 2010 checklist of information to include when reporting a randomised trial*

Section/Topic	Item No	Checklist item	Reported on page No
Title and abstract			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	3-4
Introduction			
Background and objectives	2a	Scientific background and explanation of rationale	5
	2b	Specific objectives or hypotheses	5-6
Methods			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	6
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	N/A
Participants	4a	Eligibility criteria for participants	6
	4b	Settings and locations where the data were collected	6
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	7-8
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	8
	6b	Any changes to trial outcomes after the trial commenced, with reasons	N/A
Sample size	7a	How sample size was determined	9
	7b	When applicable, explanation of any interim analyses and stopping guidelines	N/A
Randomisation:			
Sequence generation	8a	Method used to generate the random allocation sequence	7
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	N/A
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	7
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	7
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those	N/A

		assessing outcomes) and how	
	11b	If relevant, description of the similarity of interventions	N/A
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	9
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	N/A
Results			
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	10, figure 1(p.18)
	13b	For each group, losses and exclusions after randomisation, together with reasons	10, figure 1(p.18)
Recruitment	14a	Dates defining the periods of recruitment and follow-up	7-8
	14b	Why the trial ended or was stopped	N/A
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	10, Table 1 (p20)
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	See Tables 2,3,4,5 and page 9 (ITT)
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	See pages 10/11, and Tables 2,3,4,5. P values reported
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	N/A
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	N/A
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	N/A
Discussion			
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	12
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	12-13
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	13
Other information			
Registration	23	Registration number and name of trial registry	4

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Protocol	24	Where the full trial protocol can be accessed, if available	N/A
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	14

*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.

For peer review only